Wayne State University
Wayne State University Dissertations

1-1-2017

The Effects Of Bone Marrow Adipocytes On
Metabolic Regulation In Metastatic Prostate
Cancer
Jonathan Diedrich
Wayne State University,

Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations
Part of the Oncology Commons
Recommended Citation
Diedrich, Jonathan, "The Effects Of Bone Marrow Adipocytes On Metabolic Regulation In Metastatic Prostate Cancer" (2017). Wayne
State University Dissertations. 1797.
https://digitalcommons.wayne.edu/oa_dissertations/1797

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

THE EFFECTS OF BONE MARROW ADIPOCYTES ON METASTATIC PROSTATE
CANCER CELL METABOLISM AND SIGNALLING
by
JONATHAN DRISCOLL DIEDRICH
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2017
MAJOR: CANCER BIOLOGY
Approved By:
Advisor

Date

© COPYRIGHT BY
JONATHAN DIEDRICH
2017
All Rights Reserved

DEDICATION
To my Family, Friends, and Wally

ii

ACKNOWLEDGMENTS
When I joined the Podgorski laboratory in April of 2014, I had finished my rotations
and spent some time in a collaborating laboratory honing my technical and creative
thinking skills to become a valuable asset to her team; however, I was still unprepared for
the exciting journey it would be through Izabela’s laboratory over the last three years. I
was extremely lucky to have landed in Dr. Podgorski’s laboratory and will be forever
thankful for the tremendous support she has given me to aid in my development as an
independent investigator. Along, with Dr. Podgorski, there are many other members of
the Wayne State University community that I would also like to extend my thanks to.
Advisors:
I would like to thank Dr. Izabela Podgorski for accepting me into her laboratory and her
continuous support for me and my research endeavors. Izabela has always been there
when I need to ask her questions about my project, about future career goals and how to
achieve them, aiding my scientific writing and presenting skills, and has also been a great
friend over the course of my PhD training. I will truly miss sitting with Dr. Podgorski and
discussing ideas for various projects within the lab and am extremely thankful that she
gave me the opportunity to be creative and explore new ideas. Also, she allowed me to
present my data at multiple domestic and international conferences that have helped me
network and hone my presentation abilities. Lastly, her help with my scientific writing has
helped me obtain a NIH/NCI F31 predoctoral grant, setting me up for a successful career
in academia. She has been an excellent mentor and model academic advisor and I can
only hope that I will be as successful as she is in my future.

iii

Dr. Manohar Ratnam, thank you for all of your help and guidance as a co-mentor on my
studies and always being there for me for questions or guidance whether it be at
committee meetings or me just dropping by your office. You are a brilliant scientist and
have always had my best interest in mind as you guided me through my project and gave
me career advice. You have been an invaluable member of my research team and I am
both lucky and thankful to have you as a co-mentor.
Committee Members:
Dr. Karin List, thank you for your help with my project and being such a great mentor and
friend to me throughout my PhD training. I will truly miss your sense of humor and
stopping by your office to talk to you about anything and everything. You kept me sane
whenever things seemed to fall apart and also kept me laughing every day. Additionally,
your expertise in mouse models provided instrumental input for the design of my in vivo
work.
Dr. Sokol Todi, thank you for all of your help throughout my graduate studies. You always
have a surprisingly vast knowledge base of just about everything and I know I can come
to you with any question and you are able to help me through it. Thank you for being both
critical and constructive, helping me to think “outside of the box.” Additionally, I will miss
being reminded by you how bad I am at cutting my own hair and wearing clothes that
match.
Dr. Elisabeth Heath, thank you for all of your help throughout my graduate studies and
helping me not forget the translational side of research. It is easy to forget that what we
do can make a difference and your clinical input is extremely beneficial when developing
a project with the potential to be clinically significant. Thank you for letting me present

iv

my work at the Prostate Cancer Research Team meeting and letting me expand my
knowledge into renal cancer as we collaborated on a grant submission. It is always a
pleasure talking with you and I will always be impressed with how you juggle so many
different responsibilities!
Lab Members:
Erandi, thank you so much for being patient with me and my awful jokes and as I stole all
of your TBST and Western gels over the years! Thank you for teaching me the techniques
in the laboratory and answering all of my questions. Thank you for knowing where literally
everything in lab is at any given time. I will miss hearing about your kids and getting to
try new foods that you bring in, but you are one of the hardest working people I have ever
met and I will miss you, even if you won’t miss me!
Mackenzie, thank you so much for putting up with me over the last couple of years. You
re-taught me cell culture and how to set up adipocyte cultures and are always there to
bounce ideas and questions off of. It has truly been a pleasure staying in lab until midnight
with you! I think I saw you more than any other person over the last 3 years. I’m lucky
you have a sense of humor and helped me transition into a more liberal mindset! I will
miss getting coffee with you every day!
Rebecca, thank you for being a wonderful addition to our team in the Podgorski
laboratory. Your hard work and dedication to science will be rewarding and I have full
faith that you will be successful in your career endeavors. It has really been a pleasure
getting to “mentor” you and I will miss showing you songs on the guitar that I learned and
talking to you every time you sit down to work!
Collaborators:

v

Dr. Siddhesh Aras, thank you for teaching me the proper assays for mitochondrial work
and assisting in my preparation and analysis of the Seahorse machine. You are always
incredibly knowledgeable and I am lucky to have had you as a collaborator through my
training.
Dr. Gargi Mahapatra, thank you for always being so kind to me and assisting in my
preparation and analysis of the Seahorse machine. I have truly missed you since you
graduated and I am sure you will be successful in your career in science!
Dr. Maik Huttemann, thank you for your help and guidance throughout my PhD and
learning everything there is to know about mitochondria and glucose metabolism. From
letting me present in your lab meeting to co-sponsoring my F31 grant, I am truly
appreciative of everything you have done for me.
Cancer Biology Program:
Dr. Larry Matherly, thank you for welcoming me into the program and all of your help
finding a lab to call home. I am proud to graduate from the strong program that you have
developed here at WSU and your dedication to the students has been instrumental for
our success. Thank you for being a co-sponsor on my F31 and also meeting with me to
discuss both scientific questions and also career choices. I am truly honored to have you
as a director and personal friend.
Dr. George Brush, thank you for your help with the academic requirements of the
program. It’s always a pleasure sitting down and talking with you about everything from
questions I have about curriculum to guitars. I really appreciate your help and support
throughout my training and will miss our talks.

vi

Nadia Daniel, thank you for keeping the programming going. I have relied on you for
reimbursements for conference travel and you have always been extremely patient as I
gathered all of my receipts and information for you.
Cancer Biology Steering Committee, thank you for allowing me to transition into Izabela’s
laboratory and awarding me the T32 training fellowship in 2015 and the

DeRoy

Fellowship in 2016.
Cancer Biology Students, thank you for being great colleagues and, more importantly,
friends. The friendships I have developed here I will maintain and hope to keep in contact
with as future collaborators across the world.
Others:
Dr. Abdo Najy, thank you so much for being a great friend and mentor. You got me
through some of the hardest times in graduate school and helped train me both technically
and to think independently. You won the award for the smartest person in the world and
you earn that title every day. You are always there for me and I am truly honored to call
you a friend. I hope one day to be half the scientist and mentor that you are.
Dr. Bonnie Sloane, thank you so much for being so supportive of me and always willing
to sit down and talk to me and give me advice about my future in academia. I am truly
grateful to have you in the Pharmacology Department and will miss our talks.
Family:
Lastly, I would like to thank my parents for their continuous support over the course of my
PhD training and encouragement to reach my goals and never give up. Also, my twin
brother and my older sister for always being there for me and giving me constant support
and motivation.

vii

TABLE OF CONTENTS
Dedication ....................................................................................................................... ii
Acknowledgments......................................................................................................... iii
List of Tables ............................................................................................................... xiv
List of Figures .............................................................................................................. xv
Chapter 1: Introduction ................................................................................................. 1
1.1 Introduction: Fifty Shades of Fat ............................................................................... 1
1.2 Different Types of Adipose Tissue............................................................................. 1
1.3 Bone Marrow Fat and its Roles in Physiological Processes and Disease ................. 3
1.4 Adipocyte Artillery...................................................................................................... 6
1.4.1 Hormones ............................................................................................................... 6
1.4.2 Inflammatory Cytokines .......................................................................................... 8
1.4.3 Lipolysis ................................................................................................................. 9
1.5 Obesity-Cancer Link: The Concerning Problem ...................................................... 10
1.5.1 Role of Circulating Adipokines in Tumorigenesis and Tumor Progression ........... 11
1.5.2 Bone Marrow Adipocytes and Skeletal Metastasis ............................................... 13
1.6 Feeding the Enemy ................................................................................................. 13
1.6.1 Warburg Effect ..................................................................................................... 13
1.6.2 HIF-1α Signaling Pathways in Cancer .................................................................. 17
1.6.3 Adipocyte Artillery and their Effects on Metabolism .............................................. 21

viii

1.7 Current Therapeutic Options in Targeting Tumor Metabolism ................................. 23
1.7.1 Tools to regulate Glycolysis ................................................................................. 23
1.8 Conclusions ............................................................................................................. 25
Chapter 2: Hypothesis and Specific Aims ............................................................... 30
Chapter 3: Materials and Methods ............................................................................. 33
3.1 Materials .................................................................................................................. 33
3.2 Cell Lines ................................................................................................................ 34
3.3 Animals ................................................................................................................... 34
3.4 Diets ........................................................................................................................ 35
3.5 Intratibial and Subcutaneous Injections of Prostate Cancer Cells ........................... 35
3.6 Taqman RT-PCR Analyses ..................................................................................... 36
3.7 Transwell Co-Culture............................................................................................... 37
3.8 Direct Co-Culture..................................................................................................... 38
3.9 Co-Culture Conditioned Media Treatment ............................................................... 38
3.10 Immunoblot Analyses ............................................................................................ 38
3.11 Carbonic Anhydrase 9 Immunohistochemical Analyses ........................................ 39
3.12 Immunofluorescence Analyses.............................................................................. 39
3.13 ATP Analysis ......................................................................................................... 40
3.14 Assessment of Lactate Levels in Media ................................................................ 40
3.15 Seahorse Analysis................................................................................................. 41
ix

3.16 Determination of Mitochondrial Membrane Potential/Intrinsic Apoptosis ............... 41
3.17 Determination of Cell Viability ............................................................................... 41
3.18 Free Glycerol Assay Analysis ................................................................................ 42
3.19 Triglyceride Assay ................................................................................................. 42
3.20 Activation of HIF-1α in vitro ................................................................................... 42
3.21 siRNA Approaches ................................................................................................ 43
3.22 In silico Analysis .................................................................................................... 43
3.23 Statistical Analyses ............................................................................................... 44
3.24 Lipidomics Analyses .............................................................................................. 44
3.25 IL-1β Treatment and Inhibition .............................................................................. 44
3.26 EP Receptor Inhibition ........................................................................................... 45
3.27 PGE2 and 15-(S)-15 Methyl PGE2 Treatments..................................................... 45
3.28 SPHK1 Inhibition ................................................................................................... 46
3.29 S1P Receptor Inhibition......................................................................................... 46
3.30 S1P/S1P Receptor Agonist Treatments ................................................................ 46
3.31 Stable SPHK1 Overexpression in Tumor Cells ..................................................... 47
3.32 Clonogenic Assays ................................................................................................ 48
3.33 Mitochondrial Fractionation ................................................................................... 48
3.34 Chemotherapy Treatment ..................................................................................... 49
Chapter 4: Bone Marrow Adipocytes Promote the Warburg Phenotype in
Metastatic Prostate Cancer Cells Through the Activation of HIF-1α ...................... 50
x

4.1 Introduction ............................................................................................................. 50
4.2 Results .................................................................................................................... 53
4.2.1 In silico Analysis of Glycolysis-Associated Genes in Prostate Cancer Patients ... 53
4.2.2 Bone Marrow Adiposity Contributes to the in vivo Glycolytic Phenotype in Prostate
Bone Tumors ................................................................................................................. 54
4.2.3 Bone Marrow Adipocytes Alter the Metabolism of PCa Cells in vitro.................... 61
4.2.4 Functional Evidence of Enhanced Glycolytic Phenotype in Response to Marrow
Adipocytes..................................................................................................................... 65
4.2.5 Prostate Cancer Cells Stimulate Lipolysis in Adipocytes...................................... 70
4.2.6 Marrow Adipocytes Induce HIF-1α Signaling ....................................................... 80
4.2.7 HIF-1α Knockdown Inhibits the Acquisition of a Glycolytic Phenotype in PCa Cells
Exposed to Adipocytes .................................................................................................. 81
4.2.8 Adipocyte-Activated Pro-Survival and Chemoresistance Pathways in PCa Cells 87
4.3 Discussion ............................................................................................................... 89
Chapter 5: Bone Marrow Adipocyte-Derived Prostaglandin E2 Activates Canonical
PGE2 Signaling in Metastatic Prostate Cancer Cells ............................................... 98
5.1 Introduction ............................................................................................................. 98
5.2 Results .................................................................................................................. 100
5.2.1 In silico Analysis of Prostaglandin E2 Receptors, EP1-4, in Metastatic Prostate
Cancer Patients ........................................................................................................... 100
5.2.2 Adipocytes Exposed to Intraibially Injected Prostate Cancer Cells have Increased
Expression of COX-2 in vivo ....................................................................................... 101
5.2.3 Adipocytes Exposed to PCa Cells have Increased COX-2 Expression and
Elevated Levels of Secreted PGE2 in vitro.................................................................. 102

xi

5.2.4 Adipocyte COX-1 and COX-2 are Regulated by PCa Cell Secreted IL-1β
Stimulation of Lipolysis ................................................................................................ 105
5.2.5 Adipocyte-Derived PGE2 Activates the GSK3β/β-Catenin Pathway through the
EP1 Receptor .............................................................................................................. 106
5.2.6 Activation of the EP1 Receptor in Tumor Cells by Adipocyte-Derived PGE2 Leads
to HIF-1α Activation ..................................................................................................... 108
5.3 Discussion ............................................................................................................. 109
Chapter 6: Conclusions and Future Directions ...................................................... 116
6.1 Conclusions ........................................................................................................... 116
6.2 Future Directions ................................................................................................... 118
6.2.1 Pro-Survival Mechanisms/Chemoresistance ...................................................... 119
6.3 Clinical Relevance/Novel Therapeutic Targets ...................................................... 120
Appendix .................................................................................................................... 123
A.1 Introduction ........................................................................................................... 123
A.2 Results .................................................................................................................. 125
A.2.1 Sphingosine Kinase 1 (SPHK1) is Upregulated in Adipocytes Exposed to
Intratibially Injected Prostate Cancer Cells in vivo ....................................................... 125
A.2.2 SPHK1 Expression and S1P Levels are Elevated in Adipocytes Exposed to PCa
Cells in vitro ................................................................................................................. 125
A.2.3 Inhibition of Adipocyte SPHK1 on PCa Cell Metabolism .................................... 128
A.2.4 Sphingosine-1-Phosphate Rece ........................................................................ 128
A.2.5 S1P Receptor 1-5 Expression Levels in Tumor Cells Exposed to Adipocytes in
vitro ............................................................................................................................. 128

xii

A.2.6 S1P May Act as a Necessary, but not Sufficient, Cofactor for HIF-1α Activation in
Tumor Cells ................................................................................................................. 129
A.2.7 Intrinsic SPHK1 Overexpression does not Activate a Hypoxic or Glycolytic
Phenotype in PCa Cells .............................................................................................. 130
A.2.8 Activation of Hormone Sensitive Lipase-Mediated Lipolysis by PCa Cells
Enhances SPHK1 Expression in Adipocytes............................................................... 134
A.3 Discussion ............................................................................................................ 137
References ................................................................................................................. 143
Abstract...................................................................................................................... 204
Autobiographical Statement .................................................................................... 207

xiii

LIST OF TABLES
Chapter 1: Introduction
Table 1: Clinical Trials of Drugs Targeting Tumor Metabolism ..................................... 27
Chapter 4: Bone Marrow Adipocytes Promote the Warburg Phenotype in
Metastatic Prostate Cancer Cells through the Activation of HIF-1α
Table 1: In silico analysis of glycolytic genes in metastatic PCa .................................. 56
Table 2: In silico analysis of additional glycolytic genes in metastatic PCa ................. 58
Chapter 5: Bone Marrow Adipocyte-Derived Prostaglandin E2 Activates Canonical
PGE2 Signaling in Metastatic Prostate Cancer Cells through the EP1, EP2, and EP4
Receptors
Table 1: EP1-4 Primer Sequences ............................................................................ 110

xiv

LIST OF FIGURES
Chapter 1: Introduction
Figure 1: Effects of enhanced glycolysis on tumor cell signaling ................................. 28
Chapter 4: Bone Marrow Adipocytes Promote the Warburg Phenotype in
Metastatic Prostate Cancer Cells through the Activation of HIF-1α
Figure 1: Warburg Effect-Associated Genes in vivo and in silico ................................ 57
Figure 2: CBioportal analysis of glycolytic genes ........................................................ 59
Figure 3: Glycolytic genes in tumors from mice switched from HFD to LFD ................ 62
Figure 4: Warburg Effect genes in PCa cells in co-culture with adipocytes in vitro ..... 63
Figure 5: Effect of bone marrow stromal cells on Warburg gene induction ................. 66
Figure 6: Adipocytes enhance Warburg Effect in DU145/C4-2B cells ......................... 67
Figure 7: Warburg Effect is mediated through paracrine signaling .............................. 68
Figure 8: Warburg phenotype is driven by adipocyte-supplied lipids ........................... 69
Figure 9: Decreased oxidative phosphorylation in prostate cancer cells exposed to
bone marrow adipocyte-derived factors ........................................................................ 71
Figure 10: Expression of mitochondrial enzymes in intratibial prostate tumors is not
affected by HFD-induced marrow adiposity................................................................... 72
Figure 11: Prostate cancer cells stimulate lipolysis in bone marrow adipocytes ......... 74
Figure 12: Taqman RT-PCR analysis of adipose triglyceride lipase (ATGL) expression
in adipocytes grown in transwell co-culture with PC3 or ARCaP(M) cells ..................... 75
Figure 13: Atglistatin does not prevent lipid accumulation by the tumor cells and is not
sufficient to prevent the induction of Warburg phenotype.............................................. 76
Figure 14: Inhibition of adipocyte lipolysis does not reduce the expression of lipid
transporters and hypoxia-associated genes in tumor cells ............................................ 78
xv

Figure 15: Inhibition of adipocyte lipolysis does not reduce the expression of lipid
transporters and Warburg-associated genes in tumor cells .......................................... 79
Figure 16: Bone marrow adiposity enhances HIF-1α signaling in PCa cells in in vivo
prostate tumors ............................................................................................................. 82
Figure 17: Bone marrow adipocytes activate HIF-1α Signaling in PCa Cells in vitro .. 83
Figure 18: siRNA-mediated knockdown of HIF-1α abrogates bone marrow adipocyteinduced Warburg phenotype in PC3 cells ..................................................................... 84
Figure 19: Adipocytes induce HIF-1α signaling in ARCaP(M) cells ............................. 85
Figure 20: Tumor cells exposed to bone marrow adipocytes have increased clonogenic
potential......................................................................................................................... 86
Figure 21: Hexokinase 2 localizes to the mitochondria in tumor cells exposed to bone
marrow adipocytes or under hypoxic conditions ............................................................ 90
Figure 22: PC3 cells are more resistant to Docetaxel treatment under hypoxic
conditions ...................................................................................................................... 91
Chapter 5: Bone Marrow Adipocyte-Derived Prostaglandin E2 Activates Canonical
PGE2 Signaling in Metastatic Prostate Cancer Cells through the EP1, EP2, and EP4
Receptors
Figure 1: Gene targets of GSK3β/β-catenin signaling through the prostaglandin
receptors are upregulated in patients with metastatic prostate cancer ........................ 103
Figure 2: COX-2 expression and activity increases in bone marrow adipocytes
exposed to tumor cells in vitro ..................................................................................... 104
Figure 3: COX-1 and COX-2 are regulated by tumor-secreted IL-1β ........................ 107
Figure 4: EP1 is upregulated in PC3 and ARCaP(M) cells exposed to bone marrow
adipocytes in vitro and in vivo ..................................................................................... 111
Figure 5: Bone marrow adipocytes activate the GSK3β/β-catenin pathway in PCa cells
through the EP receptors ............................................................................................ 113
Figure 6: Activation of the EP1 receptor in PCa cells leads to the activation of HIF-1α
signaling ...................................................................................................................... 114
xvi

Appendix: Adipocyte-Derived Sphingosine-1-1Phosphate does not affect the
Metabolic Phenotype of Metastatic Prostate Cancer Cells
Figure 1: SPHK1 expression increases in bone marrow adipocytes exposed to
prostate cancer in vivo ................................................................................................ 127
Figure 2: SPHK1 expression and activity increases in adipocytes exposed to prostate
cancer cells in vitro ...................................................................................................... 131
Figure 3: SPHK1 inhibition using SKI2 abrogates metabolic effects of adipocytes on
prostate cancer cells ................................................................................................... 132
Figure 4: S1P receptor expression status in patients with metastatic prostate cancer
compared to primary prostate cancer and PCa cells exposed to bone marrow
adipocytes in vitro........................................................................................................ 133
Figure 5: S1PR inhibition does not abrogate effects of adipocytes on tumor
metabolism .................................................................................................................. 135
Figure 6: Treatment with S1P is not sufficient to induce Warburg phenotype in PCa
cells as seen by bone marrow adipocytes ................................................................... 136
Figure 7: Overexpression of SPHK1 in PC3 cells does not affect the metabolic
phenotype ................................................................................................................... 138
Figure 8: Adipocyte SPHK1 expression is regulated by the induction of HSL-mediated
lipolysis by tumor cells................................................................................................. 139

xvii

1

CHAPTER 1: INTRODUCTION
1.1 INTRODUCTION: FIFTY SHADES OF FAT
Adipose tissue is a versatile organ, crucial for maintaining homeostasis by storing and
dispersing energy, producing and releasing adipokines and cytokines, with the ability to
influence other cells of a body in autocrine, paracrine and endocrine fashion [1]. This
highly metabolically active tissue is distributed throughout the body in discrete depots,
and its development, expansion and energy balance are regulated by an integrated
network of genetic, environmental, epigenetic and pharmacological factors [1, 2]. When
unbalanced, or when caloric intake exceeds energy expenditure, adipose tissue becomes
problematic and can detrimentally affect physiological processes.
1.2 Different types of adipose tissue: Brown vs. White Fat
Long-thought to have homogenous characteristics throughout the entire body,
adipose tissue actually exhibits depot-specific differences in metabolic profiles, and these
variations appear to correlate with susceptibility to obesity and specific metabolic
disorders [1]. In addition to its localization-based classification, adipose tissue is also
commonly categorized based on its coloration, and is divided into brown, white and beige
tissues with distinct functional, metabolic and endocrine differences [1].
The main role of brown adipose tissue (BAT) is to provide non-shivering
thermogenesis by the means of energy expenditure. mitochondria and cytochrome
content are abundant in BAT, a characteristic that attributes, in part, to the color and name
of BAT [3]. Brown adipocytes are multilocular, meaning they contain multiple fat droplets.
Uniquely, they express an uncoupling protein-1 (UCP1), the function of which is to
uncouple respiratory chain proteins in the abundant cellular mitochondria.

The
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uncoupling of respiratory chain proteins results in the metabolic substrates being oxidized
purely for the purpose of heat energy dissipation [3]. The progenitors of BAT can be traced
through the expression of myogenic factor 5 (Myf5) that is also expressed in skeletal
myocytes [4]. In humans, BAT develops during the fetal stage and is the most abundant
throughout the body at infancy and throughout the first decade of life. It eventually
declines in its abundance and retires predominately to areas surrounding vital organs
such as suprarenal and para-aortic [3, 5] and the supraclavicular area [6]. Cold
temperature [6-8] and β-adrenergic stimulation [9, 10] can trigger the expression of UCP1,
induction of substrate oxidation and activation of BAT. Increased expression of UCP1 in
rodents caused by overfeeding sprouted a theory of the relevance of BAT in evading
obesity. The fact that activity of BAT declines in overweight individuals [7, 11] supports
the evidence of inverse correlation between propensity to obesity and abundance of BAT
[12, 13].
In contrast to BAT, the white adipose tissue (WAT) development begins in utero
and continues to evolve throughout life [14, 15]. WAT serves as primary energy storage
and based on its location in the body, it is often referred to as subcutaneous or visceral
(intra-abdominal) fat that includes mesenteric, epididymal and perirenal depots. In
humans, subcutaneous fat develops prior to visceral [16] and can be distinctively different
in its pathophysiological processes [17]. Importantly, the morphology of white adipocytes
differs from brown as they are unilocular cells containing less mitochondria and do not
express UCP1 [18].
“Browning” is a phenomenon described when adipocytes located in the typical
WAT sites switch from anabolic to catabolic mechanism producing “beige” adipocytes
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[19]. They do so by developing multilocular morphology with increased number of
mitochondria and expression of UCP1. This occurrence has been well described in
rodents and is triggered by cold exposure and β3-adrenergic stimulation [20-22]. Although
closely resembling the brown fat morphology, BAT occurring in the WAT depots does not
express the same lineage marker, Myf5, as a “classic BAT” [23]. There has been a
growing interest in understanding the capacity of brown and beige adipocytes to
counteract obesity, diabetes and other metabolic diseases [19]. Strategies are being
developed to selectively enhance respiratory uncoupling in adipose tissue to induce
weight loss and reverse obesity-driven pathological processes.
1.3 Bone marrow fat and its roles in physiological processes and disease
Bone marrow fat, known as yellow adipose tissue (YAT), represents a depot
dispersed throughout the bone marrow with primary localization to trabecular cavities [24,
25], and often viewed as having mixed characteristics of both WAT and BAT [25-27]. No
longer considered just a “space-filler”, YAT is recognized as a highly active organ,
functions of which extend far beyond the storage of triglycerides and lipid metabolism,
and they include systemic energy regulation and management of insulin sensitivity [28,
29]. Importantly, the systemic changes related to adipose tissue homeostasis critically
affect glucose and energy balance [30] and reciprocally influence bone health. If the
stability in signaling pathways that integrate bone remodeling and energy metabolism
gets perturbed by metabolic events related to age and obesity, the physiological
processes in the bone, like osteogenesis and hematopoiesis are critically affected [25,
28]. The latter results in susceptibility to pro-inflammatory events and dysregulated bone
remodeling [24].
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It is well-established, that during the normal aging process, healthy, hematopoietically
active red marrow of the bone is progressively replaced by the fatty yellow marrow [2426]. There is also increasing evidence that obesity and associated metabolic pathologies
can have detrimental effects on bone health that go beyond age-driven changes in
skeletal homeostasis [24, 31, 32]. Until recently, obesity was thought to have a protective
effect on bone metabolism due to positive impact of body weight on bone formation [31,
33]. Current evidence suggests that percent body fat, waist circumference, and waist-tohip ratio correlate with the risk of osteoporotic fractures, especially in men, who have
larger amounts of marrow fat than age-matched women [34-36]. These epidemiological
data are mirrored by the results of animal studies, where marrow adiposity has been
shown to result in decreases in trabecular bone volume and overall reduced bone mineral
density (BMD) [31, 37, 38]. Despite these findings, the relationship between adiposity and
bone turnover remains controversial and additional, controlled studies are needed to truly
understand the effects of obesity on bone health in humans.
There is growing clinical and epidemiological evidence that metabolic syndrome
(MetS), a cluster of metabolic abnormalities that include abdominal obesity,
hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure,
and glucose intolerance [39-41] is a strong contributor to marrow adiposity. This condition
is highly prevalent in the United States as demonstrated by its presence in approximately
25-30% of adults over the age of 18 years [42, 43], and is a strong risk factor for
cardiovascular disease, diabetes and stroke [44, 45]. A study of metabolic syndrome in
normal-weight individuals with only regional accumulation of fat (visceral/abdominal and
inter-muscular) was associated with fasting hyperinsulinemia, a risk factor for type 2
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diabetes mellitus (T2DM) [46, 47]. Importantly, general obesity was shown to correlate
with accumulation of marrow fat in both control and diabetic individuals [48]; however,
only in diabetic patients, marrow adiposity was correlated with visceral adipose tissue
(VAT) [48]. This finding pinpoints the potential importance of visceral fat depot in bone
health, and its implications for development of diabetes. This also underlines the
importance of distinguishing VAT from other adipose tissues in studies investigating the
impact of obesity and metabolic disorders on skeletal health, because using the central
obesity measures continues to lead to inconsistent results [49].
One specific metabolic consequence of excess adiposity is diabetes, a condition
highly linked with marrow adiposity [48, 50] and profound effects on bone health [51, 52].
Numerous reports suggest that the following are potential biological links between obesity
and diabetes: changes in insulin levels, altered calcium metabolism, reduced renal
function, vitamin D regulation, higher concentrations of inflammatory molecules and
collagen glycation products, polypeptides, such as osteocalcin and osteopontin, and
certain adipokines [27-29, 53, 54]. Increases in circulating levels of bone resorption
markers such as Tartrate Resistant Acid Phosphatase (TRAP 5b) and Cathepsin K
(CTSK) have been reported in diabetic patients [55] and animal experimental models of
diabetes [56, 57]. Serum levels of osteocalcin, an osteoblast-specific polypeptide, were
reported to be inversely correlated with adiposity and measures of insulin resistance [58,
59]. In contrast, a positive association with insulin sensitivity and HDL cholesterol was
demonstrated for osteoprotegerin, a known inhibitor of bone resorption, further evidence
of clear association between the metabolic features and bone degradation [60]. It is
noteworthy, similar to other fat depots, adipogenesis in the bone marrow is under the

6

regulation of PPARγ [28]. This has led to serious concerns in terms of treatment with antidiabetic thiazolidinedione drugs, which were shown to induce bone marrow adiposity [61],
likely even further exacerbating the environment already altered by diabetes itself. It is
also important to keep in mind that marrow adiposity associated with diabetes appears to
be characterized by low unsaturation and high saturation levels of fats [48, 62]. This
suggests that perhaps apart from overall increase in adiposity, the composition of marrow
fat might be a more important factor in bone health, and potentially other physiological
processes, a phenomenon that warrants further investigations.
1.4 ADIPOCYTE ARTILLERY
Contrary to the previous view of adipocytes being metabolically inert, growing
evidence from the last decades of research has revealed that they are in fact metabolically
active cells highly involved in the uptake, production, and secretion of many different
factors with systemic implications [63]. Through the production of lipids and secretion of
hormones, cytokines or adipokines, adipocytes have the ability to influence neighboring
cells within their microenvironment and throughout the body as a whole, working as a
functional paracrine and endocrine tissue [1, 2, 63]. \
1.4.1 Hormones
The two most commonly studied hormones secreted by adipocytes are adiponectin
and leptin. Adiponectin is a protein hormone responsible for regulating multiple metabolic
processes [64]. This hormone is secreted primarily by adipocytes and is released into
the bloodstream where it binds to adiponectin receptor 1 (AdipoR1), adiponectin receptor
2 (AdipoR2), and has the potential to bind a membrane receptor, T-cadherin [65, 66].
Adiponectin-receptor binding results in activation of AMP-activated protein kinase
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(AMPK) and subsequent signaling through peroxisome proliferator-activated receptor
(PPAR)-α transcription factor [67-69]. Adiponectin levels have been associated with many
different metabolic diseases. Interestingly, adiponectin is shown to be down-regulated in
patients with obesity and/or diabetes and is upregulated upon treatment with insulinsensitizers [70, 71]. It was recently discovered that bone marrow adipose tissue (MAT),
in response to caloric restriction and chemotherapy, secretes adiponectin at a much
larger scale comparing to the levels secreted by WAT, suggesting that MAT-derived
adiponectin is circulated throughout the body, exhibiting endocrine and metabolic effects
on cells [72]. Circulating adiponectin is shown to be decreased in patients with T2DM,
cardiovascular disease, liver disease, and hypertension [73-75]. In addition, adiponectin
binding to AdipoR1 and AdipoR2 has been shown to have anti-diabetic effects, which
further underlines positive effects of this hormone on metabolic homeostasis [76].
Leptin, also known as the “satiety hormone,” is the other most commonly studied
factor produced and secreted by adipocytes [77, 78]. Canonical leptin signaling occurs
through the leptin receptor which, upon the binding of its ligand, dimerizes and induces
phosphorylation and activation of Janus tyrosine kinase-2 (JAK2) [79]. This leads to
STAT3 phosphorylation and downstream transcription of leptin target genes. Mutations
in the gene encoding leptin or its receptors in the hypothalamus result in disturbed leptin
signaling and consequently promote hyperphagic obesity, diabetes mellitus, and
neuroendocrine dysfunctions [80].

Interestingly, although leptin is secreted by

adipocytes to inhibit hunger, this adipokine is produced and secreted at high rates in
obese individuals [81]. Enhanced leptin signaling has been implicated in many different
cancers [82]. Leptin binding to its receptor on mammary cancer cells has been shown to
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play a role in maintaining cancer stem cell phenotype and promoting stem cell-like
properties of triple-negative breast cancers [83].
1.4.2 Inflammatory Cytokines
Obesity is characterized as a state of chronic inflammation. It has been speculated
that expansion of adipose tissue occurring in obesity results in oxygen deprivation of
adipocytes which are most distant from the capillary network [84]. This hypoxia triggers
the activation of hypoxia inducible factor 1-alpha (HIF-1α), which in turn, signals for the
macrophage infiltration and induction of inflammation [85]. There is growing evidence that
multiple pro- and anti-inflammatory cytokines in obese adipose tissue form a functional
circuitry that regulates local and systemic glucose tolerance and insulin sensitivity [86].
These cytokines are secreted by adipocytes, macrophages and other cell types residing
in the inflamed tissue [86, 87].
TNF- was one of the first identified WAT-derived proinflammatory cytokines,
thought to be primarily secreted by myeloid cells via activation of MAPK and NFB
signaling pathways and stimulating the release of other inflammatory cytokines, such as
IL-1 and IL-6 [88]. It has since been determined that adipocytes themselves are a
significant source of TNF-, whose induction in fat cells occurs in response to free fatty
acids (FFA), and activation of JNK signaling pathway [89]. TNF-α, in turn, via activation
of ERK signaling pathway stimulates lipolysis, a process resulting in a positive feedback
mechanism that further contributes to the chronic state of obesity-induced inflammation
[90]. The abundant secretion of this TNF-α has been directly linked to obesity-associated
insulin resistance [89, 91] and tumorigenesis [92].
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IL-6 is a pleiotropic cytokine, that is released in response to hypoxic stimulation of
adipocytes [93] and its secretion is associated with insulin resistance [94], immune
responses and host defense mechanisms [88], as well as tumorigenesis and metastatic
potential [95]. Approximately 30% of circulating IL-6 levels are thought to originate from
adipose tissue, categorizing it as an adipokine [88]. Circulating levels of IL-6 appear to
correlate with increased body mass, waist circumference and FFA concentrations;
however, its functions in obesity and insulin resistance in regards to tissue and metabolic
rate remain controversial [88].
IL-1 is another important regulator of inflammatory responses whose levels are
elevated in obesity and associated metabolic disorders [86]. A blockade of IL-1 activity
in animal models and human subjects with neutralizing antibodies to this cytokine or its
receptor improve insulin sensitivity and help to treat T2DM [86, 96, 97]. However, IL-1deficient animals have reported glucose intolerance, while IL-1RA-null mice are resistant
to diet induced obesity, findings revealing the need for further investigations of proinflammatory axes in obesity and metabolic disorders.
1.4.3 Lipolysis
Key components released by adipocytes that can influence metabolic processes
in neighboring cells are glycerol and FFA. In times of excess energy, fatty acids are stored
as triglycerides, forming lipid droplets that are housed in the specialized domains within
the endoplasmic reticulum [98, 99].

Fat cells are constantly both synthesizing

triglycerides, and breaking them down to glycerol and fatty acids during a catabolic
process known as lipolysis [100]. This process is driven by activation of the rate-limiting
enzyme, adipose triglyceride lipase (ATGL), phosphorylation and activation of hormone-
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sensitive lipase (HSL), and monoacylglycerol hydrolysis by monoglyceride lipase (MGL).
Lipolysis and its rates are regulated by hormonal and biochemical signaling. The process
of lipid breakdown is stimulated through the binding of catecholamines, epinephrine and
norepinephrine, to β-adrenergic receptors 1 and 2 and the α-adrenergic receptor [101]. A
key process for lipolysis and lipase regulation occurs through activation or suppression
of protein kinase A (PKA) [102, 103]. PKA has the ability to both activate HSL and also
facilitate the trafficking of proteins involved in lipolysis [104]. ATGL, on the other hand, is
not a direct target of PKA and has high affinity for triacylglycerides and no activity against
either diacylglycerides or monoacylglycerides [105]. HSL-null mice exhibit severely
impaired glycerol release and large accumulation of DAG in several tissues, confirming
that this lipase is a rate-limiting enzyme in DAG hydrolysis [106]. In contrast to HSL,
ATGL deficiency leads to severe lipid-associated phenotype with high lipid accumulation,
poor lipid mobilization, reduced biochemically-induced lipolysis, and myopathy [107-112],
indicating its essential function in lipolysis. Absence of ATGL reduces fatty acid release
from adipose tissue by 75% and a mutation in ATGL gene in humans causes lipid storage
dysfunction called neutral lipid storage disease with myopathy (NLSDM) [113, 114].
Because lipolysis is such a fundamental and crucial process for energy homeostasis and
metabolism, dysfunction in this process has been suggested as a hallmark to the onset
or maintenance of obesity [115].
1.5 OBESITY-CANCER LINK: THE CONCERNING PROBLEM
Currently, obesity is a global epidemic characterized by excess adipocyte size and
numbers. Recent reports indicate that more than two thirds of Americans are overweight
or obese and this number has been increasing for decades [116, 117]. Obesity is a
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serious health concern and a major risk for the development and onset of a multitude of
different cancers [118-120]. Studies have demonstrated that the fraction of patients that
have cancer caused by excess weight has reached about 20% of all cancers [120]. The
Million Women Study reported that around 50% of cancers in postmenopausal women
are linked to obesity [121]. For the high-risk obese patients in general, the most common
malignancies appear to be esophageal adenocarcinoma, colorectal, postmenopausal
breast, prostate, and renal cancers [122, 123]. Malignant melanoma, thyroid cancers,
leukemias, non-Hodgkin’s lymphomas, and multiple myelomas have been associated
with obesity but to a lesser extent [124, 125].
1.5.1 Role of Circulating Adipokines in Tumorigenesis and Tumor Progression
As experimental and epidemiological evidence linking obesity with cancer risk or
recurrence increases, the mechanisms behind this association are still largely unknown.
It is becoming increasingly accepted that dysregulation of adipocyte function and obesitydriven chronic inflammation are the main culprits in adiposity-induced tumorigenesis [118,
126]. This is particularly evident in cancers that grow in adipocyte-rich environments like
breast carcinomas, or cancers that have propensity to metastasize to fat-rich sites, such
as ovarian or gastric malignancies [127]. In addition to acting as local paracrine signaling
molecules, adipokines also exert systemic effects and allow for communication with
distant sites. The increased levels of adipose tissue-derived factors, such as TNF-α, IL6, IL-8, macrophage chemoattractant protein (MCP-1), and leptin and their role in tumor
progression have been well-documented [82, 127].
Levels of circulating leptin are enhanced in obese individuals, and elevated leptin
is a poor prognostic factor for breast cancer patients, underlining the role of this adipokine

12

in tumor progression [128]. Leptin expression is higher in patients that have prostate
cancer compared to benign prostate hyperplasia and higher in patients with advanced,
metastatic disease compared to patients with localized, early stage prostate cancer,
implicating leptin expression as a biomarker for prostate cancer staging and prognosis
[129, 130]. Notably, a polymorphism associated with an overexpression of the mutated
leptin in some patients has been suggested as a risk factor for prostate cancer [131].
Furthermore, increased levels of leptin receptor were reported in breast cancer tissue as
compared to normal tissue and suggested to correlate with immune response,
angiogenesis, reproduction, growth factor signaling and lipid metabolism pathways [132135]. In gastric cancer, leptin has been shown to increase tumor invasiveness by
activating Rho/ROCK signaling pathways [136] while inhibitory effects of this adipokine
on mitochondrial respiration have been linked with colon cancer progression [137].
In contrast to leptin, adiponectin, an adipokine with insulin-sensitizing effects, has
been suggested to have anti-tumor effects [127, 138]. Low levels of adiponectin, as
observed in obese individuals, have been correlated with an increased risk of prostate
cancer [139]. Treatment with recombinant adiponectin has resulted in anti-tumor effects
in some cancer types such as fibrosarcoma, myelomonocytic leukemia, and breast
carcinoma [140-143].

Similarly, inhibitory effects of adiponectin on survival and

proliferation of prostate cancer cells was reported, with anti-tumor effects linked to the
high molecular form (HMW) of this adipokine, which is known to be responsible for its
biological activity [144, 145]. These results were shown both in androgen-dependent
LNCaP-FGC cells and androgen-independent DU145 cells, indicating a global effect on
prostate cancer cells regardless of androgen receptor status.
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1.5.2 Bone Marrow Adipocytes and Skeletal Metastases
Although numerous studies have identified obesity as a risk factor for various
cancers [146-149], it is only recently that accumulation of bone marrow fat has emerged
as a risk factor for the development and progression of skeletal metastases, particularly
from prostate cancer [24, 150]. Specifically, we and others have shown that marrow
adipocytes mediate translocation of the lipids to the metastatic cancer cells [151, 152].
These adipocyte-supplied lipids serve as an energy source for cancer cells, and
consequently induce tumor cell proliferation, motility and invasion [150, 153]. Moreover,
fatty acid binding protein 4 (FABP4), a lipid transporter expressed predominantly in
adipocytes, macrophages, and endothelial cells [154], and originally identified as a key
mediator of adipocyte-tumor interactions in ovarian cancer [127, 155], is highly
upregulated in metastatic prostate cancer cells interacting with adipocytes [150]. We
have shown that through its interplay with PPARγ and IL-1β, FABP4 is involved in driving
the aggressiveness of prostate tumors in bone [150].

Our studies have also

demonstrated that additional pro-inflammatory factors such as cyclooxygenase-2 (COX2) and MCP-1 are highly induced in metastatic tumor cells under conditions of high
marrow adiposity [24]. This underlines the interaction between the lipid-driven and the
inflammatory pathways in bone and offers new avenues for investigation of mechanisms
behind development and progression of skeletal metastases.
1.6 FEEDING THE ENEMY
1.6.1 Warburg Effect
The role of adipocytes in regulating tumor metabolism is largely understudied and
not well-understood. The growth-, proliferation-, and survival-promoting effects of fat cells
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on the tumor cells have been clearly demonstrated in breast, prostate, gastric, colon and
ovarian cancers [127]; however, little is known about the contribution of altered tumor
metabolism to these effects. A recent publication by Nieman et al. showed that ovarian
cancer cells utilize adipocytes to gain energy for rapid division by inducing fat cell-driven
lipolysis and increasing availability of lipids for uptake by the tumor cells [155].
Subsequent to lipid uptake, there is an overexpression of fatty acid transporter, FABP4,
and significant elevation of -oxidation, which can be blocked by the treatment with
inhibitor of carnitine-palmitoyltransferase 1 (CPT-1), etomoxir [155]. Notably, -oxidation
has also been shown to be a main source of energy in prostate cancer cells [156], further
suggesting that metabolic reprogramming may be playing an important role in
tumorigenesis.
For most of the normal cells in the human body, glucose is an essential energy
source. In the presence of oxygen glucose is broken down to pyruvate, which enters the
mitochondria and is further oxidized to carbon dioxide with the release of energy in the
form of ATP [157].

In the absence of oxygen, normal cells will produce high rates of

lactate and undergo a metabolic shift to a more glycolytic phenotype. It has been well
documented that unlike normal cells, tumor cells show high rates of glycolysis and lactate
production, regardless of the presence or absence of oxygen [158]. This metabolic switch
to aerobic glycolysis, also known as the Warburg Effect, provides energy and essential
carbon sources for lipogenesis and nutrient production for the rapidly dividing cancer cells
[159, 160]. This enhanced glycolytic phenotype was originally postulated to be a direct
effect of mitochondrial dysfunction within cancer cells [161]. Under normal physiological
conditions ATP is generated through oxidative phosphorylation in the mitochondria in
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which acetyl-CoA is oxidized to CO2, releasing energy in the form ATP [162]. It has been
shown that oncogenic transformation leads to an increase in glycolytic genes, while tumor
suppressor proteins induce expression of oxidative phosphorylation (OxPhos) genes,
showing the implications of glycolysis in carcinogenesis [163, 164].
Many of the enzymes responsible for glucose metabolism have significant
functions that are non-glycolytic and tumor promoting [165]. Specifically, it was revealed
that hexokinase II (HKII) has an anti-apoptotic effect on the mitochondria by binding to
the mitochondrial membrane, antagonizing interaction with pro-apoptotic factors Bad and
Bax [166-168]. Along the same lines, pyruvate kinase M2 (PKM2) was shown to have
non-glycolytic functions in facilitating tumor survival [169, 170]. PKM2 appears to be
activated through epidermal growth factor receptor (EGFR) signaling and obese patients
have higher levels of serum heparin-binding epidermal-like growth factor, which is able to
activate EGFR [171, 172]. Other functions of PKM2 include the phosphorylation of histone
H3 and releasing histone deacytelase 3, which leads to induction of many cell cycle genes
including cyclin D and metabolic regulator c-MYC [173]. PKM2 is also known to act as a
transcriptional regulator through its interactions with Oct4, a transcription factor that drives
the expression of many genes in tumorigenesis and nuclear signaling [174, 175].
Glycolysis is much less energy efficient compared to the OxPhos pathway as it
generates two net ATP molecules, versus 36 molecules of ATP produced by the OxPhos
pathway. Consequently, cancer cells must undergo very high rates of glycolysis in order
to generate a large amount of ATP quickly. Interestingly, cells utilizing aerobic glycolysis
have high ratios of ATP/ADP and NADH/NAD+ even when proliferating at high rates
[176]. The aerobic glycolytic phenotype is important for tumor progression through the
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following postulates: 1) high rates of lactate production and secretion can break down
and degrade the surrounding extracellular matrix and aid tumor expansion and
metastasis; 2) enhanced glycolysis supplies an abundance of ATP to the cancer cells;
and 3) associated mitochondrial dysregulation inhibits or reduces apoptosis [177-179]. It
has also been shown that aerobic glycolysis creates byproducts that increase the ability
of the cells to produce precursors for biosynthesis of multiple different macromolecules
essential for rapid division such as lipids, nucleic acids, and proteins [180]. Also, the
generated lactate can create a toxic environment for immune cells, contributing to
decreased immunosurveillance and thus the ability of the tumor to hide from an immune
response within its microenvironment and prevent detection [181].

Excess lactate

production has also been implicated in the stimulation of endothelial cells surrounding the
tumor to allow vascularization of the tumor and to provide nutrients through the circulation
[182, 183].
It is known that the transcription factor c-MYC acts as a master regulator of cellular
metabolism by actively transcribing genes associated with glycolysis. Specifically, it has
been shown that c-MYC upregulates lactate dehydrogenase alpha (LDH-α), an enzyme
crucial for the conversion of pyruvate to lactate during the Warburg Effect [184, 185]. The
c-MYC transcription factor is also known to regulate key proteins involved in both nucleic
acid synthesis and fatty acid synthesis, processes utilized by tumor cells to meet the
demands of rapid cellular division, which underlines its role as a crucial regulator of
cellular metabolism [186, 187].

Furthermore, overexpression of c-MYC has been

correlated with upregulation of pyruvate kinase M2, the splice variant most commonly
seen in tumor cells during aerobic glycolysis [188-190]. The M2 isoform of pyruvate
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kinase is overexpressed in cancer cells through c-MYC-regulated overexpression of
heterogeneous nuclear ribonucleoprotein 1 and 2 (hnRNPA1 and hnRNPA2). These
ribonucleoproteins preferentially splice the M2 isoform over the M1 isoform, which is
critical for aerobic glycolysis [188, 191]. There is a proposed positive feedback in which
PKM2 is upregulated by c-MYC and, in turn, PKM2 is involved in the upregulation of cMYC [192]. Notably, c-MYC has been shown to be overexpressed in an estimated 50%
of all human cancers [193, 194].
Along with an enhanced glycolytic phenotype, tumorigenesis is often associated
with mitochondrial dysfunction [195].

Mitochondria become dysfunctional when the

mitochondrial DNA (mtDNA) is reduced or mutated and obese individuals have been
shown to have a reduction in mitochondrial DNA in adipocytes [196]. Dysregulation in
mitochondrial activity has also been shown to play a role in the inhibition of tumor
suppressor protein p53, leading to aberrant proliferation checkpoints and tumorigenesis
[197]. There is also emerging evidence demonstrating that obesity-induced adipokines
promote mitochondrial defects and promote glycolytic phenotype in normal tissue,
thereby driving tumorigenesis [198].
1.6.2 HIF-1α Signaling Pathways in Cancer
Anaerobic respiration, a hallmark of tumorigenesis, drives a hypoxic phenotype in
cancer cells even in the presence of oxygen [199].

Hypoxic signaling occurs when

transcription factor HIF-1α becomes stabilized and translocates to the nucleus where it
binds to and activates hypoxic response elements (HRE) [200]. In normoxia, prolyl
hydroxylase domain (PHD) proteins hydrolyze HIF-1α, which is then ubiquitinated by Von
Hippel-Lindau (VHL) and targeted to the proteasome. However, under hypoxic conditions,
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PHD is inhibited and HIF-1α is stabilized and translocated to the nucleus where it
dimerizes with HIF-1 to activate hypoxia-responsive genes [201]. In addition to the
hypoxic effect seen in low oxygenated tissue, there is also an oxygen-independent HIF1α signaling in which HIF-1α becomes stabilized and activates target genes in the
presence or absence of oxygen [202].
The role of HIF-mediated signaling pathway in tumorigenesis and clinical response
to treatments is well established [203]. Many tumors have areas of low oxygenation or
intratumoral hypoxia. Patients with poorly oxygenated primary tumors have a higher risk
of both metastases and mortality due to a more aggressive cancer phenotype [204].
Elevated HIF-1α expression has been correlated to increased mortality risk in a plethora
of different cancers including solid tumors of the bladder, brain, breast, colon,
esophageal, head and neck, oropharynx, liver, lung, pancreas, skin, stomach, and uterus
as well as acute lymphocytic and myeloid leukemias [205].
HIF-1α acts as a transcriptional activator and regulates the expression of many
different glycolytic enzymes involved in metabolic reprogramming. Specifically, LDH-α,
the enzyme responsible for the high conversion of pyruvate to lactate in cancer cells, is
trans-activated only through HIF-1α transcriptional regulation [206]. Along with HIF-1α,
the HIF-2α isoform signals in a similar way, but trans-activates different target genes. A
study in renal cell carcinoma cells showed that HIF-1α and HIF-2α signaling converge at
genes involved in glucose transport [207], lipid metabolism [i.e., adipose differentiationrelated protein (ADRP)], pH homeostasis (i.e., carbonic anhydrase IX (CAIX)), interleukin
responses, (i.e., IL-6), and angiogenesis (i.e., VEGF) [208]. Interestingly, however, there
were many significant differences in gene regulation between HIF-1α and HIF-2α. This
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study also revealed that HIF-1α but not HIF-2α is highly involved in a glycolytic response,
functioning as a trans-activating factor for the following enzymes involved in glycolysis:
hexokinase1, hexokinase2 (HK2), phosphofructokinase (PFK), aldolase A (ALDA),
phosphoglycerate kinase 1 (PGK1), and LDH-α [208]. There has also been a proposed
feed-forward mechanism in which the Warburg Effect-associated enzyme PKM2 can act
as a co-activator for HIF-1α target gene transcription [209]. It was recently demonstrated
that Jumonji c domain-containing dioxygenase (JMJD5), is upregulated through HIF-1
signaling and that JMJD5 interacts with PKM2, enhancing its translocation to the nucleus
and is recruited to the LDH- promoter [210, 211]. The inhibition of JMJD5 causes a
decrease in glucose metabolism and lactate secretion associated with Warburg Effect
[210, 211].
HIFs do not only regulate glycolytic genes to promote a more glycolytic phenotype,
but they are also involved in mitochondrial effects and decreased OxPhos activity.
Among HIF target genes are microRNAs, particularly miR-210, which has been reported
to be overexpressed in hypoxia [212]. MicroRNAs bind to sequences in messenger RNA
and either inhibit their translation or, in some cases, initiate their degradation [213]. MiR210 targets the iron-sulfur cluster assembly enzyme (ISCU) gene, which is required for
the activity of complex I in the mitochondrial electron transport chain during oxidative
metabolism, the constituents of cytochrome c oxidase assembly protein (COX10), NADHdehydrogenase 1a subcomplex 4 (NDUFA4), and subunit D of succinate dehydrogenase
complex (SDHD) [214-218]. Accordingly, miR-210 has been labeled as a biomarker of
tumor hypoxia, and its high levels have been implicated in poor patient prognosis for
several cancers [219]. Because many of the targets of miR-210 affect mitochondrial
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activity, it is evident that this molecule plays a central role in cellular metabolism and
homeostasis. Notably, it was also reported that there is a positive feedback loop between
miR-210 and HIF-1α in human lung cancer cell lines, where miR-210 stabilizes HIF-1α
[220]. This leads to increased transcription of HIF-1α target genes and establishment of
hypoxic tumor microenvironment. In addition, lung cancer cells that overexpress miR210 have been shown to have decreased mitochondrial activity and increased glycolytic
phenotype, and exhibit elevated resistance to radiotherapy [217]. This decrease in βoxidation in parallel with increased HIF activity is important for tumor cell survival because
it prevents malignant cells from developing high levels of reactive oxygen species (ROS)
and allows them to survive under hypoxic stress.
Another important effect of hypoxia on tumor cells is the initiation of angiogenesis,
a process of formation of new blood vessels from pre-existing vasculature. Tumor growth
and metastatic progression depend heavily on angiogenesis for the continuing supply of
nutrients [221]. Accordingly, studies have shown that tumors with functional angiogenesis
grow much larger than those without proper vascularization and blood supply, and that
reduced blood supply often results in necrosis or apoptosis [222, 223]. The most wellknown pro-angiogenic factor regulated by HIF-1α is vascular endothelial growth factor
(VEGF) [224]. It has been shown that VEGF transcript and protein levels are upregulated
in response to hypoxia and that targeting HIF-1α with small-interfering RNA (siRNA)
significantly reduces VEGF gene and protein expression [225]. Interestingly, we have
previously demonstrated that treatment of tumor cells with media conditioned by bone
marrow adipocytes in vitro, as well as in vivo establishment of skeletal tumors under
conditions of high marrow adiposity result in significant upregulation of oxidative stress
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markers and VEGF, suggesting potential activation of HIF-1 [150]. Particularly important
to the obesity-cancer link might be the evidence, that obese patients have higher levels
of HIF-1α activity in adipocytes due to rapid proliferation and expansion of the fat cells
and an increase in VEGF expression [226-230]. VEGF alone has been implicated in
tumorigenesis through the stimulation of proliferative signaling pathways through the
vascular endothelial growth factor receptor (VEGFR) and through cancer stem cell
maintenance [231, 232]. Further studies are required to elucidate the role of adipose
tissue hypoxia and VEGF secretion in obesity on tumor initiation and maintenance.
1.6.3 Adipocyte Artillery and their Effects on Metabolism
Few studies have demonstrated the effects of adipocyte-derived factors on tumor
metabolism. The majority of reported studies focus on TNF-α, leptin, and lipids or lipolysis
products [233, 234].

A study utilizing genetically obese ob/ob mice showed an

association between TNF-α secretion and OxPhos dysregulation [235]. A marked
decrease in mitochondrial respiratory chain activity in liver cells of ob/ob mice was
reported. Also reported were elevated levels of TNF-α, inducible nitric oxide synthase
(iNOS), and tyrosine nitrated proteins correlated with increased adiposity.

It was

determined that ob/ob mice not only have diminished activity of OxPhos system, but also
a reduction in the assembly of the OxPhos subunits in the mitochondria to about 50-60%
[236]. Most of the decreases were seen in subunits transcribed by mitochondrial-DNA,
which was reduced by approximately 60% relative to control mice.
Along with TNF-α, adipocyte-secreted factors such as leptin and Wnt peptides can
also cause mitochondrial impairment [237, 238]. The observed effects of leptin appear
to not only result from canonical leptin signaling, but also from its non-canonical signals
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associated with crosstalk with both the phosphatidylinositol 3-kinase (PI3-K) pathway and
the Ras-dependent pathways [239]. These pathways are both commonly deregulated in
cancers and affect cellular survival, growth, and metabolism [240, 241]. PI3-K activation
leads to subsequent activation of the downstream target protein Akt, and PI3-K/Akt
signaling has been shown to directly regulate cellular metabolism [241]. Induction of this
pathway leads to the expression of glucose, amino acid, lipoprotein, and iron transporters
at the cellular surface [158]. Additional effects include stimulation of glycolytic enzymes
hexokinase and phosphofructokinase, increased transcription of glycolytic genes, and
relative increases in protein synthesis essential for rapid cellular division [242, 243].
It has been recently demonstrated, that Wnt signaling, which, when elevated, is
commonly associated with tumorigenesis and tumor survival, suppresses mitochondrial
respiration and cytochrome C oxidase activity [244]. An enhanced Wnt signaling through
the β-catenin pathway leads to the inhibition of cytochrome C oxidase subunits COXVIc,
COXVIIa, and COXVIIc, and this inhibition of mitochondrial activity results in an enhanced
glycolytic phenotype. It has been postulated that with higher adipocyte content, levels of
Wnt ligands are increased, leading to enhanced positive correlation with Wnt signaling in
neighboring cells [245, 246].
Little is known to date on how adipocyte-derived lipids directly influence tumor
metabolism; however, there is increasing evidence that lipids generated by the tumor cells
during lipogenesis modulate metabolic pathways in cancer cells and stimulate the
Warburg Effect.

One consequence of the Warburg Effect is an increase in lipid

biosynthesis, and de novo lipogenesis is, in fact, performed at high rates in cancer cells
[236]. An example of a bioactive lipid with implications for prostate tumorigenesis is
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sphingosine-1/2 phosphate (S-1/2P) [247, 248]. S1P is activated by the phosphorylation
of sphingosine by sphingosine kinase 1 or 2 (SK1 or SK2). S1P has been shown to induce
cell growth, survival, and migration and to play a role in variety of cancers [249]. Similarly,
upregulation of SK1 has been associated with glioblastomas, lung, thyroid, and breast
cancers [250-254]. Notably, S1P has also been shown to highly present in obese patients
compared to lean patients [255] and its potential involvement in obesity-driven
tumorigenesis calls for further investigations.
1.7 CURRENT THERAPEUTIC OPTIONS IN TARGETING TUMOR METABOLISM
1.7.1 Tools to Regulate Glycolysis
Because tumor metabolism is deregulated in almost all cancers, targeting
glycolytic intermediates has become a hot topic in therapeutic research. One of the first
inhibitors developed to target glycolysis was 2-deoxyglucose (2-DG), a glucose analog
that downregulates glucose metabolism through competitive inhibition [256]. 2-DG is
transported into the cell and phosphorylated by hexokinase to 2-deoxy-glucosephosphate (2-DG-P). 2-DG-P cannot be further metabolized and accumulates in the
cells, leading to competitive inhibition of hexokinase during glycolysis [257]. In vitro
studies have shown that this effect causes a decrease in cellular ATP production, and
leads to the blockage of cell cycle progression and subsequent cell death [258]. A recent
study has demonstrated that a combination of 2-DG treatment with photodynamic therapy
induces tumor cell death in a synergistic manner [259]. Decreased cellular proliferation
and increased apoptosis of cancer cells was also demonstrated upon 2-DG treatment in
the N-diethylnitrosamine-induced rat hepatocarcinoma model [260].

Along with a

decrease in glycolysis, there was an observable decrease in the tricarboxylic acid (TCA)
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cycle activity, fatty acid and cholesterol biosynthesis, and ATP production, all pathways
associated with tumor progression and metabolism. Other studies have shown that
inhibiting glyoxylase 1, an enzyme responsible for the conversion of the glycolysis
byproduct methylyglyoxyl to D-lactate, in a highly metabolically active tumor cells leads
to an increase in apoptosis and a decrease in cellular proliferation [261, 262].
Targeting glycolysis in order to reverse the Warburg Effect has sparked interest as
a potential anti-cancer therapy and has led to recent breakthroughs in therapeutics. One
particularly intriguing target gaining a significant amount of attention from the
pharmaceutical industry is LDH-α, an enzyme converting pyruvate to lactate, and a
biomarker of advanced disease, poor prognosis, and resistance to therapy in many
different cancers [263-265]. LDH-α inhibitors have a high specificity for cancer cells
because of the high demand for lactate production in cancer cells during aerobic
glycolysis [266]. It was recently reported that inhibition of LDH-α reduced ATP levels and
led to an accumulation of reactive oxygen species (ROS) in lymphoma cells [267]. This
accumulation of ROS resulted in increased incidence of apoptosis, suggesting that LDHα is critical for tumor maintenance and cancer cell metabolism [268, 269]. These results
have been recapitulated in a variety of diverse cancer types including lung cancer, renal
cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and
pancreatic cancer [267, 270-276].
There has been clinical success with drugs designed to target other enzymes in
the glycolysis pathway, such as hexokinase II (HKII), phosphofructokinase (PFK),
glyceraldehyde-3 phosphate dehydrogenase (GAPDH), and pyruvate kinase M2 (PKM2).
Lonidamine, a selective HKII inhibitor, reached phase III trials in the 1990’s as a
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therapeutic option for patients with lung cancer and was mildly successful but had toxic
side effects [277, 278]. A novel approach by Wang et al. used the natural compound
curcumin as a potential drug that could target HKII specifically and was shown to have
anti-cancer effects in vitro [279]. The authors reported that colorectal cancer cells treated
with curcumin in vitro have decreased mitochondria-associated anti-apoptotic HKII,
leading to enhanced cell death.

3-bromopyruvate (3-BrPA), a selective inhibitor of

another glycolytic enzyme, glyceralaldehyde-3-phosphate dehydrogenase (GAPDH),
has been shown to downregulate PI3K/Akt signaling axis, leading to induced apoptosis
in breast cancer cells [280, 281]. This finding suggests potential benefits of dual targeting
of glycolysis enzymes and PI3K/Akt-mediated cellular metabolism. 3-BrPA has been
FDA approved for phase I clinical trials as a selective glycolysis inhibitor [282-284] and
was shown to induce ER stress, inhibit global protein synthesis and thereby induce tumor
cell death [285]. Attempts have also been made to target phosphofructokinase,
particularly PFKB3, the isoform commonly upregulated in cancers. Specifically, the use
of selective PFKB3 inhibitors, such as 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
(3PO) shown that inhibition of PFKB3 leads to autophagy and could be an effective antitumor therapy [286]. 3PO is currently being tested in clinical trials [287].
1.8 CONCLUSIONS
With obesity toll spreading to pandemic levels, it is critical that the underlying
mechanisms linking obesity to metabolic pathologies and tumorigenesis are elucidated.
It is clear that adipocyte-derived factors and lipolysis products have the capacity to alter
cellular homeostasis in neighboring cells. Abnormal adiposity and chronic inflammation
in obesity can lead to the secretion of a multitude of factors, all of which can influence
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tumor metabolism. Our understanding of tumor metabolism over the last century has
revealed a complex, integrated network of enzymes and metabolites cooperating together
to facilitate tumor cell growth and survival. The dynamic functions of metabolic proteins
make tumor metabolism an intricate and attractive field of research.

Further

understanding of the interactions between these metabolites and their oncogenic nature
will provide insight into elucidating targetable mechanisms and development of novel
therapies. Many leaps have been made in cancer therapies in a context of tumor
metabolism. It remains crucial to advance our understanding of adipose tissue and
disease in order to determine the molecular mechanisms behind adiposity and
pathologies and, specifically, cancer.
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Table 1: Current, on-going clinical trials targeting different aspects of cellular
metabolism in different cancer types.
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Figure 1: The proposed schematic of possible mechanisms of metabolic regulation
of tumor cells by dysfunctional adipocytes in obesity. The major consequence of
obesity is adipose tissue inflammation and associated increases in circulating levels of
lipolysis-generated lipids and pro-inflammatory cytokines and adipokines. Through
paracrine, autocrine, and endocrine effects, adipocyte-derived factors activate metabolic
pathways in tumor cells and facilitating growth and survival. Pathways of interest include
the following: phosphoinositol 3-kinase (PI3-K) signaling cascade, hypoxia-inducible
factor 1α (HIF-1α), increased glucose uptake and enhanced glycolysis, and the potentially
oncogenic endoplasmic reticulum (ER stress) pathway. The stimulation of PI3-K pathway
leads to downstream activation of Akt and mTOR, enhancing the transcription of genes
involved in growth, proliferation and survival. PI3-K signaling can also activate c-MYC and
lead to the induction of glycolytic genes. A potential crosstalk between the glycolysis
pathway and the HIF-1α signaling axis potentiates HIF activity, and exacerbates the
glycolytic and hypoxic phenotypes. HIF-1α signaling leads to the expression of miRNA210, which disrupts mitochondrial integrity, affecting cellular metabolism. Additionally,
FFA have the ability to disrupt mitochondrial and ER membrane integrity and cause
mitochondrial dysfunction and ER stress. The interactions of the ER stress response
protein, XBP-1, with HIF-1α drive the expression of HIF- and glycolysis-targeted genes.
This adipocyte-driven dynamic network of events results in metabolic adaptation of tumor
cells, implicating adiposity in tumor aggressiveness and chemoresistance to therapy.
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PI3K, phosphoinositide 3-kinase; AKT, protein kinase b; mTOR, mammalian target of
rapamycin; c-MYC, myc proto-oncogene; HIF-1α, hypoxia-inducible factor 1; HK2,
hexokinase 2; PKF, phosphofructokinase; GAPDH, glyceralaldehyde-3-phosphate
dehydrogenase; PKM2, pyruvate kinase isoform; LDHα, lactate dehydrogenase; FFA,
free fatty acids; miR-210, micro RNA 210.
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
Bone is a preferential site of metastasis from prostate cancer (PCa). Around 90%
of patients with metastatic disease present with skeletal lesions. Although there have
been many advances in therapeutic options for patients suffering from metastatic PCa,
this disease remains incurable with an estimated five-year survival of 33%. To design
effective therapeutic interventions for metastatic PCa, it is essential that we elucidate the
molecular mechanisms in which tumor cells adapt to and thrive within the bone metastatic
niche. Age and obesity, conditions that increase adipocyte numbers in bone marrow,
are risk factors for skeletal metastases from PCa. Marrow fat has a potential to influence
neighboring cells in paracrine and endocrine fashion by releasing a plethora of molecules
including lipids, cytokines, hormones, complement factors, fatty acids, and free glycerol.
We have shown previously that the progression of experimental intraosseous tumors is
accelerated in mice with increased marrow adiposity. We have also demonstrated that
tumor cells can utilize adipocyte-supplied lipids to support their proliferation and
invasiveness. Our novel preliminary results indicate that exposure of tumor cells to
marrow adipocytes in vitro and in vivo enhances their glycolytic phenotype and promotes
tumor hypoxia driven by HIF-1α. Stemming from these findings, our overall hypothesis
is that adipocyte-supplied lipids within the bone microenvironment cause a metabolic
switch to glycolysis in metastatic PCa cells by activation of HIF-1α, leading to increased
aggressiveness and survival. We proposed to test this hypothesis in two specific aims:
Specific Aim 1: Establish the contribution of adipocyte-supplied factors to
metabolic changes in tumor cells. Our working hypothesis is that PCa cells stimulate
lipid release and lipolysis in marrow adipocytes, a process that increases lipid availability
for tumor cells and leads to an enhanced glycolytic phenotype and tumor hypoxia. We
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propose to examine the interactions between adipocytes and PCa cells in vivo and in vitro
to answer the following questions:
a) Do adipocyte-supplied lipids affect cellular glycolysis and β-oxidation in tumor
cells?
b) Are the metabolic effects of adipocytes on PCa cells driven through the
activation of HIF-1α?
Specific Aim 2: Determine the adipocyte-induced changes in the PCa cell fatty acyl
lipidome and identify key lipid metabolites contributing to altered tumor
metabolism and hypoxia. Our working hypotheses are that: 1) PCa cells adapt to
adipocyte-rich bone marrow and alter their lipidome to support own growth and survival;
and 2) PCa cells influence the secretome of marrow adipocytes and stimulate them to
release factors that promote tumor survival through metabolic regulation. Based on our
findings, we proposed to:
a) Characterize fatty acyl lipidomic profiles of metastatic tumor cells in the absence
and presence of adipocyte-derived factors;
b) Define the lipid secretome of marrow adipocytes interacting with tumor cells;
c) Elucidate fatty acyl lipidomic signature associated with glycolytic and hypoxic
phenotype in tumor cells
The proposed aims were designed to unravel specific aspects of bone marrow
adipocyte involvement in PCa progression in bone. Findings from this study demonstrated
a functional relationship between marrow adiposity and tumor growth, metabolic adaption
and survival in the metastatic niche, and implicated adipocyte-supplied lipids and tumor
metabolism as novel potential therapeutic targets in metastatic disease. This work
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establishes a basis for future exploration of 1) the mechanisms behind adipocyte-driven
metabolic adaptation and chemoresistance of skeletal tumors, and 2) the potential options
for targeting of tumor metabolism for improved therapy and/or prevention of aggressive
disease. This work will have high relevance beyond PCa and extend to other bone-trophic
cancers.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Materials
Dulbecco’s modified Eagle’s medium (DMEM), RPMI-1640 medium and other
chemicals, unless otherwise stated, were obtained from Sigma (St. Louis, MO). HyClone
fetal bovine serum (FBS) was from ThermoFisher (Pittsburg, PA). Trypsin-EDTA,
collagenase, BODIPY (493/503), Gentamicin (G418), Alexa Fluor 488-conjugated goat
anti-rabbit IgG, and rabbit anti-human FABP4 were from Invitrogen (Carlsbad, CA).
PureCol® collagen type I was from Advanced Biomatrix (San Diego, CA). Mouse
monoclonal E7 Beta tubulin antibody was from Developmental studies Hybridoma Bank
(Iowa City, IA). StemXVivo Adipogenic Suppliment, was from R&D Systems (Minneapolis,
MN). Rabbit anti-human/mouse ß-actin antibodies were from Novus Biologicals (Littleton,
CO). Mouse anti-human neuron-specific Enolase was from Dako-Agilent Technologies
(Denmark). Rabbit anti-human-pyruvate dehydrogenase kinase, lactate dehydrogenase
alpha, rabbit anti-human hexokinase 2 were from Cell Signaling Technologies (Beverly,
Massachusetts). Rabbit anti-human phosphorylated pyruvate dehydrogenase, rabbit
monoclonal anti-carbonic anhydrase 9 antibody, and the fluorometric L-lactate detection
kit were from Abcam (Cambridge, UK). Adipolyze lipolysis detection kit was from Lonza
(Switzerland). RNeasy Mini Kits were from Qiagen (Valencia, CA). Immunoblotting
“Western Lightning ECL Plus” detection kits were from Perkin Elmer LLC (Waltham, MA).
Rosiglitazone and the Triglyceride Colorimetric Assay kit were from Cayman Chemical
(Ann Arbor, MI). ImmPACT NovaRED Peroxidase Substrate and ImmPRESS Anti-Rabbit
Peroxidase Reagent kit were from Vector Laboratories (Burlington, CA). Cobalt Chloride
was from MP Biomedicals (Solon, OH). Atglistatin was from Axon Medchem (Groningen,
Netherlands).
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3.2 Cell lines
PC3 cell line, derived from a bone metastasis of a high-grade adenocarcinoma
[288], and DU145 cells, derived from human prostate adenocarcinoma metastatic to the
brain [289], were purchased from American Type Culture Collection (ATCC; Manassas,
VA). The ARCaP(M), an Androgen-Repressed Metastatic Prostate Cancer Cells M
(‘Mesenchymal’ Clone) [290] were purchased from Novicure Biotechnology (Birmingham,
AL). The human prostate cancer C4-2B cell line was kindly provided by Dr. Leland W. K.
Chung, Cedars-Sinai Medical Center (Los Angeles, CA). PC3 and DU145 cells were
grown in DMEM medium with 10% FBS, ARCaP(M) cells in RPMI medium with 5% FBS,
and C4-2B cells in RPMI medium with 10% FBS. Cells were maintained in a 37°C
humidified incubator ventilated with 5% CO2.
Primary mouse bone marrow stromal cells (mBMSC) were isolated from femurs
and tibiae of 6- to 8- week old FVB/N mice according to previously established protocols
[291]. To induce bone marrow adipocyte differentiation, mBMSC cells were plated in 3D
collagen I gels, grown to confluency for 48-72 hours and treated with adipogenic cocktail
(30% StemXVivo Adipogenic Suppliment, 1 μM insulin, 2 μM Rosiglitazone; DMEM and
10% FBS) for 8-10 days as previously described [150]. Differentiated bone marrow
adipocyte cultures were washed 3 times with PBS and used in experiments.
3.3 Animals
All experiments involving mice were performed in accordance with the protocol
approved by the institutional Animal Investigation Committee of Wayne State University
and NIH guidelines. In vivo xenograft studies were performed in male mice in the FVB/N
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background with homozygous null mutation in the Rag1 gene [FVB/N/ N5, Rag-1−/−]. All
mice were bred in-house.
3.4 Diets
At 5 weeks of age, mice caged in groups of 4 were started on either a low-fat (LFD)
diet (10% calories from fat; Research Diets no. D12450Ji) or a high-fat (HFD) diet (60%
calories from fat; Research Diets no. D12492i). D12450Ji is a standard matched control
diet for D12492i as recommended by Research Diets. Mice were maintained on
respective diets for 8 weeks prior to the tumor implantation and continued on the diets for
additional 6 weeks (PC3 tumors) or 8 weeks (ARCaP(M) tumors). Where indicated, mice
were switched from HFD to LFD at time of tumor implantation and maintained on LFD for
the remainder of the experiment.
3.5 Intratibial and subcutaneous injections of prostate cancer cells
Intratibial tumor injections were performed under isoflurane inhalational anesthesia
according to the previously published procedures [150, 291, 292]. Briefly, a cell
preparation containing 5 ×105 of PC3 /ARCaP(M) cells in PBS (20 μl, right tibia), or PBS
alone (control, 20 μl, left tibia) was injected into the bone marrow. Mice were euthanized
six weeks (PC3 cells) or eight weeks (ARCaP(M) cells) post-injection, and control and
tumor-bearing tibiae were removed. For microenvironmental control, separate groups of
LFD and HFD mice were injected subcutaneously with 50 μl of PC3 cell suspension (5
x105 cells in PBS/Cultrex). Half of the intratibial tumor samples from each group and half
of each subcutaneous tumor were fixed in Z-fix, bone tumors were decalcified, and all
samples were embedded in paraffin. Remaining tissues were snap-frozen in liquid
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nitrogen, powderized using a tissue pulverizer and RNA was isolated using Trizol and
RNeasy Mini Kit.
3.6 TaqMan RT-PCR analyses
The cDNA from cells and in vivo samples was prepared from 1-2 μg of total RNA
using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). The analyses
of genes associated with glycolysis, lipolysis, hypoxia and mitochondrial markers were
performed using TaqMan® Individual Gene Expression assays for Human ENO2
(Hs00157360), LDHa (Hs00855322), HK2 (Hs00606086), PDK1 (Hs01561850), GLUT1
(Hs00892681), CS (Hs 02574374), IDH2 (Hs00158033), HIF-1α (Hs00153153), CA9
(Hs00154208), MAGL (Hs00200752), CD36 (Hs01567185), Perillipin 2 (Hs00605340),
VEGF

(Hs00900055),

Il-1β

(Hs01555410),

EP1

(Hs00909194),

and

SPHK1

(Hs00184211). Assays were done on three biological replicates using TaqMan® Fast
Universal PCR Master Mix and 50 ng of cDNA/well and all reactions were run on an
Applied Biosystems StepOnePlus™ system. Three biological replicates of each sample
were pooled together and assays were run in at least triplicate. The same assays (ENO2,
LDHa, PDK1, HK2, GLUT1, CA9 and VEGF) were performed on triplicate samples of
PC3 bone tumors from LFD and HFD mice and normalized to human epithelial cell marker
CD326 (EPCAM) (Hs00901885). Specificity of each Taqman probe was cross-checked
against RNA from control mouse bones and murine adipocytes (Supplementary Table 4).
For

all

human

genes

in

vitro,

data

were

normalized

to

hypoxanthine

phosphoribosyltransferase (HPRT1; Hs02800695). For assessment of adipocyte-specific
genes in adipocytes grown in co-culture with tumor cells, the following murine Taqman
assays were used: HSL (Mm00495359), ATGL (Mm00503040), COX-2 (Mm00478374),
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COX-1 (Mm00477214), SPHK1 (Mm004488416). Data were normalized to Adiponectin
(Mm00456425). DataAssist™ Software (Applied Biosystems) was used for all analyses.
CA9 and CD326 primers (IDT, Coralville, IA) for PCR were used according to
manufacturer’s protocol. Human CA9 forward and reverse primer sequences are as
follows:

Forward:

5’-GGGTGTCATCTGGACTGTGTT-3’;

Reverse:

5’-

CTTCTGTGCTGCCTTCTCATC-3’. CD326 forward and reverse primers are as follows:
Forward: 5’- CTG GCC GTA AAC TGC TTT GT-3’; Reverse: 5’-AGC CCA TCA ATT GTT
CTG GAG-3’. EP1 forward and reverse primers are as follows: Forward: 5’- CTT GTC
GGT ATC ATG GTG GTGTC-3’; Reverse: 5’- GGT TGT GCT TAG AAG TG GCT GAGG3’. EP2 forward and reverse primers are as follows: Forward: 5’- CCA CCT CAT TCT
CCT GGCTA-3’; Reverse: 5’- CGA CAA CAG AGG ACT GAA CG-3’; EP3 forward and
reverse primers are as follows: Forward: 5’- CTT CGC ATA ACT GGG GCA AC-3’;
Reverse: 5’- TCT CCG TGT GTG TCT TGC AG-3’; EP4 forward and reverse primers are
as follows: Forward: 5’- TGG TAT GTG GGC TGG CTG-3’; Reverse: 5’- GAG GAC GGT
GGC GAG AAT-3’. S1PR primers were generously provided Dr. Meng-Jer Lee at Wayne
State University [293].
In vitro models
3.7 Transwell co-culture
The mBMSC cells were embedded in Collagen, plated in 6-well plates,
differentiated into adipocytes, and tumor cells were seeded on top of a Transwell filter
(0.2 μm pore size) to allow sharing of soluble factors between the two cell types. After 48
hours, tumor cells were washed with PBS, trypsinized and harvested for RNA and protein
extraction. Adipocytes were collected using 1% collagenase. For protein analyses,
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lysates were re-suspended in SME buffer with protease and phosphatase inhibitors [150,
294]. For RT PCR analyses, cells were collected into RLT buffer and RNA was purified
using RNeasy Mini Kit [150, 294].
3.8 Direct co-culture
Adipocytes embedded in Collagen I were differentiated in 100 mm dishes as
previously described [29]. 600,000 PC3 or ARCaP(M) cells were plated in co-culture with
adipocytes and on top of Collagen I without adipocytes as control. After 48 hours, 1%
collagenase was used to break down the Collagen I and isolate the cells. Human specific
qPCR probes were used to measure transcriptional responses in glycolytic genes.
3.9 Co-culture CM treatment
Conditioned media was obtained from either adipocytes alone (Adipo CM) or from
PCa-adipocyte direct co-cultures (CCM) and either stored in -80 °C or used fresh after
collection. PCa cells were seeded at 200,000 cells per well in 6-well plates 24 hours prior
to treatment, then treated with either fresh DMEM containing 10% FBS Adipo CM, or
CCM. After 24 hours of treatment, the cells were washed with PBS and collected for RNA
and protein as previously described.
Tumor conditioned media was collected the identically for treatment of adipocytes
with PC3 or ARCaP(M) conditioned media.

Adipocytes were treated with either

PC3/ARCaP(M) conditioned media or fresh DMEM containing 10% FBS and 1% P/S and
collected for RNA as described above.
3.10 Immunoblot analyses
Lysate and media samples were loaded based on DNA/protein concentrations and
the corresponding lysates were electrophoresed on 12% or 15% SDS-PAGE gels,
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transferred to PVDF membranes and immunoblotted for human ENO2 (1:1,000), LDHa
(1:1000), PDK1 (1:500), p-PDH (1:1000), HK2 (1:1,000), FABP4 (1:500), p-GSK3β
(1:1000), total GSK3β (1:1000), β-catenin (1:1000), laminin A/C (1:500), cyclin D
(1:1000), phosphorylated-Akt (1:1000), phosphorylated-ERK (1:1000), VDAC/Porin
(1:1000) Tubulin (1:1000), and β-actin (1:1,000). To analyze the adipocyte protein
expressions mouse COX-2 (1:1,000) was used. All horseradish peroxidase-labeled
secondary antibodies were used at 1:10,000. Quantification and analyses of bands were
performed using a Luminescent Image Analyzer LAS- 1000 Plus (Fujifilm, Stamford, CT).
3.11 CA9 immunohistochemical analyses
Tumor-bearing tibiae from LFD and HFD mice were fixed, decalcified, and embedded
in

paraffin.

Deparaffinized

and

rehydrated

tissues

were

then

analyzed

by

immunohistochemistry for expression and localization of CA9 (rabbit anti-human CA9;
1:250). ImmPRESS Anti-Rabbit Peroxidase Polymer Detection systems along with a
NovaRED kit as a substrate were used for the peroxidase-mediated reaction.
3.12 Immunofluorescence analyses
Cells were plated on coverslips (50,000 per coverslip) in a 24-well plate, allowed to
attach for at least 4 hours, and transferred to control or transwell wells. After 48 hours,
cell were stained with BODIPY (493/503) by washing with PBS, fixing with 3.7%
formaldehyde at RT for 40 minutes, and incubating with BODIPY (493/503) (1:1000) at
RT for 1 hour. Coverslips were washed and mounted onto slides using Vectashield with
DAPI (Vector Laboratories). Images were taken using a Zeiss LSM 510 META NLO
confocal microscope (Carl Zeiss AG, Göttingen, Germany) and a 40 × oil immersion lens.
For CA9 staining, cells were washed with PBS and fixed with cold methanol. Coverslips
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were stained with rabbit monoclonal anti-CA9 antibody (1:50) at 4°C overnight. Alexa
Fluor 488-conjugated goat anti-rabbit IgG (1:1,000) was used as a secondary antibody,
and DAPI was used as a nuclear stain. Coverslips were mounted using Vectashield and
imaged using a Zeiss LSM 510 META NLO confocal microscope using a 63 × oil
immersion lens.
3.13 ATP analysis
Cells were seeded in 6-well dishes, cultured overnight and treated with either fresh
media (control conditions) or CCM. At 12 and 24 hours, the cells were washed and
scraped into PBS. The cells were collected in a timely manner to ensure reliability of the
sample, snap frozen in liquid nitrogen and stored in -80 ºC. The ATP Bioluminescence
Assay Kit HS II (Roche Applied Science) and the boiling method for ATP release were
used [124]. Briefly, 700 μl of incubation buffer was added to the cells (100 mM Tris-Cl, pH
7.75, 4 mM EDTA) and the solution was immediately transferred to a boiling water bath
for 2 minutes. Samples were diluted 1:25 and 40 μl aliquots were used to determine the
ATP concentration following the manufacturer’s protocol. The experiments were done as
biological duplicates, and then two aliquots were taken from each sample and assayed in
triplicate. The concentrations were normalized to total protein using NanoDrop 2000
(Thermofisher Scientific). Data are shown as mean ± SD.
3.14 Assessment of lactate levels in media
Conditioned media was obtained from PC3 and ARCaP(M) cells alone and in
transwell with adipocytes after 48-hour co-culture. The media was heat-inactivated at 65
°C for 8 minutes. Abcam’s L-lactate Detection Kit was used and conditioned media was
assayed using a TECAN plate reader (535nm/590nm) according to manufacturer’s
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instructions. Data were normalized to the total DNA or RNA concentrations in cell lysates.
Experiments were done in triplicate and reported as mean ± SD.
3.15 Seahorse analysis
PC3 and ARCaP(M) cells were plated on a Collagen I matrix at concentrations of
30,000 cells per well in XF24 Cell Microplates and cultured overnight. The following day,
cells were treated with fresh DMEM medium or Co-culture CM (CCM) for 12 and 24 hours.
One hour prior to reading the plate, the media was changed to DMEM containing 10 mM
glucose and 2 mM glutamine. Basal readings were performed on the Seahorse analyzer
and the third reading of each experiment was used. Experiments were done in triplicate
with at least three wells per sample condition and reported as mean ± SD.
3.16 Determination of mitochondrial membrane potential/intrinsic apoptosis
The JC-1 probe (Thermofisher Scientific) was used to assess mitochondrial
membrane potential as a measure mitochondrial integrity [125] Cells were plated in 96well black plates at a density of 5,000 cells/well and grown overnight. The following day,
media was replaced with either fresh DMEM or CCM and cells were allowed to incubate
for 12 and 24 hours. JC-1 probe was then added at a final concentration of 1 μM to the
media and the plates were incubated for 20 minutes. The plates were then read at
excitation and emission wavelengths of 535 nm and 595 nm, respectively, for the red
fluorescence and excitation and emission wavelengths of 485 nm and 535 nm,
respectively, for the green fluorescence. Data were normalized based on cell viability.
Experiments were done in triplicate with quadruplicate wells per condition at each time
point and shown as mean ± SD.64872
3.17 Determination of cell viability
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Calcein AM Assay (Trevigen) was used to assess cell viability. Cells were seeded in
black-walled 96- well plates at a density of 5,000 cells/well and grown overnight. The
following day, media was removed and fresh DMEM or CCM was added to the wells and
the cells were incubated for 12 or 24 hours. The plate was then read at excitation and
emission wavelengths of 490 nm and 520 nm, respectively. Experiments were done in at
least triplicate with quadruplicate wells analyzed per experiment and shown as mean ±
SD.
3.18 Free glycerol assay analysis
Conditioned media was obtained from adipocytes alone, adipocytes in transwell with
PC3 or ARCaP(M) cells, or adipocytes treated with conditioned media from PC3 or
ARCaP tumor cells and analyzed using manufacturer’s protocol for the AdipoLyze
Lipolysis Detection Kit (Lonza). Experiments were done in triplicate and reposted as mean
± SD.
3.19 Triglyceride assay
Tumor cells were grown in transwell with adipocytes in the presence or absence of
10 μM Atglistatin. After 48 hours, adipocytes were collected as previously indicated and
re-suspended in the Standard Diluent (provided in the Triglyceride assay kit; Cayman
Chemical). Samples were sonicated and centrifuged. The supernatant was then used for
the assay. All steps were performed according to manufacturer’s protocol. Experiments
were done in triplicate and reported as mean ± SD.
3.20 Activation of HIF-1α in vitro
PC3 cells were pre-plated in 6-well plates and allowed to settle overnight. For
pharmacological HIF-1α activation, cells were treated the following day with 150 μM
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cobalt chloride (CoCl2). After 24 hours, cells were lysed, and processed for RNA analyses
as described above. For establishment of hypoxic cultures, cells were plated in 6-well
plates and allowed to settle overnight in normoxia, and then either maintained in normoxia
(control cells) or grown in Biospherix hypoxia chamber (Biospherix, Parish, NY) under 1%
O2 (hypoxic cells). After 24 hours, all cells were processed for RNA isolation as previously
described.
3.21 siRNA Approaches
PC3 or ARCaP(M) cells were pre-plated in 6-well plates or on Transwell filters and
grown overnight. The following day, when the cells reached ~70% confluency, a unique
27mer siRNA duplex targeting HIF-1α transcripts (OriGene-SR302102) or Trilencer-27
Universal scrambled negative control (Origene-SR30004) were added using RNAiMAX
transfection reagent (Thermofisher Scientific) at a final concentration of 20 μM (based on
manufacturer’s protocol). After 6 hours, cells were washed and moved into transwell coculture with differentiated bone marrow adipocytes or grown alone. After 24 hours, cells
were collected and processed for RNA analyses as described above. Two unique 27mer
siRNA duplexes that efficiently knocked down HIF-1α transcripts were used.
Following the same protocol, we used a unique 27mer siRNA duplex targeting IL1β transcripts (OriGene-XM_017003988) and the Trilencer-27 Universal scrambled
negative control (OriGene-SR30004).
3.22 In silico analyses
The Oncomine database (OncomineTM v4.5: 729 datasets, 91,866 samples) was
used for the analysis of primary (P) vs. metastatic (M) tumors by employing filters for
selection of conditions and genes of interest (prostate cancer; metastasis vs. primary;
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genes). Data were ordered by ‘overexpression’ and the threshold was adjusted to P-value
< 1E-4; fold change, 2 and gene rank, top 10%. For each database, only genes that met
the criteria for significance were reported.
3.23 Statistical analyses
Data were presented as means ± SD and statistically analyzed using unpaired
student T-test. For three or more groups, one-way analysis of variance was used.
3.24 Lipidomics analyses
PC3 and ARCaP(M) cells were plated in 6 well plates or transwell inserts for coculture with bone marrow adipocytes and allowed to grow for 48 hours in complete media.
After 48 hours, the media was changed to serum-free DMEM overnight. The subsequent
day, media was collected from tumor cells alone, adipocytes alone, and tumor/adipocyte
co-cultures and delivered to the lipidomics core facility at Wayne State University. LCMS methods available through our Lipidomics core (http://lipidomics.wayne.edu) cover
the entire range of fatty acyl lipidome. Using Information Dependent Acquisition (IDA)
mass spectrometry, we collected the mass spectra of differentially biosynthesized lipids
for further structural characterization and identification. The data was analyzed by
MarkerView (a multivariate analysis software to analyze the mass spectral data by
ABSCIEX) to identify compounds that significantly (p<0.05) differ between samples.
Additionally, cell lysates were given to the lipidomics core to measure intracellular
sphingosine-1-phosphate levels.

Cells were washed 3 times with PBS, trypsinized,

collected, spun down, washed once with PBS, and then snap-frozen with liquid nitrogen
and delivered to the core for analysis.
3.25 IL-1β Treatment and Inhibition
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A-9-11-08 cells were differentiated in 6 well plates (See Cell Lines section above)
into mature adipocytes. Adipocytes were then treated with 5ng/mL recombinant IL-1β
(R&D Systems) for 48 hours and collected for RNA analyses as described above.
To assess IL-1β inhibition with a blocking antibody or receptor antagonist, PC3
cells were plates alone in a 6 well plate or in transwell co-culture in complete media in the
presence or absence of an IL-1β Blocking Antibody (R&D Systems; 1 μg/ml) or IL-1R
Antagonist (Sigma, 1 μg/ml).

Adipocytes were also grown in alone conditioned in

complete DMEM with or without the blocking antibody or receptor antagonist in order to
assess changes in adipocytes in response to IL-1β inhibition.
3.26 EP Receptor Inhibitors
PC3 cells were grown in 6 well plates or in transwell inserts with bone marrow
adipocytes as previously described in the presence or absence of the EP1-3 inhibitor,
AH6809 (Cayman, 2 µM), the EP2 inhibitor, TG4-155 (Cayman, 1 µM), or the EP4
inhibitor GW628368X (Cayman, 1 µM) for 48 hours. Cells were collected for RNA and
protein analysis as previously described.

3.27 PGE2 and 15-(S)-15-Methyl PGE2 Treatment
PC3 cells were plated in 6 well plates and allowed to settle overnight in complete
DMEM. The following day, the media was removed and serum-free media was added
after washing the cells with PBS. The subsequent day cells were treated with either PGE2
(Cayman, 1 µM) or 15-(S)-15-Methyl PGE2 (Cayman, 1 µM) or DMSO control in the
presence or absence of the EP receptor inhibitors (described in 6.26) for 24 hours. After
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24 hours of treatment, cells were collected and processed for RNA or protein expression
as described above.
3.28 SPHK1 Inhibition
PC3 cells were grown in 6 well plates or in transwell inserts overnight and allowed
to settle. Adipocytes were pre-treated with SKI2 (Sigma, 5 µM) overnight. The following
day, the tumor cells grown in the transwell inserts were moved into co-cultures with the
adipocytes and fresh, complete media with the addition of DMSO or 5 µM SKI2 and
allowed to grow for 48 hours. Cells were harvested and analyzed for RNA and protein
expression as described above.
3.29 S1P Receptor Inhibition
PC3 cells were grown alone or in transwell inserts in co-culture with bone marrow
adipocytes in complete medium containing DMSO, JTE-013 (Cayman, 1 µM), a selective
S1PR4 antagonist, or VPC23019 (Cayman, 20 µM), a S1PR1-3 antagonist for 48 hours.
After 48 hours, the cells were collected and processed for RNA and protein expression
as previously detailed.
3.30 S1P Treatment/S1PR Agonists
S1P (Cayman) was resuspended in ethanol in 20 µL aliquots of 10 µM. Samples
were placed in a SpeedVac for 2 hours or until liquid evaporated. Dry pellets of S1P were
stored in -20°C and fresh S1P was used for each experiment. For experimental treatment
with S1P, aliquots resuspended in 20 µL of 0.04% BSA in PBS and sonicated for 5
seconds to form micelles and added to PC3 cells plated in 6-well plates in serum-free
media. For receptor agonist treatment, PC3 cells were grown in 6 well plates overnight
and allowed to settle in complete medium. The following day, the media was removed
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and, after a PBS wash, was replaced with serum-free media overnight. The following
day, agonists for S1PR1 (SEW2857, Cayman, 1 µM), S1PR2 (CYM5520, Cayman, 3 µM),
S1PR3 (CYM5541, Cayman, 1 µM), S1PR4 (CYM50308, Cayman, 1 µM), S1P, or DMSO
were given to the cells for 24 hours. Also, to assess the optimal concentration of S1P
treatment, PC3 and ARCaP(M) cells were grown in 6 well plates overnight and allowed
to settle. The following day the complete medium was replaced with serum-free media
after a PBS wash. The next day, cells were treated with 100 nM, 1 µM, or 10 µM S1P for
24 hours and collected for RNA analysis as previously discussed. To assess S1PR
signaling, PC3 and ARCaP(M) cells were grown in 60 mm dishes overnight and allowed
to settle. The following day the complete medium was replaced with serum-free media
after a PBS wash. The next day, cells were treated with 10 µM S1P for 0, 10, 20, and 30
minutes and collected for protein analysis as previously described. Lastly, PC3 cells were
grown in complete medium, complete medium with 10 µM S1P, Adipo CM, Adipo CM +
10 µM S1P, or CCM for 24 hours and collected for RNA analysis.
3.31 Stable SPHK1 Overexpression in Tumor Cells
PC3 cells were plated in 6-well plates. The following day, when the cells reached
~70% confluency, a plasmid encoding an overexpressing vector for SPHK1 (Generously
provided by Dr. M. Lee, WSU) was added using Lipofectamin3000 transfection reagent
(Thermofisher Scientific) at a final volume of 3.75 µL or 7.5 µL (based on manufacturer’s
protocol). After 48 hours, the cells were trypsinzed and re-plated into a 100 mm dish and
the selecting agent, neomycin (Thermofisher Scientific), was added. Cell growth was
monitored and single cell clones were selected using cloning rings and re-plated into 24well plates with neomycin. Once they became confluent in the 24-well plates, the cells
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were trypsinized and re-plated into a 6-well plate with neomycin and grown to confluency.
At confluency, the cells were collected for RNA expression as previously described.
3.32 Colony Formation Assays
PC3 and ARCaP(M) cells were plated in 6 well-plates or transwell inserts with
bone marrow adipocytes in complete media. After 48 hours grown in alone conditions
or with adipocytes, cells were trypsinized and re-plated in 6-well plates at a density of
1,000 cells/well. Cells were monitored and after 5 days of growth, media was changed
to replenish nutrients and allowed to grow for 5 more days. At the end of the 10 days,
Crystal VioletTM stain (Sigma-Aldrich) was used to stain the cells and the colonies were
imaged.
3.33 Mitochondrial Fractionation
PC3 cells were plated in 6-well plates or in tanswell inserts with bone marrow
adipocytes in complete DMEM. After 48 hours cells were harvested for mitochondrial
fractionation. To isolate mitochondria, cells were trypsinzed and washed with PBS and
centrifugated at max speed for 5 minutes to produce a cell pellet. 90 µL of Tris-buffer (10
mM Tris. pH 7.6) was added to the cell pellet and sonicated to homogenize the mixture
for 15 seconds. Immediately after homogenization, 20 µL of 1.5 M sucrose in SEKT buffer
(250 mM sucrose, 40 mM KCl, 20 mM Tris-HCL, 2 mM EGTA, pH 7.6) was added to the
mixture. Then, centrifuge at 600xg for 10 minutes at 4°C and remove the supernatant
which is the mitochondrial fraction. Add 70 µL of SEKT buffer to the remaining pellet and
collect as the “non-mitochondrial” fraction. Then, centrifuge supernatant mitochondrial
fraction at 10,000Xg for 10 minutes at 4°C and discard the supernatant. We then
resuspended the mitochondrial pellet in 500 µL of SEKT buffer and centrifuged for an
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additional 10 minutes at 10,000Xg at 4°C.

Finally, the mitochondrial pellet was

resuspended in 70 µL of SEKT buffer and stored in -80°C.
3.34 Chemotherapy Treatment
PC3 cells were plated in 96-well plates at a density of 5,000 cells/well and grown
overnight. The following day, Docetaxel (Generously provided by Dr. Elisabeth Heath)
was given to the cells at various concentrations. The cells were treated for 48 hours in
normoxia or hypoxia (1% O2) and Calcein AM viability assays were performed (See
Above).
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CHAPTER 4: BONE MARROW ADIPOCYTES PROMOTE THE WARBURG
PHENOTYPE IN METASTATIC PROSTATE CANCER CELLS THROUGH THE
ACTIVATION OF HIF-1α

4.1 Introduction:
Altered metabolic phenotype and the ability to adapt and thrive in harsh
microenvironments are features that distinguish cancer cells from normal cells [295, 296].
It is well-accepted that most tumor cells rely on accelerated glucose metabolism for
support of anabolic processes such as lipid, protein and nucleic acid syntheses, and
consequently for growth and survival [159, 297].

This phenomenon, known as the

“Warburg Effect” is one of the hallmarks of cancer, and the glycolytic fueling of growth is
thought to be the key feature behind the progression of most tumors [298]. However, it
is becoming increasingly apparent that the metabolic phenotype of a cancer cell can vary
depending on the tumor type and the stage of the disease. The possession of a distinct
metabolic phenotype is especially evident in primary prostate cancers, which unlike other
solid tumors, do not undergo the classical “glycolytic switch” [127, 299]. Instead, these
tumors generally exhibit activation of β-oxidation pathways as the means of supporting
tumor cell viability under conditions of energy stress [156, 300-302]. Primary prostate
cancer cells have unique abilities to exploit fatty acid metabolic pathways to foster
malignant transformation. The uptake of lipids from the microenvironment, aberrant de
novo lipid synthesis and alterations in fatty acid catabolism and steroidogenesis pathways
are now emerging as key mechanisms linking dysregulated lipid metabolism in the
primary prostate tumor with subsequent progression and reduced survival [299, 303,
304]. In contrast to the primary disease, however, metabolic phenotype of metastatic
prostate cancers is not well-understood. The acquisition of a glycolytic phenotype in
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advanced stages of prostate cancer has been suggested by the reports of increased
accumulation of fluorodeoxyglucose (FDG) [305] and the immunohistochemical evidence
of expression of glycolytic markers and monocarboxylate transporters in advanced
tumors. The mechanisms contributing to metabolic adaptation and progression of
metastatic prostate tumors in bone has not, however, been previously explored and are
not known.
Metastatic growth in bone is a complex process involving reciprocal interactions
between the tumor cells and the host bone microenvironment. One of the most abundant,
yet overlooked components of the metastatic marrow niche are the bone marrow
adipocytes [24, 25, 27]. Adipocyte numbers in the marrow increase with age, obesity and
metabolic disorders [26, 27, 52, 189, 306, 307], all of which are also risk factors for
metastatic disease [308-312]. We and others have shown previously that marrow fat cells,
as highly metabolically active cells, can serve as a source of lipids for cancer cells, and
promote growth, invasion, and aggressiveness of metastatic tumors in bone [24, 150,
313]. Based on the growing evidence from cancers that grow in adipocyte-rich tissues, it
is becoming apparent that one way adipocytes can affect tumor cell behavior is through
modulation of cancer cell metabolism [314]. Although direct effects of adipocyte-supplied
lipids on tumor metabolism have not been investigated in a context of metastatic prostate
cancer, there have been studies in other cancers demonstrating that some lipids do have
the ability to enhance the Warburg Effect in tumor cells [315-319]. Reciprocally, tumor
cells have been shown to act as metabolic parasites by inducing lipolysis in adipocytes
[155, 320]. This is important in the context of tumor metabolism regulation as the lipolysisgenerated glycerol can feed into the glycolytic pathway [321-323] and the released fatty
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acids can be oxidized through β-oxidation [324, 325]. As active and vital components of
the bone tumor microenvironment, adipocytes are likely to be involved in the metabolic
adaptation of tumors in the metastatic niche. However, the concept of metabolic coupling
between marrow adipocytes and tumor cells leading to metabolic reprogramming in the
tumor has not been explored before.
One of the principal mechanisms behind metabolic reprogramming is hypoxic
stress and activation of hypoxia inducible factor (HIF) [326].

HIF-1 stimulates the

conversion of glucose to pyruvate and lactate by upregulating key enzymes involved in
glucose transport, glycolysis, and lactate extrusion and by decreasing conversion of
pyruvate to acetyl-CoA through transactivation of pyruvate dehydrogenase kinase
(PDK1) and subsequent inhibition of pyruvate dehydrogenase (PDH) [326]. Regulation
of lactate dehydrogenase (LDHa) and PDK1 by HIF-1 keeps the pyruvate away from
mitochondria, and thus depresses mitochondrial respiration [297].

Under normoxic

conditions HIF-1 is rapidly degraded by the ubiquitin-proteasome pathway [327].
Decreased oxygen availability prevents HIF-1 hydroxylation leading to its stabilization and
activation of downstream pathways [296].

In cancer cells, HIF-1 stabilization and

activation can occur during normoxia via multiple oxygen-independent pathways [328].
This phenomenon, termed “pseudohypoxia” is thought to facilitate adaptation of tumor
cells to harsh conditions and to promote survival and resistance to therapy [329-331].
Whether HIF-1-dependent signaling plays a role in metabolic reprogramming of prostate
tumor cells in bone is not known.
The objective of this study was to elucidate the role of bone marrow adiposity in
the modulation of tumor metabolism and adaptation within the bone microenvironment.
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Using in vivo models of diet induced marrow adiposity in combination with in vitro models
of paracrine, autocrine, and endocrine signaling between bone marrow adipocytes and
prostate cancer cells, we show that bone marrow adipocytes are responsible for
enhancing the glycolytic phenotype of metastatic prostate cancer cells. We demonstrate
that bidirectional interaction between adipocytes and tumor cells leads to increased
expression of glycolytic enzymes, increased lactate production, and decreased
mitochondrial oxidative phosphorylation in tumor cells via necessary cancer cell-initiated
paracrine crosstalk. We also reveal that the observed metabolic signature in tumor cells
exposed to adipocytes mimics the expression patterns seen in patients with metastatic
disease. These results offer potential mechanisms underlying metabolic adaptation of
metastatic tumors in bone and implicate bone marrow adipocytes, a cell type so
abundantly present in the skeleton especially in advanced age and obesity, as viable
culprits in the progression of this currently incurable disease.
4.2 RESULTS
4.2.1 In silico analysis of glycolysis-associated genes in prostate cancer patients
The metabolic phenotype of primary prostate tumors has been well-described
[156, 300-302]; however, its characteristics in relation to the glycolytic pathway at the
metastatic site are not well-understood. Therefore, we first performed an Oncomine
analysis of primary and metastatic prostate tumors and compared mRNA expression of
genes that encode for enzymes/proteins known to be involved in different aspects of
glucose metabolism and Warburg metabolism. Specifically, thirteen available Oncomine
datasets were examined for the expression of genes covering a broad spectrum of
metabolic

responses

and

associated

with

glucose

transport
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[glucose transporter 1 (GLUT1)], glycolysis [hexokinase 2 (HK2) and enolase 2 (ENO2)],
Warburg

metabolism

[pyruvate

dehydrogenase

kinase 1 (PDK1)

and lactate

dehydrogenase (LDHa)], and hypoxia [carbonic anhydrase 9 (CA9) and vascular
endothelial growth factor (VEGF)]. Our analyses revealed significant differences in the
metabolic phenotype between primary and secondary sites observable in several prostate
cancer datasets (Table 1). The Grasso Prostate dataset, which contains most metastatic
samples, showed the most significant upward changes in the expression of PDK1, ENO2,
HK2, GLUT1, and LDHa (Figure 1A), as well as many other genes associated with the
glycolysis pathway (Table 1). Additional analyses of prostate datasets available through
cbioportal.com revealed that copy number alterations/mutations/deletions in these genes
are infrequent in prostate cancer (Figure 2), pointing to the mRNA overexpression as the
main mechanism behind the acquisition of metabolic phenotype. In addition to glycolytic
markers, HIF-1 target genes, CA9 and VEGF were also significantly upregulated in
metastatic tissue (Figure 1A, Figure 2, and Table 2). Since HIF-1 is well-known to regulate
glycolysis [326], these results further underscored the apparent metabolic differences
between primary and secondary prostate cancer and prompted us to investigate the
contribution of the metastatic environment to the tumor metabolic phenotype in bone.
4.2.2 Bone marrow adiposity contributes to the in vivo glycolytic phenotype in
prostate bone tumors
One important cell type credited with the ability to alter tumor metabolism is the
adipocyte, whose effects on the phenotype of a tumor cell have been predominantly
reported for colorectal and ovarian cancers [315, 343, 344]. Given the abundance of
adipocytes in bone marrow, we hypothesized that they are likely to have similar
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Table 1: Oncomine gene analysis of 13 prostate datasets comparing upregulated
genes involved in glycolysis and hypoxic response in prostate cancer patients with
primary and metastatic disease. Enolase (ENO2), hexokinase 2 (HK2), and glucose
transporter 1 (GLUT1) were upregulated in 3/13, 4/9, and 5/13 available datasets,
respectively. Warburg-associated enzymes lactate dehydrogenase (LDHa) and pyruvate
dehydrogenase kinase 1 (PDK1) were upregulated in metastatic sites of patients
compared to primary prostate cancer in 8/13 and 8/12 of the datasets, respectively.
Hypoxic responsive genes carbonic anhydrase 9 (CA9) and vascular endothelial growth
factor alpha (VEGFA) were upregulated in 6/12 and 5/13 metastatic tumors when
compared to primary tumors. (n = number of samples; P = Primary site; M = Metastatic
site).
Gene

Prostate Cancer

ENO2
(3/13)

Grasso [332]
LaTulippe [333]
Varambally [334]
Grasso [332]
LaTulippe [333]
Holzbeierlein [335]
Chandran [336]
Ramaswamy 2 [337]
Ramaswamy [338]
Yu [339]
Varambally [334]
Grasso [332]
LaTulippe [333]
Chandran
[336][336][336][336][336][336][33
6][336][336][336][336]
Lapointe [340]
Vanaja [341]
Yu [339]
Tamura [342]
Varambally [334]
Grasso [332]
Varambally [334]
Ramaswamy 2 [337]
Chandran [336]
Varambally[334]
Ramaswamy[338]
Ramaswamy 2[337]

LDHa
(8/13)

PDK1
(8/12)

HK2
(4/9)

GLUT1
(5/13)

Fold
Change
2.22
1.45
6.122
1.60
1.78
1.73
1.68
3.06
2.60
3.052
2.176
2.96
2.78
1.44
1.63
1.114
1.370
2.152
2.167

P Value

n

4.33E-4
0.034
0.009
0.001
0.008
0.009
0.003
0.003
0.009
2.47E-7
7.25E-4
1.27E-7
0.005
0.002
0.015
0.005
9.99E-8
0.021
0.030

P: 59; M: 35
P: 23; M: 9
P: 7; M: 6
P: 59; M: 35
P: 23; M: 9
P: 40; M: 9
P: 10; M: 21
P: 10; M: 3
P: 10; M: 4
P: 64; M: 24
P: 7; M: 6
P: 59; M: 35
P: 23; M: 9
P: 10; M: 21
P: 62; M: 9
P: 27; M: 5
P: 64; M: 24
P: 23; M: 12
P: 7; M: 6

4.755
4.427
9.507
3.291
1.633
2.049
2.132

3.53E-9
4.59E-4
0.021
3.40E-6
5.74E-5
0.017
0.019

P: 59; M: 35
P: 7; M: 6
P: 10; M: 3
P: 10; M: 21
P: 7; M: 6
P: 10; M: 4
P: 10; M: 3

56

Yu [339]
Grasso [332]
CA9
Ramaswamy [338]
(6/12)
Ramaswamy 2 [337]
Varambally [334]
Yu [339]
Grasso [332]
Chandran [336]
VEGFA Grasso [332]
Varambally [334]
(5/13)
Tamura [342]
Yu [339]
Chandran [336]

1.088
2.048
10.458
11.031
3.131
1.109
3.363
1.487
7.552
3.750
2.443
1.594
2.488

4.63E-4
1.51E-5
0.010
0.010
0.003
0.003
4.79E-6
1.22E-4
1.55E-14
1.10E-5
0.014
5.14E-5
9.27E-4

P: 64; M: 24
P: 59; M: 35
P: 10; M: 4
P: 10; M: 3
P: 7; M: 6
P: 64; M: 24
P: 59; M: 35
P: 10; M: 21
P: 59; M: 35
P: 7; M: 6
P: 23; M: 12
P: 64; M: 24
P: 10; M: 21
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Figure 1: Warburg effect-associated genes are upregulated in patients with
metastatic prostate cancer and in bone tumors from mice with enhanced marrow
adiposity. A. Oncomine gene analysis comparing the expression of metabolic genes
(VEGF, PKM2, HK2, PDK1, CA9, SCL2A1 (GLUT1), ENO2, LDHA) in patient samples
collected from metastatic or primary sites. Data were ordered by “overexpression” and
the threshold was adjusted to P-value < 1E-4; fold change, 2 and gene rank, top 10%. B.
Taqman RT-PCR (Life Technologies) analysis of expression of Warburg Effectassociated genes ENO2, LHDa, PDK1, HK2, and GLUT1 in PC3 (left) and ARCaP(M)
(right) bone tumors or C. subcutaneous tumors from LFD- and HFD-fed mice. Data were
normalized to human EPCAM and represent a mean of a minimum of 3 mice/group + SD.
Values * P < 0.05; ** P < 0.01 are considered statistically significant.
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Table 2: Oncomine gene analysis of Grasso Prostate database comparing
upregulated genes involved in glycolysis in prostate cancer patients with primary
and metastatic disease. Significantly upregulated genes are shown with a p value of p
< 0.05.
GENE

FOLD
CHANGE
Triosephosphate Isomerase 1 (TPI1)
2.31
Pyruvate Kinase M2 (PKM2)
2.67
Hexokinase 2 (HK2)
4.75
Enolase 3 (ENO3)
2.85
Glucose-6-Phosphate Isomerase (GPI)
2.01
Aldolase C (ALDOC)
2.69
Dihydrolipoamide
5-Acetyltransferase 1.95
(DLAT)
Phosphoglycerate Kinase 1 (PGK1)
6.77
Aldolase A (ALDOA)
1.85
Transmembrane Protein 54 (TMEM54)
1.99
Pyruvate Dehydrogenase Alpha 1 (PDHA1)
1.69
Aldolase B (ALDOB)
12.85
Oxoglutarate Dehydrogenase (OGDH)
1.55
Phosphoglycerate Mutase 1 (PGAM1)
1.69
Hexokinase Domain Containing 1 (HKDC1)
2.37
Glyceraldehyde-3-Phosphate
1.57
Dehydrogenase (GAPDH)
Enolase 2 (ENO2)
2.22
Phosphoglycerate Mutase 2 (PGAM2)
1.79
Lactate Dehydrogenase Alpha (LDHA)
1.60
Phosphofructokinase, Platelet (PFKP)
1.63
Hexokinase 3 (HK3)
1.45
IQ Motif Containing D (IQCD)
1.56
Pyruvate Kinase, Liver and RBC (PKLR)
1.29
Glucokinase (GCK)
1.28
Glyceraldehyde-31.68
PhosphateDehydrogenase, Spermatogenic
(GAPDHS)
Lactate
Dehydrogenase
A-Like
6A 1.64
(LDHAL6A)

P-VALUE
2.30E-13
1.47E-9
3.53E-9
1.05E-8
1.43E-8
2.41E-8
3.02E-8
8.17E-8
1.16E-7
3.10E-7
6.20E-7
1.99E-6
1.84E-5
2.12E-5
1.23E-4
2.63E-4
4.33E-4
4.99E-4
0.001
0.001
0.004
0.004
0.013
0.020
0.021

0.023

59

Figure 2: CBioPortal analysis of genetic copy number alterations (CNA) and
mutations in glycolysis associated genes enolase (ENO2), lactate dehydrogenase
alpha (LDHa), pyruvate dehydrogenase kinase 1 (PDK1), hexokinase 2 (HK2), and
glucose transporter 1 (SLC2A1), and hypoxic response genes carbonic
anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGFA) across
three different datasets of metastatic prostate cancer patients (126, 137-140).
Vertical bars represent individual patients. If there are genetic alterations within the
gene of interest, a red bar represents amplification of the gene, blue bars depict deep
deletions within the gene, and green bars signify mutations within the gene. Gray bars
represent unaffected patients.
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metabolism-modulating effects on metastatic prostate cancer cells. To study effects of
marrow fat cells on prostate tumor growth and progression in bone, we utilized a welldocumented approach of inducing marrow adiposity with high fat diet (HFD) [27, 37, 292,
345]. We have shown previously that intratibial implantation of prostate cancer cells into
this model results in accelerated tumor growth and extensive bone destruction,
suggesting potential tumor-supportive effects of marrow adipocytes [294, 345]. To
determine whether this adiposity-driven tumor progression in bone is associated with an
altered metabolic phenotype, we analyzed mRNA expression of glycolysis-associated
genes in intratibial PC3 and ARCaP(M) tumors from low fat diet (LFD) and HFD mice
using human-specific Taqman probes. Our results revealed significantly increased
transcript levels of PDK1, ENO2, HK2, GLUT1, and LDHa in tumors grown under
conditions of HFD-induced marrow adiposity (Figure 1B), whereas the levels of
mitochondrial enzymes citrate synthase (CS) and isocitrate dehydrogenase 2 (IDH2),
remained unaffected by diet-induced marrow adiposity (Figure 10). Notably, this
enhanced glycolytic phenotype was also observed in bone tumors from mice, in which
marrow adiposity was induced with HFD, but the animals were switched to LFD upon
tumor implantation into the tibia (Figure 3). This approach allowed for tumor growth in
adipocyte-rich marrow without systemic effects of HFD and revealed that expression of
Warburg genes in tumor cells does not appear to be a direct effect of HFD. Furthermore,
in contrast to bone tumors, expression of glycolysis-associated genes was not
significantly altered in subcutaneous tumors from HFD mice in comparison to LFD mice
(Figure 1C), despite the fact that HFD enhanced the growth and progression of these
tumors, as we have demonstrated previously [345]. Collectively, these findings suggest
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that Warburg metabolism might be especially important for prostate tumor progression in
bone and implicate marrow adiposity as a potential regulator of metabolic adaptation in
the skeleton.
4.2.3 Bone marrow adipocytes alter the metabolism of prostate cancer cells in vitro
To determine if the glycolytic phenotype observed in intratibial tumors in vivo is
indeed a direct effect of bone marrow adipocytes and to specifically investigate the
mechanisms behind this metabolic regulation, we utilized in vitro models of tumor celladipocyte interactions. First, using human-specific Taqman RT PCR probes, we
examined the expression of glycolytic markers ENO2, LDHa, PDK1, HK2, and GLUT1 in
PC3 and ARCaP(M) cells grown in direct contact co-culture with bone marrow adipocytes
(Figure 4A). Transcript levels of nearly all investigated markers were significantly
increased in tumor cells grown in co-culture as opposed to those cultured alone (Figure
4B). Next, to determine if this change in metabolic phenotype requires direct interaction
with adipocytes, we employed a transwell system in which adipocytes were differentiated
in the bottom chamber and tumor cells were then plated on top of the insert and cultured
together for 48 hours. This allowed the two cell types to share the media without direct
interaction (Figure 4C). Mirroring the findings from the direct co-culture, gene expression
of ENO2, LDHa, PDK1, HK2, and GLUT1 was significantly increased in both PCa cell
lines co-cultured with marrow adipocytes (Figure 4D). Notably, PCa cells grown in
transwell co-culture with bone marrow stromal cells that were not induced to differentiate
into adipocytes had no effect on the expression of glycolysis-associated genes (Figure
5), suggesting that this observed metabolic switch in tumor cells is indeed adipocytedriven. This enhancement of a glycolytic phenotype upon interaction with adipocytes was
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Figure 3: Comparative RT-PCR analysis of Warburg Effect-associated genes in
bone tumors from mice on LFD vs. mice with HFD-induced marrow adiposity that
were switched to LFD upon tumor implantation into the tibia (HFD to LFD). Data,
showing persisting glycolytic phenotype in ‘HFD to LFD’ mice were normalized to
human EPCAM and represent a mean of a minimum of 3 mice/group ± SD. Values * p
<0.05; ** p <0.01 are considered statistically significant.
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Figure 4: Bone marrow adipocytes enhance a glycolytic phenotype of prostate
cancer cells in direct co-culture and in transwell co-culture in vitro. A. Schematic
representation of a direct co-culture of tumor cells and bone marrow adipocytes. B.
Taqman RT-PCR analysis of ENO2, LDHa, PDK1, HK2, and GLUT1 expression in PC3
(Top) and ARCaP(M) (Bottom) cells cultured directly with bone marrow adipocytes. Data
are normalized to HPRT1 and shown relative to control. C. Schematic representation of
transwell co-cultures of tumor cells and bone marrow adipocytes. D. Taqman RT-PCR of
ENO2, LDHa, PDK1, HK2, and GLUT1 expression in PC3 (top) and ARCaP(M) (bottom)
in transwell co-culture. E. Western blot for ENO2, LDHa, HK2, phospho-PDH, and PDK1
in PC3 (left) and ARCaP(M) (right) exposed to bone marrow adipocytes in transwell coculture. Beta-actin was used as loading control. F. Analysis of lactate secreted (Abcam)
by PC3 (left) and ARCaP(M) (right) cells exposed to bone marrow adipocytes in transwell
co-culture. Results represent a mean of at least 3 independent experiments ± SD. Values
* P < 0.05; ** P < 0.01, *** P < 0.001 are considered statistically significant.
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confirmed by the marked increases in the protein expression of ENO2, LDHa, PDK1, and
HK2 (Figure 4E). We also observed increased levels of phosphorylated pyruvate
dehydrogenase (p-PDH) in cells grown in transwell co-culture, which indicates elevated
PDK1 activity and a shift in glucose metabolism from pyruvate to lactate (Figure 4E). To
test this functionally we performed lactate analyses of media conditioned by the tumor
cells in the absence or presence of adipocytes as a conventional, well-accepted approach
for measuring extracellular acidification and glycolytic shift [346, 347].

Our results

revealed significant increases in lactate secretion by the tumor cells exposed to
adipocytes (Figure 4F), while contribution of adipocytes to lactate secretion was not
significant (data not shown). This provided further evidence of acquired Warburg
phenotype in tumor cells exposed to adipocytes. We also observed an augmented
expression of glycolytic genes in other prostate cell lines (i.e., DU145 and C4-2B) grown
in transwell co-culture with fat cells (Figure 6), confirming the important contribution of
marrow adipocytes to the metabolic phenotype of prostate tumors in bone.
The fact that both direct and transwell co-culture with adipocytes induced a
glycolytic phenotype in tumor cells suggested that this process does not require physical
interaction between the tumor cells and adipocytes. Therefore, we next examined
whether the media conditioned by the marrow adipocytes alone (Adipo CM; Figure 7A)
can bring on similar metabolic changes in tumor cells as observed in transwell co-culture.
Interestingly,

no

changes

in

the

mRNA

expression

of ENO2, LDHa, PDK1,

HK2, and GLUT1 were observed in either of the PCa cell lines in response to Adipo CM
(Figure 7B). However, when the adipocytes were directly co-cultured with PC3 or
ARCaP(M) cells for 24 hours prior to the collection of conditioned media, and then the co-
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culture conditioned media was used to treat the tumor cells (Adipo CCM; Figure 7C), a
significant upregulation of glycolysis-associated genes was observed in both tumor lines
(Figure 7D). This altered gene expression was mirrored by the increased levels of
glycolysis-associated proteins (Figure 7E), suggesting that paracrine signaling is required
between the adipocytes and tumor cells for the subsequent metabolic shift towards the
glycolytic phenotype. Interestingly, inactivation of proteins in the co-culture media by
boiling did not reduce the expression of glycolytic genes (Figure 8), suggesting that the
observed Warburg phenomenon might be driven by lipid rather than protein mediators.
4.2.4 Functional evidence of enhanced glycolytic phenotype in response to marrow
adipocytes
The increased expression of glycolytic genes and proteins in tumor cells exposed to
adipocytes, and significantly elevated levels of lactate in transwell co-cultures, clearly
indicated augmented glycolytic activity in tumor cells interacting with adipocytes. An
enhanced glycolytic phenotype in cells undergoing Warburg metabolism can often be
associated with dysfunction in mitochondrial activity and consequently reduced rates of
oxidative phosphorylation (OXPHOS) [348]. To determine if this is true in our system we
performed an XFe Seahorse analysis in tumor cells grown in the absence or presence of
Adipo CCM and used oxygen consumption rate (OCR) as a tool to quantify OXPHOS.
Significantly reduced OCR was detected in both PC3 and ARCaP(M) cells exposed to
Adipo CCM for 12 hours. (Figure 9A). A decrease in OCR was also observable at 24
hours and did not appear to be due to a reduction in mitochondrial integrity, since there
were no significant changes in JC-1 fluorescence, indicating that membrane matrices
remained intact (Figure 9B). This was further supported by the lack of significant changes
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Figure 5. Bone marrow stromal cells (pre-adipocytes) do not induce Warburg
Effect-associated genes. Taqman RT-PCR analysis of ENO2, LDHa, PDK1, HK2, and
GLUT1 in PC3 cells grown in transwell co-culture with pre-adipocytes. Data are
normalized to HPRT1 and shown as increase relative to control. Results represent a
mean of at least 3 independent experiments ± SD.
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Figure 6. Bone marrow adipocytes enhance Warburg Effect in DU145 and C4-2B
cells. Taqman RT-PCR analysis of ENO2, PDK1, and HK2 in DU145 (top) and C4-2B
(bottom) cells cultured alone or in transwell co-culture with bone marrow adipocytes.
Data are normalized to HPRT1 and shown as increase relative to control. Results
represent a mean of at least 3 independent experiments ± SD. Values * p < 0.05; ** p <
0.001 are considered statistically significant.
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Figure 7: Paracrine signaling between PCa cells and bone marrow adipocytes is
required for the induction of glycolytic gene and protein expression in PCa cells.
A. Schematic representation of tumor cells treated with media conditioned by bone
marrow adipocytes (Adipo CM). B. Taqman RT-PCR analysis of ENO2, LDHa, PDK1,
HK2, and GLUT1 in PC3 (top) and ARCaP(M) (bottom) cells in the presence or absence
of Adipo CM. Data are normalized to HPRT1 and shown as increase relative to control.
C. Schematic representation of tumor cell- adipocyte co-culture system (CCM). D.
Taqman RT PCR analysis of mRNA expression of ENO2, LDHa, PDK1, HK2, and GLUT1
in PC3 (top) and ARCaP(M) (bottom) cells in the presence of CCM. E. Western blot
analysis of ENO2, LDHa, HK2, and phospho-PDH in PC3 (left) and ARCaP(M) (right) in
the presence of CCM. Beta-actin was used as a loading control (bottom). Results
represent a mean of at least 3 independent experiments ± SD. Values * P < 0.05; ** P <
0.01 are considered statistically significant.
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Figure 8. Warburg phenotype in prostate cancer cells is driven by adipocytederived lipids. Taqman RT-PCR analysis of ENO2, PDK1, HK2, and GLUT1 in PC3 (top)
and ARCaP(M) (bottom) in the presence or absence of co-culture conditioned media
(CCM) and boiled co-culture conditioned media (boiled CCM). Data are normalized to
HPRT1 and shown as increase relative to control. Results represent a mean of at least 3
independent experiments ± SD. Values * p < 0.05; ** p < 0.01 are considered statistically
significant.

70

in expression of two mitochondrial enzymes, CS and IDH2 in PCa cells exposed to Adipo
CCM (Figure 9C), a result mirroring their unaltered expression in vivo (Figure 10).
Since oxidative phosphorylation is much more efficient at producing copious
amounts of ATP than glycolysis, a decrease in OXPHOS activity should expectedly result
in a depletion of cellular ATP levels. Indeed, exposure of PC3 and ARCaP(M) cells to
Adipo CCM for 12 hours led to a significant decrease in ATP concentration; however,
further exposure to Adipo CCM for up to 24 hours led to a rescue of cellular ATP further
suggesting an enhanced glycolytic phenotype upon Adipo CCM treatment (Figure 9D).
This was further confirmed by additional recovery of ATP levels with 48-hour exposure to
Adipo CCM (Supplementary Figure 8). It is important to note that the reduction in cellular
ATP levels at 12 hours was not due to an enhanced proliferation induced by Adipo CCM
as the Calcein AM assay showed no significant differences in cell numbers or viability of
Adipo CCM-treated cells compared to cells grown under control conditions (Figure 9E).
The uncompromised viability of Adipo CCM-treated tumor cells at 12 or 24 hours was
further confirmed by the apoptosis assay showing no differences between control and
Adipo CCM-treated cells (Figure 9F).
4.2.5 Prostate cancer cells stimulate lipolysis in adipocytes
Adipocytes store triglycerides and hydrolyze them into glycerol and free fatty
acids via the process of lipolysis [320] and lipolysis-generated glycerol can feed into the
glycolytic pathway [321-323]. Based on the above-presented evidence that bone marrow
adipocytes induce metabolic changes in tumor cells, and the fact that these changes
appear to require paracrine interaction between the two cell types, we sought to
investigate whether this could be due to tumor cell-induced lipolysis in adipocytes, as
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Figure 9: Decreased oxidative phosphorylation in prostate cancer cells exposed to
bone marrow adipocyte-derived factors. A. Seahorse XFe24 analyzer (Seahorse
Bioscience) analysis of the oxygen consumption rate (OCR) in PC3 (top) and ARCaP(M)
(bottom) cells upon 12- and 24-hour incubation in the absence or presence of CCM. B.
Mitochondrial membrane potential measured via JC-1 fluorescence. C. Taqman RT-PCR
analysis of oxidative phosphorylation genes isocitrate dehydrogenase 2 (IDH2) and
citrate synthase (CS) after 12 and 24 hours in culture in the absence or presence of CCM.
Data are normalized to HPRT1 and shown relative to control. D. ATP levels in PC3 (top)
and ARCaP(M) (bottom) cells cultured in the absence or presence of CCM. Significant
decrease in ATP levels was observed after 12 hours. CCM exposure had no effect on
viability as shown by Calcein AM assay E. and JC-1 apoptosis analyses F. Values *P <
0.05; **P < 0.01 are considered statistically significant.
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Figure 10: Expression of mitochondrial enzymes in intratibial prostate tumors is
not affected by HFD-induced marrow adiposity. Taqman RT-PCR analysis of citrate
synthase (CS) and isocitrate dehydrogenase 2 (IDH2) in PC3 bone tumors. Data are
normalized to EPCAM and shown as increase relative to control. Results represent a
mean of at least 3 independent experiments ± SD.
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previously demonstrated in ovarian cancer [343]. We have shown previously that
exposure to adipocyte-derived factors leads to lipid accumulation by prostate tumor cells
[345] and lipids have been shown to contribute to the Warburg phenotype in tumor cells
[315-319]. Indeed, our analysis of media from marrow adipocytes grown alone or in a
transwell co-culture with tumor cells revealed significant increases in free glycerol levels
under co-culture conditions (Figure 11A). Similar changes were observed when
adipocytes were treated with media conditioned by PC3 or ARCaP(M) cells (Figure 11B).
The master regulator and the rate-limiting enzyme driving lipolysis in adipocytes is
adipose triglyceride lipase (ATGL) [349, 350]. Our analysis of gene expression of ATGL in
adipocytes co-cultured with tumor cells or exposed to tumor cell-conditioned media
showed significant upregulation indicating an induction of a lipolytic phenotype (Figure
12) and suggesting that tumor cells may be secreting factors that induce lipolysis in fat
cells. We next utilized a selective ATGL inhibitor Atglistatin, known to effectively block
lipolysis in adipocytes [351] and recently shown to attenuate the growth of cancer cells
[352]. A complete abrogation of free glycerol release by 10 μM Atglistatin (Figure 11C),
mirrored by an accumulation of un-hydrolyzed triglycerides (Figure 11D) was observed
for fat cells cultured in the absence of tumor cells. A very effective (~80%), but not
absolute, reduction in free glycerol levels was also observed in transwell co-cultures
(Figure 11C). This incomplete inhibition of lipolysis in adipocytes grown in transwell cocultures was reflected in overall lower triglyceride levels as compared to adipocytes grown
alone (Figure 11D). This suggests a dynamic, paracrine interaction between the two cell
types that results in ongoing hydrolysis, uptake and release of lipids.
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Figure 11: Prostate cancer cells stimulate lipolysis in bone marrow adipocytes.
Free glycerol release from adipocytes in transwell co-culture with PC3 or ARCaP(M) cells
A. or adipocytes treated with conditioned media from PC3 and ARCaP(M) cells B. C. Free
glycerol release by adipocytes cultured alone or in transwell with tumor cells in the
absence or presence of 10µM Atglistatin. Samples were measured in triplicate and are
representative of three separate experiments (shown as percent control). Data are shown
as the mean ± SD. D. Intracellular triglyceride (TG) levels were measured in adipocytes
cultured alone or in transwell with PC3 cells. Measurements were done in triplicate and
are representative of three separate experiments. Data are shown as µmoles TG/µg
protein in cell lysates (Mean ± SD). Values *P < 0.05; *** P < 0.001, and ****P < 0.0001,
are considered statistically significant.
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Figure 12. Taqman RT-PCR analysis of adipose triglyceride lipase (ATGL) expression in
adipocytes grown in transwell co-culture with PC3 or ARCaP(M) cells (A) or treated with
PC3 or ARCaP(M) conditioned media (B). RT-PCR data are normalized to mouse
adiponectin and shown relative to control. Results represent a mean of at least 3
independent experiments ± SD. Values * p < 0.05; ** p < 0.01 are considered statistically
significant.
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Figure 13: Atglistatin does not prevent lipid accumulation by the tumor cells and is
not sufficient to prevent the induction of Warburg phenotype. A.
Immunofluorescence imaging of lipid droplets (BODIPY 493/503 nm) in PC3 cells alone
(left panels) or in transwell co-culture with bone marrow adipocytes (right panels) and in
the presence or absence of 10µM Atglistatin. DAPI was used as a nuclear stain; 40x
images. Bar 100µm. B. Fluorescent intensity of the BODIPY 493/503 staining was
quantified using Volocity (Perkin Elmer, Waltham, MA) and shown relative to PC3 cells
alone. Results represent a mean of at least 3 independent experiments ± SD. C. Taqman
RT-PCR analysis of ENO2, HK2, and PDK1 in PC3 cells in transwell co-culture in the
absence or presence of 10µM Atglistatin. Data are normalized to HPRT1 and shown
relative to control. Values *P < 0.05 are considered statistically significant.
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Since lipolysis-generated glycerol can incorporate into the glycolytic pathway, we
went on to determine whether inhibition of adipocyte ATGL with Atglistatin could reverse
the Warburg phenotype in tumor cells. Our previous studies have shown that prostate
tumor cells are capable of taking up adipocyte-supplied lipids [345]. To determine if this
uptake can be reduced by inhibitors of lipolysis, we treated the tumor cells grown alone
or in transwell co-culture with Atglistatin and performed BODIPY staining (Figure 13A). In
agreement with our previous results [345], significantly increased lipid labeling was
observed in tumor cells exposed to adipocytes in transwell co-culture (Figure 13A, right
panels). Interestingly, treatment with Atglistatin had little effect on adipocyte-induced lipid
uptake, as demonstrated by sustained BODIPY fluorescence (Figure 13A and 13B). This
was further confirmed by significantly increased gene expression of lipid droplet
marker perilipin 2 and lipid transporter CD36 in tumor cells exposed to adipocytes both in
the absence and presence of Atglistatin (Figure 14A).
Consistent with limited effects of adipocyte ATGL inhibition on lipid uptake by the
tumor cells, only modest reduction in mRNA levels of ENO2 and HK2 was revealed
indicating limited impact on glycolytic phenotype in the tumor cells. Even more
surprisingly, the presence of Atglistatin in transwell co-cultures led to a small, but
significant increase in the expression of PDK1 (Figure 13C). This upregulation at the gene
level corresponded to sustained higher levels of p-PDH at the protein level, suggestive of
enhanced PDK1 activity in tumor cells interacting with adipocytes (Figure 15).
Interestingly, in addition to the effects on PDK1, Atglistatin treatment increased the
expression of lipid transporter fatty acid binding protein 4 (FABP4) in tumor cells grown
in transwell with adipocytes (Figure 15). We have shown previously that FABP4 levels
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Figure 14. Inhibition of adipocyte lipolysis does not reduce the expression of lipid
transporters and hypoxia-associated genes in tumor cells. Taqman RT-PCR analysis
of Perilipin 2, CD36, and MAGL, expression (A) and CA9, VEGF, and GLUT1 expression
(B) in PC3 cells alone or in transwell co-culture with bone marrow adipocytes. Cells were
cultured in the presence or absence of 10 μM Atglistatin. Data are normalized to HPRT1
and shown as increase relative to control. Values * p < 0.05; ** p < 0.01 are considered
statistically significant.
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Figure 15. Inhibition of lipolysis with Atglistatin enhances phosphorylation of
PDH and increases expression of lipid transporter FABP4. Western blot analysis of
phosphorylated PDH (top) and FABP4 (middle) in PC3 cells alone or in transwell coculture in the absence or presence of 10 μM Atglistatin. Tubulin was used as a loading
control (bottom).
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are significantly induced in tumor cells exposed to adipocyte-derived factors [345]. Given
the known role of FABP4 in lipid transport and hydrolysis [353], its apparent induction by
the inhibitors of lipolysis suggests a potential feedback response by tumor cells
overwhelmed with adipocyte-supplied lipids. It is noteworthy that the expression of tumorderived monoacyl glycerol lipase (MAGL), a lipase previously implicated in prostate
cancer progression [354, 355], was also induced in response to adipocytes and persisted
upon inhibition of adipocyte ATGL with Atglistatin, suggesting an additional possible
compensatory mechanism in tumor cells that might be contributing to the adipocyte-driven
metabolic phenotype (Figure 14A).
4.2.6 Marrow adipocytes induce HIF-1α signaling in prostate tumor cells
One of the major mechanisms behind metabolic re-programming towards a
glycolytic phenotype is the activation of HIF-1α signaling [326]. Hypoxia has been linked
with aggressiveness and metastatic progression in prostate cancer [356] and we have
shown previously that HIF-1α gene expression is increased in prostate bone tumors from
HFD mice as compared to LFD mice [345]. To determine whether bone marrow adiposity
might be contributing to HIF-1α activation in the bone microenvironment, we analyzed the
mRNA levels of HIF-1α target genes, CA9 and VEGF, in intratibial PC3 tumors from LFDor HFD-fed mice. Both target genes were significantly upregulated in bone tumors from
mice on HFD as compared to LFD mice (Figure 16A), a result that complemented a
significant increase in the levels of GLUT1 (Figure 1B), another direct target of HIF-1α
activity [202]. Notably, no difference in CA9 and VEGF expression between LFD and
HFD conditions was observed in subcutaneous tumors (Figure 16B), in line with our
earlier finding demonstrating that an increase in GLUT1 and augmented levels of other
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glycolysis-associated genes are observable only in metastatic tumors but not in primary
tumors in PCa patients (Figure 1A), and in bone tumors but not in subcutaneous tumors
in mice (Figure 1B and 1C). We next performed an immunohistochemical analysis of CA9
expression (Figure 16C-16G). Our results showed weak, diffuse CA9 staining in bone
tumors from LFD mice (Figure 7C, 7D), whereas an abundance of CA9 protein with its
typical membrane localization was detected in tumors from HFD mice (Figure 16E, 16F),
a result further confirming a glycolytic phenotype of bone tumors under conditions of high
marrow adiposity.
To determine whether bone marrow adipocytes are in fact capable of activating
HIF-1α in PCa cells, we examined the expression of CA9 and VEGF in PC3 cells under
transwell conditions. Indeed, expression of both genes was highly increased in cells
grown in transwell co-culture with adipocytes (Figure 17A, 17B). In addition,
immunofluorescence analysis of CA9 protein revealed a significant increase in expression
and typical membrane localization of CA9 in PC3 cells exposed to adipocytes (Figure
17C-17G). Notably, adipocyte treatment with Atglistatin had no effect on CA9,
VEGF or GLUT1 expression in PC3 cells (Figure 14B), suggesting that inhibition of
adipocyte lipolysis is not sufficient to reverse adipocyte-driven HIF-1α activation in tumor
cells and offers a potential explanation for the persisting glycolytic phenotype.
4.2.7 HIF-1α knockdown inhibits acquisition of a glycolytic phenotype in PCa cells
exposed to adipocytes
Activation and stabilization of HIF-1α is known to be a major event in metabolic
transformation to a glycolytic phenotype [326]. Indeed, culture of PC3 cells under hypoxic
(1% oxygen) conditions or treatment with HIF-1α inducer CoCl2 (Figure 18A and 18B)
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Figure 16: Bone marrow adiposity enhances HIF-1α signaling in PCa cells in vivo
prostate bone tumors. Taqman RT-PCR analysis of CA9 and VEGF in PC3 cells grown
intratibially A. and subcutaneously B. in LFD and HFD fed mice. Data are normalized to
EPCAM and shown relative to LFD tumors. C.-G. Immunohistochemical (NovaRED)
staining for CA9 protein in prostate bone tumors from mice on LFD C. and HFD E., 10x
images D.,F. High magnification (40x) images depicting membrane CA9 localization in
HFD F. but not LFD D. tumors. G. No primary antibody control. Bar, 100µm.
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Figure 17: Bone marrow adipocytes activate HIF-1α signaling in PCa cells in vitro.
Carbonic anhydrase 9 (CA9; A. and VEGF B. gene expression (Taqman RT PCR) in PC3
cells in transwell co-culture with bone marrow adipocytes. Data are representative of at
least 3 separate experiments, normalized to HPRT1 and shown relative to tumor cells
cultured alone. Values *P < 0.05 are considered statistically significant. C.-G.
Immunofluorescence staining of CA9 (green fluorescence) in PC3 cells grown alone (left)
or in transwell co-culture with bone marrow adipocytes (right); DAPI (blue) was used as
nuclear dye; 63x images. Bar, 50µm. G. No primary antibody control was used as a
control.
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Figure 18: siRNA-mediated knockdown of HIF-1α abrogates bone marrow
adipocyte-induced Warburg phenotype in PC3 cells. A. Taqman RT-PCR analysis of
CA9, ENO2, LDHa, HK2, PDK1, GLUT1, and VEGF in PC3 cells cultured in normoxia
(20% O2) or hypoxia (1% O2) B. mRNA expression of CA9, ENO2, LDHa, HK2, PDK1,
GLUT1, and VEGF in response to treatment with 150 µM CoCl2. C. mRNA levels of HIF1α in PC3 cells grown under control conditions or treated with 20 µM scrambled siRNA,
or 20 µM HIF-1α siRNA. D. Taqman RT-PCR analysis of the expression of HIF-1α target
gene CA9 to further confirm HIF-1α knockdown from cells grown in the presence or
absence of adipocytes. E-G: Effect of HIF-1α knockdown on the mRNA expression of
glycolysis associated genes: PDK1 E., LDHA F., and ENO2 G. Data are the mean of
analyses with 2 different siRNA constructs done in triplicate. Values *P < 0.05; **P < 0.01,
and ***P < 0.001 are considered statistically significant.
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Figure 19. Adipocytes induce HIF-1α signaling in ARCaP(M) cells. A: CA9 expression
in ARCaP(M) cells alone or in transwell co-culture with bone marrow adipocytes as
measured by semi-quantitative PCR. PCR products were resolved on 2% agarose gel.
EPCAM (CD326) is used as a loading control (bottom). CA9 expression is not detectable
under control conditions. B: Taqman RT-PCR analysis of VEGF expression in ARCaP(M)
alone or in tranwell co-culture with bone marrow adipocytes. C: mRNA levels of HIF-1α
in ARCaP(M) cells grown under control conditions or treated with 10 μM scrambled
siRNA, or 10 μM HIF-1α siRNA. D: Taqman RT-PCR analysis of the expression of HIF1α target gene CA9 to further confirm HIF-1α knockdown fromcells grown in the presence
or absence of adipocytes. Changes in CA9 mRNA levels are shown as ΔCT due to its
low baseline expression under control conditions and upon HIFARCAP(M) cells. E-G: Effect of HIFassociated genes: PDK1 (E), LDHA (F), and ENO2 (G). Data are the mean of analyses
with 2 different siRNA constructs done in triplicate. Data are normalized to HPRT1 and
shown as increase relative to control. Values * p < 0.05; ** p < 0.01, and *** p < 0.001 are
considered statistically significant.
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Figure 20: Tumor cells exposed to bone marrow adipocytes have increased
clonogenic potential. A. Colony formation assay of PC3 (Left) and ARCaP(M) (Right)
cells after grown alone or in transwell co-culture with bone marrow adipocytes after 10
days. B. Western blot analysis of pro-survival proteins in PC3 cells cultured alone or in
transwell with adipocytes.
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efficiently increase the expression of glycolytic genes to levels comparable to those
observed in tumor cell-adipocyte co-cultures (Figure 4B). This suggests that adipocytedriven Warburg phenotype in tumor cells is likely a downstream effect of HIF-1α activation
under normoxic conditions. To test this, we downregulated HIF-1α in PC3 cells by siRNA
and cultured control and knockdown cells alone or in transwell with marrow adipocytes
(Figure 18C, 18D). A significant reduction in HIF-1α activity in siRNA-treated cells was
evident by almost complete abrogation of CA9 expression (Figure 18D). This coincided
with reduced expression of glycolytic genes PDK1, LDHA and ENO2 (Figure 17E-17G).
Analogous to PC3 cells, ARCaP(M) cells also showed HIF-1α activation upon exposure
to adipocytes, as evidenced by the increases in CA9 mRNA expression, which is
otherwise undetectable under control conditions (Figure 19A). Exposure to adipocytes
also

led

to

augmented

expression

of VEGF (Figure

19B),

as

well

as

increased GLUT1 (Figure 4B). Upon siRNA-mediated knockdown of HIF-1α (Figure 19C),
expression of CA9, PDK1, LDHA and ENO2 was significantly reduced (Figure 19D-19G),
further underscoring the importance of HIF-1α signaling in marrow adipocyte-driven
metabolic adaptation of PCa tumors in bone.
4.2.8 Adipocyte-Driven Pro-Survival and Chemoresistance in PCa Cells
Metabolic adaptation within the bone microenvironment is important for prostate
cancer growth and survival. Stemming from the work showing the PCa cells exposed to
bone marrow adipocytes exhibit enhanced Warburg metabolism and activation of HIF-1α,
we sought to interrogate pro-survival pathways affected by enhanced glycolysis and
hypoxic signaling. We first performed a clonogenic colony formation assay and observed
that tumor cells exposed to adipocytes have higher clonogenic potential indicative of the
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activation of pro-survival pathways (Figure 20A), result confirmed by the increased
expression of pro-survival factors Bcl-XL, Mcl1 and surviving (Figure 20B) Interestingly,
many of the glycolytic enzymes not only perform functions in glycolysis, but have other
functions that can affect cellular survival [357, 358].

One enzyme of particular

importance, hexokinase 2 (HK2), has a known role of inhibiting apoptosis by binding to
voltage-dependent anion channel (VDAC) as a competitive inhibitor of pro-apoptotic
factors such as Bax [359]. As has been shown herein, HK2 expression is increased in
metastatic tumors in patients compared to primary sites, in tumor cells intratibially injected
into mice with elevated marrow adiposity compared to control mice, and in tumor cells
exposed to bone marrow adipocytes in vitro through the activation of HIF-1α [360]. This
led us to investigate the localization and binding of HK2 to the mitochondria in tumor cells
exposed to adipocytes as a mechanism of survival within the bone microenvironment.
We isolated mitochondria from PC3 cells grown alone or exposed to adipocytes in
transwell, and immunoprobed for HK2. We observed that HK2 levels increased in tumor
cells in transwell co-culture with adipocytes in the non-mitochondrial fraction and,
importantly, the mitochondrial fractions (Figure 21A). Additionally, this was shown in
hypoxic conditions as well, mimicking the pseudohypoxic phenotype in tumor cells
exposed to adipocytes (Figure 21B).
Stemming from the induction of this pro-survival phenotype observed, we then
assessed the sensitivity of these prostate cancer cells to standard chemotherapy agent
for patients with metastatic disease, docetaxel [361-363]. Our preliminary data show that
culture of PCa cells under hypoxic conditions makes them less sensitive to Docetaxel and
that in hypoxia, Warburg genes are induced at similar levels as seen when cultured with
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adipocytes, suggesting the activation of HIF-1α does confer chemoresistance to
Docetaxel in these cells (Figure 22).
4.3 Discussion:
Adipocytes are metabolically active cells with the ability to regulate the phenotype
and function of neighboring cancer cells through the processes of lipid transfer and
lipolysis [127, 152, 343, 364, 365]. They have been linked to metabolic reprogramming
and tumor progression in a handful of cancers, including tumors of breast, ovaries and
colon, all with tendencies to grow in fat-enriched sites [127, 343, 366-368].In the context
of prostate cancer, adipocytes from visceral and periprostatic tissues have been linked to
the progression of localized disease [127, 369]. The data have been lacking, however,
on how adipocytes that occupy bone marrow space might be influencing the metabolism
and consequently the progression of prostate tumors that have colonized this fat-enriched
metastatic niche. The results presented above reveal an important contribution of bone
marrow adipocytes to the metabolic phenotype of metastatic PCa tumors. We show that
marrow fat cells are capable of inducing the glycolytic phenotype in PCa cells through
paracrine upregulation of glycolytic enzymes, increases in lactate secretion and reduction
in oxidative phosphorylation. We also demonstrate that tumor cells are able to modulate
the metabolism of a fat cell. They do so by stimulating adipocyte lipolysis in the effort of
utilizing the fat cell-supplied lipids to fuel the glycolytic pathway. This speaks to the
importance of the supportive host microenvironment in tumor progression and
demonstrates the metabolic coupling between the tumor cells and host adipocytes. This
adipocyte-tumor cell interaction ultimately shapes the metabolism of the tumor cell
allowing for the adaptive survival in the metastatic niche [314].
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Figure 21: Hexokinase 2 localizes to the mitochondria in tumor cells exposed to
bone marrow adipocytes or under hypoxic conditions. A. Immunoblot analysis of
HK2 expression and localization in PC3 cells alone or in transwell co-culture with bone
marrow adipocytes in mitochondrial and non-mitochondrial fractions. B. Western blot
analysis of HK2 expression and localization in normoxia and hypoxia (1% O2) in PC3
cells in mitochondrial and non-mitochondrial fractions. VDAC/Porin was used as a
loading control for mitochondrial fractions. Tubulin was used as a loading control for nonmitochondrial fractions.
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Figure 22: PC3 cells are more resistant to Docetaxel treatment under hypoxic
conditions. Calcein AM viability assay of tumor cells grown in normoxia or hypoxia
treated with 5, 10, 50, or 100 nM Docetaxel.
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We focused on metabolism because of the important selective advantage an
enhanced glycolytic phenotype can have on tumor aggressiveness and survival within a
harsh metastatic niche [370, 371]. Glycolysis is not the most effective way, but it is the
quickest way of creating ATP that allows the tumor cells to efficiently gain metabolic
autonomy in the tumor microenvironment [371]. It permits the continuous supply of
nutrients for biosynthetic processes, protection from oxidative stress, and, potentially, an
activation of survival pathways [372, 373]. Warburg metabolism is often associated with
a more hypoxic tumor signature, which is also a very well-documented facilitator of tumor
aggressiveness and chemoresistance [374-377]. Glycolytic enzymes, such as ENO2,
LDHa, PDK1, and HK2, and proteins involved in glucose uptake, such as GLUT1, are all
regulated through HIF-1α [378-380]. In hypoxia, HIF-1α compromises oxygen-consuming
OXPHOS by inducing the expression of PDK1 and preventing conversion of pyruvate into
acetyl-CoA [381, 382].

The resulting production and secretion of lactate by highly

glycolytic cells is known to increase tumor invasion, but it can also serve as an alternative
carbon source for surrounding oxygenated cells [383]. Hypoxia is also known to induce
acidosis via increased acid load in the tumor microenvironment, a process that leads to
upregulation of enzymes, such as carbonic anhydrase 9 (CA9) that can regulate
extracellular pH allowing the tumor cells to thrive in the acidic microenvironment [371]. It
is the membrane-bound CA9, whose expression correlates with aggressive disease and
poor survival in many cancers [371], that is thought to modulate pH through the interaction
with bicarbonate transporters on the cell surface [384]. Notably in our study, evidence of
clearly increased CA9 expression in human metastatic prostate cancer samples and
experimental bone tumors from HFD mice, together with immunocytochemical data
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showing its surface expression in response to adipocytes, suggest that metastatic PCa
cells might be utilizing CA9-dependent mechanisms to adapt and grow in the metastatic
niche.
Bone tissue is intrinsically hypoxic [385, 386], with O2 concentrations ranging from
~1.3 to 3% based on the proximity to the vessels and distance from the endosteum [387].
This makes bone an environment already prone to hypoxic stress. Our data presented
herein show that PCa cells exposed to low oxygen concentration in a hypoxia chamber
show the same glycolytic phenotype as cells interacting with marrow adipocytes under
normoxic conditions. This suggests that adipocytes promote oxygen-independent
mechanism of HIF-1α activation in PCa cells, known as ‘pseudohypoxia’ [331, 388, 389].
HIF-1α, under some circumstances, can be directly activated in well-oxygenated
microenvironments [390], or its activation and stabilization can be a consequence of
mutations in metabolic genes [331, 391]. The mechanisms behind its regulation by bone
marrow adipocytes are currently unknown and are subject of ongoing investigations in
our laboratory.
One important consequence of hypoxia is the induction of HIF-1α-mediated
accumulation of lipid droplets in tumor cells [392]. Hypoxic tumor cells have been recently
shown to bypass lipogenesis and to rely on scavenging of unsaturated lipids from the
microenvironment [393, 394].
Hypoxia has also been linked to the upregulation of proteins that stabilize the integrity
of lipid droplets, such as perilipin and adipose differentiation-related protein (ADRP), as
well as members of the FABP4 family of lipid transporters [392]. This is of relevance to
our study, as hypoxia and glycolytic phenotype in our PCa cells interacting with
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adipocytes coincide with both an enhanced lipid uptake and an upregulation of lipid
transporters and lipid droplet markers. Whether HIF-1α activation is a cause or a
consequence of lipid accumulation in metastatic tumor cells remains to be uncovered. It
is plausible that the initial exposure to adipocyte-supplied lipids triggers HIF- 1α
stabilization and that consequent activation of HIF-1α signaling leads to further lipid
uptake, perpetuating the hypoxic and glycolytic phenotype in tumor cells. The fact that
hypoxia-mediated effects persist even upon the inhibition of adipocyte-driven lipolysis
speaks to the importance of HIF-1α signaling in driving the Warburg phenotype in tumor
cells. The mechanism by which tumor cells exposed to adipocytes in the presence of
ATGL inhibitor continue to accumulate and utilize fat cell-supplied lipids remains to be
elucidated. One potential player in this process might be the MAGL, an enzyme implicated
in lipid remodeling and scavenging by tumor cells and shown recently to be associated
with aggressive phenotype of PCa cells [354, 355, 395].
Although the acquisition of a glycolytic phenotype appears to be the predominant
metabolic change in PCa cells in response to marrow adipocytes, it is important to
mention that some of the glycolytic enzymes we see upregulated in response to fat cells
are also known to have non-glycolytic functions that are important for tumor cell growth
and survival. Specifically, hexokinase-2 (HK2), an enzyme critical for first step of
glycolysis, elicits its functions by binding to the outer mitochondrial membrane protein
voltage-dependent anion channel (VDAC). This allows for receipt of newly synthesized
ATP and rapid and efficient production of glucose-6-phosphate, which contributes not
only to the glycolytic pathway but also to metabolite synthesis in the pentose-phosphate
pathway and TCA cycle, both important for tumor growth and proliferation [396-399].
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Intriguingly, interaction of HK2 with VDAC prevents pro-apoptotic proteins such as BAX
and BAD from binding to the mitochondrial pores to facilitate apoptosis resulting in cells
that are more resistant to cell death and chemotherapy [400-402]. Because around 80%
of total HK2 is reported to be bound to the mitochondrial VDAC [403], and because we
see elevated levels of HK2 in tumor cells that are exposed to bone marrow adipocytes, it
is plausible to expect that the mitochondrial binding of HK2 is occurring in PCa cells, a
process that could be promoting tumor cell survival via inhibition of intrinsic apoptosis in
response to adipocyte-supplied factors.
In this study we utilized an intratibial model of intraosseous tumor growth, a widely
used in vivo experimental system designed to specifically study tumor-bone interactions,
and tumor growth and expansion in the bone microenvironment [404-406]. We and others
have used this system previously in combination with diet induced obesity (DIO) models
to study effects of marrow adiposity on tumor progression in bone [24, 345, 407]. The DIO
model is a well-documented approach to induce marrow adiposity [27, 37, 292, 345] and
we have previously shown that eight-week exposure to HFD significantly augments
adipocyte numbers in this system [24, 345]. We do acknowledge we cannot exclude
potential systemic consequences of the diet itself on both the tumor growth and metabolic
phenotype in bone. There is an ongoing debate on the role of dietary lipids in prostate
cancer development and progression [408, 409] and future studies utilizing genetic
models of obesity and age-induced models of marrow adiposity will provide a more
detailed understanding of adipocyte impact on metabolic adaptation and survival of tumor
cells in the bone marrow niche. An additional value will be added by the comparative
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metabolic profiling of experimental bone prostate tumors and orthotopic primary prostate
tumors.
The rationale for our study was based on the Oncomine analyses of human prostate
cancer samples suggesting clearly distinct metabolic phenotype of metastatic sites as
compared to primary tumors. We recognize that currently available datasets do not allow
for distinction of bone metastases from other potential metastatic sites. However, given
the fact that more than 80% of metastatic patients present with bone lesions, it is highly
likely that majority of these tumors represent skeletal lesions. Limited availability of bone
metastatic tissues is certainly an ongoing, unresolved issue in prostate cancer research.
We believe that this distinct metabolic phenotype in metastatic tissues revealed by our
Oncomine analyses provides an important starting point for future studies investigating
the contribution of tumor metabolism to progression and survival of metastatic prostate
tumors in the bone microenvironment.
Metabolic requirements of a tumor cell are much more complex than previously
appreciated and they likely involve multiple pathways and nutrients that aid in malignant
transformation and progression [410]. There is also no doubt that metabolic adaptation
and consequent growth and survival of a tumor is the result of a complex interaction
between the cancer cell and the surrounding host microenvironment. Data presented
herein reveal marrow adipocytes as important players involved in shaping tumor
metabolism in bone. To our knowledge, this is the first study demonstrating the
importance of bi-directional interactions between marrow fat cells and tumor cells in
activating HIF-1α signaling and driving the Warburg phenotype in metastatic prostate
cancer cells. Adipocyte-supplied factors have been shown to enhance glycolysis in
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primary cancer cells and render them more aggressive and resistant to therapy [167, 411413]. Understanding the molecular mechanisms behind this metabolic regulation in bone
is of critical importance in terms of potential treatment options for metastatic disease.
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CHAPTER 5: BONE MARROW ADIPOCYTE-DERIVED PROSTAGLANDIN E2
ACTIVATES CANONICAL PGE2 SIGNALING METASTATIC PROSTATE CANCER
CELLS
5.1 Introduction
The uptake of lipids from the microenvironment, aberrant de novo lipid
synthesis and alterations in fatty acid catabolism and steroidogenesis pathways are now
emerging as key mechanisms linking dysregulated lipid metabolism in the primary
prostate tumor with subsequent progression and reduced survival [299, 303, 304]. These
lipids have the propensity to regulate signaling networks within cancer cells through
receptor-mediated signaling pathways [414, 415]. Previous work stemming from our
laboratory has shown that metastatic prostate tumors in bone both induce lipolysis in bone
marrow adipocytes and also utilize lipids from adipocytes to fuel their own metabolic
processes that are largely lipid-driven [345, 360]; therefore, it is crucial to understand
what lipids are responsible for tumor growth and survival in bone.
Prostaglandin E2 (PGE2), a bioactive lipid that has been implicated across many
different cancer types in facilitating many of the hallmarks of cancer such as cell
proliferation, angiogenesis, inflammation, immune surveillance, and apoptosis [416-418],
is secreted by adipocytes [419-421]. PGE2, as a prostaglandin, is a member of the
eicosanoid family of lipids and can be produced by all cell types within the body [422]. Its
synthesis is catalyzed by a multiple step process involving the conversion of arachidonic
acid (AA) to prostaglandin H2 (PGH2) by cyclooxygenases (COX) and then PGH2 to
PGE2 with the aid of the enzyme prostaglandin E synthase [423]. There are two distinctly
different cyclooxygenases, COX-1 and COX-2. COX-1 is constitutively expressed in
almost all tissues, while COX-2 needs stimuli in order to be induced [424]. Because COX-

99

1 is constitutively expressed, its functions are thought to be more in maintenance of tissue
homeostasis by regulating basal levels of prostaglandins. The inducible COX-2, however,
has a variety of stimuli such as cytokines, growth factors, and tumor-derived factors [425427]. Interestingly, we have shown previously that tumor cells secrete large amounts of
IL-1β in response to exposure to adipocytes [154, 345] and IL-1β is a known inducer of
COX-2 [428]. PGE2 produced from COX enzymes can signal in a paracrine or autocrine
manner where it activates its receptors EP1-4 [429, 430]. EP receptors are G protein
coupled receptors that are expressed ubiquitously throughout the body. Deregulated EP
receptor activity has been shown across many cancers including breast [431], colorectal
[432, 433], and esophageal cancers [416, 434].
Importantly, there have been some studies in prostate cancer showing PGE2/EP
receptor signaling to play critical roles in proliferation [435], vascular endothelial growth
factor expression and angiogenesis [436], and invasion [437].

Extending from our

previous work, we have shown that bone marrow adipocytes induce vascular endothelial
growth factor (VEGF) expression in metastatic prostate cancer cells and have increased
invasion, both downstream indicators of EP receptor signaling [345, 360]. We have shown
that HIF-1α is activated in tumor cells exposed to bone marrow adipocytes [360] and
VEGF is regulated by HIF-1α signaling [438]. Intriguingly, PGE2 signaling has been
shown to have the propensity to activate HIF-1α signaling through EP1, EP2, and EP4
receptors [439, 440].
The objective of this study was to elucidate the role of bone marrow adiposity in
the modulation of tumor signaling networks within the bone microenvironment. Using in
vivo models of diet induced marrow adiposity in combination with in vitro models of
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paracrine signaling between bone marrow adipocytes and prostate cancer cells, we show
that tumor-derived IL-1β activates COX-2 in bone marrow adipocytes. COX-2 then is
responsible for the synthesis and secretion of prostaglandin E2 that activates the EP
receptors in tumor cells, leading to the induction of downstream signaling pathways.
These results offer potential mechanisms underlying metabolic adaptation of metastatic
tumors in bone and implicate bone marrow adipocytes, a cell type so abundantly present
in the skeleton especially in advanced age and obesity, as viable culprits in the
progression of this currently incurable disease.
5.2 Results
5.2.1 In silico analysis of prostaglandin E2 receptors EP1-4 and EP receptor
signaling in metastatic prostate cancer patients
Because COX-2 has been shown to be elevated in PCa and its signaling pathways
are implicated in many cellular processes required for cancer cell survival and growth
[441], we first performed an Oncomine analysis and compared mRNA expression of
genes linked to PGE2 signaling in primary and metastatic prostate cancer samples
(Figure 1A). A significant upregulation of the gene encoding the EP1 receptor was
revealed in patients with metastatic disease compared to those with primary prostate
cancer (Figure 1A). In addition to the PGE2 receptor, genes involved in downstream
signaling of EP1 activation such as cyclin d1 (CCND1) and c-myc (MYC) were also
significantly upregulated in metastatic tissue. These data link our previous observations
showing a hypoxic phenotype in metastatic PCa compared to primary PCa, indicative of
HIF-1α activation, suggesting a correlation between EP receptor signaling and HIF-1α
activity in these patients [442]. These results further underscore the importance of
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eicosanoid signaling between primary and secondary prostate cancer that might be
playing a role in metastatic progression.
5.2.2 Adipocytes exposed to intratibially injected prostate cancer cells have
increased expression of COX-2 in vivo
Although previous reports from our laboratory have focused on how bone marrow
adipocytes are affecting PCa cells, it is of critical importance to study the effects of tumor
cells on adipocytes as well. To examine the effects of metastatic prostate cancer cells
on bone marrow adipocytes, we utilized a well-documented approach of inducing marrow
adiposity with high fat diet (HFD) [27, 37, 150, 292]. We have shown previously that
intratibial implantation of prostate cancer cells into this model results in accelerated tumor
growth and extensive bone destruction compared to normal diet (LFD), suggesting
potential tumor-supportive effects of marrow adipocytes and that the tumor metabolism is
altered to a more glycolytic and hypoxic state [150, 294]. To determine whether this
observed pseudohypoxic phenotype in the tumor cells exposed to adipocytes was
correlated with increased PGE2 secretion by adipocytes and EP receptor activation of
HIF-1α signaling in the tumor, we analyzed mRNA expression of mouse COX-1 and COX2 genes in adipocytes exposed to intratibially injected PC3 and ARCaP(M) tumors from
LFD and HFD mice. Our results revealed significantly increased transcript levels of both
COX-1 and COX-2 in adipocytes in tumor bearing bone compared to control bone and in
the effect was exacerbated in the HFD model compared to the LFD model, suggesting
contribution of adipocytes to tumor-induced COX-1/2 expression in the bone [443]. These
findings implicate tumor cells as a potential regulator of adipocyte PGE2 production
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through the COX-2 pathway in bone and led us to further investigate the mechanism of
this regulation in vitro.
5.2.3 Adipocytes exposed to PCa cells have increased expression of COX-1 and
COX-2 in vitro
We utilized in vitro models of tumor cell-adipocyte interactions to determine if the
activation of COX-2/PGE2 axis in adipocytes exposed to PCa cells as observed in
intratibial tumors in vivo is a direct effect of tumor cells. We first examined COX-1/-2
expression in adipocytes exposed to PCa cells by employing a transwell system in which
adipocytes were differentiated in the bottom chamber and tumor cells were then plated
on top of the insert and cultured together for 48 hours. This allowed the two cell
types to share the media without direct interaction. COX-2, the inducible cyclooxygenase
involved in prostaglandin synthesis was significantly increased in adipocytes co-cultured
with PCa cells (Figure 2A). COX-2 was also upregulated at the protein level in adipocytes
exposed to tumor cells (Figure 2B).

Interestingly, although COX-1 is constitutively

expressed, its levels are still induced in adipocytes exposed to PC3 and ARCaP(M)
prostate cancer cells (Figure 2C). Activation of COX1/2 signaling was further supported
by significantly elevated levels of Prostaglandin E2 in media conditioned by transwell cocultures as opposed to adipocytes or tumor cells grown in alone conditions (Figure 2D).
The fact that transwell co-culture with tumor cells caused the activation of COX-1
and COX-2 and PGE2 production in adipocytes suggested that this process does not
require physical interaction between the tumor cells and adipocytes. Therefore, we next
examined whether the media conditioned by the PCa cells alone (PC3/ARCaP(M) CM)
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Figure 1: Gene targets of GSK3β/β-catenin signaling through the prostaglandin
receptors are upregulated in patients with metastatic prostate cancer. A. Oncomine
gene analysis comparing the expression of GSK3β/β-catenin target genes (VEGF, MYC,
PPARD, and CCND1) in patient samples collected from metastatic or primary sites. Data
were ordered by “overexpression” and the threshold was adjusted to P-value < 1E-4; fold
change, 2 and gene rank, top 10%. B. Taqman RT-PCR analysis of expression of COX1 and COX-2 in adipocytes exposed to PC3 and ARCaP(M) tumors in LFD- and HFD-fed
mice. Data were normalized to human EPCAM and represent a mean of a minimum of 3
mice/group + SD. Values * P < 0.05; ** P < 0.01 are considered statistically significant.
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Figure 2: COX-2 expression and activity increases in bone marrow adipocytes
exposed to tumor cells in vitro. A. Taqman RT-PCR analysis of COX-2 in adipocytes
exposed to PC3 prostate cancer cells in transwell co-culture. Data were normalized to
mouse Adiponectin and shown as increase relative to control. B. Immunoblot analysis of
COX-2 in adipocytes alone or in transwell co-culture with PC3 cells. C. Taqman RT-PCR
of COX-1 expression in adipocytes exposed to PC3 or ARCaP(M) cells in transwell coculture. D. Lipidomics analysis of PGE2 levels in media conditioned by PC3 cells alone,
adipocytes alone, or PC3 cells and bone marrow adipocytes cultured together in
transwell. E. Taqman RT-PCR of COX-2 expression in adipocytes treated with tumor cell
conditioned media. Results represent a mean of at least 3 independent experiments ±
SD. Values * P < 0.05; ** P < 0.01, *** P < 0.001 are considered statistically significant.
can bring on similar changes in adipocytes as observed in transwell co-culture.
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Interestingly, treatment with either PC3 or ARCaP(M) conditioned media induced
expression of COX-1 and COX-2 in adipocytes (Figure 2E), suggesting that paracrine
signaling is required between the adipocytes and tumor cells for the subsequent
phenotype.
5.2.4 Adipocyte COX-1 and COX-2 are regulated by PCa cell secreted IL-1β
stimulation of lipolysis
Because treatment of adipocytes with tumor cell conditioned media increases the
expression of COX-1 and COX-2 and adipocytes exposed to tumor cells secrete
elevated levels of PGE2, we then sought to determine what factors released from the
tumor cells activate the COX/PGE2 axis. Previously, our laboratory has published that
prostate tumor cells secrete high levels of IL-1β when exposed to adipocytes [150].
Additionally, IL-1β has been shown to have the propensity to activate COX-1 and COX2 and increase PGE2 production [428]. With this knowledge, we then treated
adipocytes with recombinant IL-1β and observed a marked increase in COX-1 and
COX-2 expression, suggesting the increased activation of the COX/PGE2 axis in
adipocytes is driven by tumor-secreted IL-1β (Figure 3A). We then used blocking
antibodies against IL-1β (R&D Systems, 1µg/mL) and an IL-1R receptor antagonist
(Sigma-Aldrich, 1µg/mL) to determine if increased expression COX-1 and COX-2 were
due to IL-1β signaling between prostate cancer cells and bone marrow adipocytes.
Intriguingly, using the blocking antibody against IL-1β or receptor antagonist against IL1R did not abrogate the induction of COX-1 or COX-2 (Figure 3B); however, levels of IL1β increased in tumor cells grown in transwell with adipocytes as a possible negative
feedback mechanism to compensate for inhibition of IL-1β.. To resolve this issue, we
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then performed a siRNA-mediated knock down of IL-1β (OriGene) and observed a
substantial knockdown of IL-1β (Figure 3C). Studies utilizing this siRNA-mediated
knockdown of IL-1β in tumor cells to determine the requirement of IL-1β on COX-1 and
COX-2 expression in adipocytes are currently ongoing.
5.2.5 Adipocyte-derived PGE2 activates the GSK3β/β-catenin pathway through the
EP receptors
After confirming that the COX/PGE2 pathway is activated in adipocytes exposed to
prostate cancer cells through tumor-secreted IL-1β activation of COX-1 and COX-2, we
then examined the effects of PGE2 release on tumor cell signaling.

There are four

receptors that can be activated by PGE2 (PTGER1-4) [444] and we first performed a
screen looking at the receptor expression in PCa cells grown alone and exposed to
adipocytes in transwell co-culture (Figure 4A) using primers for each specific gene (Table
1). Our results showed that PTGER1 (EP1) was upregulated in PCa cells exposed to
adipocytes in transwell co-culture, while there were no observable differences in
expression of PTGER2 (EP2) or PTGER4 (EP4), and PTGER3 (EP3) was not detected
in any of our samples. Importantly, the increased expression of EP1 in PCa cells exposed
to adipocytes in vitro was also observed in PCa cells intratibially injected in HFD mouse
tibia compared to LFD tibia (Figure 4B), supporting our observations that adipocytederived PGE2 is playing a role in tumor cell signaling. Taqman RT-PCR confirmed this
increase in EP1 expression in both PC3 and ARCaP(M) cells in tumor cells exposed to
adipocytes in transwell co-culture in vitro (Figure 4C) and in vivo in HFD tumors compared
to LFD tumors (Figure 4D).
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Figure 3: COX-1 and COX-2 are regulated by tumor-secreted IL-1β. A. Taqman RTPCR analysis of COX-1 and COX-2 expression in bone marrow adipocytes treated with
5ng/mL IL-1β. B. Gene expression of COX-1 and COX-2 in adipocytes alone or exposed
to PC3 cells in transwell co-culture in the absence or presence of an IL-1β blocking
antibody (BA) or receptor anatagonist (RA). C. Taqman RT-PCR of IL-1β in tumor cells
alone or in transwell co-culture with bone marrow adipocytes with or without the IL-1β
blocking antibody (BA) or IL-1R receptor antagonist (RA). D. IL-1β gene expression upon
knockdown using three different siRNA constructs compared to the nontransfected
control and scrambled siRNA control.
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We then examined the canonical PGE2 signaling in tumor cells exposed to
adipocytes by looking at the activation of GSK3β and β-catenin and cyclin D. We showed
that tumor cells exposed to adipocytes have increased GSK3β activation as shown
through a decrease in phosphorylated GSK3β (Figure 5A) and increased nuclear βcatenin (Figure 5B). Additionally, cyclin D, a target of β-catenin, was shown to be
upregulated in tumor cells exposed to fat cells in transwell co-culture (Figure 5C).
Lastly, to determine which receptor the PGE2 signaling is occurring through, we
used specific inhibitors that target either EP1-3 (AH6809) or EP4 (GW627368X) in tumor
cells exposed to adipocytes in transwell co-culture. Looking at phosphorylated GSK3β
as a marker of PGE2 signaling, there was an observable decrease in phospho-GSK3β in
tumor cells exposed to adipocytes and with the inhibition of EP4 there was a slightly
abrogated effect with little reduction in phospho-GSK3β, while AH6809 treatment
completely inhibited the activation of GSK3β, showing this signaling pathway is mainly
activated through EP1-3 (Figure 5D).
5.2.6 Activation of the EP1 receptor in tumor cells by adipocyte-derived PGE2 leads
to HIF-1α activation
Stemming from previous work from our laboratory showing that tumor cells
exposed to adipocytes have enhanced HIF-1α activity [360] and knowing that there is a
mechanism for β-catenin stabilization of HIF-1α [439, 445, 446], we then looked at PGE2
signaling activating a hypoxic response in tumor cells similar to effects observed in tumor
cells exposed to adipocytes in transwell co-culture. We first treated PCa cells with PGE2
and its non-metabolizable form 15-S-15 Methyl-PGE2, which is a more potent activator
of PGE2 signaling, and assessed HIF-1α activation by analyzing expression of HIF-1α
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target genes VEGF and CA9 [447]. Taqman real-time PCR analysis showed increased
expression of CA9 in PCa cells treated with PGE2 and the methylated PGE2 metabolite,
demonstrating that activated PGE2 signaling in our cells increases hypoxic signaling and
HIF-1α activation (Figure 6A). Unfortunately, however, inhibition of EP1 receptor with
AH6809, EP2 receptor with TG4-155, or EP1-3 receptors with GW627368X did not alter
CA9 expression levels, indicating inhibition of the receptors themselves is not sufficient
to halt the psuedohypoxic phenotype in tumor cells induced by PGE2 signaling (Figure
6B).
5.3 Discussion
Adipocytes are metabolically active cells with the ability to regulate the phenotype
and function of neighboring cancer cells through the processes of lipid transfer and
lipolysis [127, 152, 343, 364, 365]. In the context of prostate cancer, adipocytes from
visceral and periprostatic tissues have been linked to the progression of localized disease
[127, 369]. The data have been lacking, however, on how adipocytes that occupy bone
marrow space might be influencing tumor cell signaling and consequently the progression
of the disease for tumors that have colonized this fat-enriched metastatic niche. The
results presented above reveal an important contribution of bone marrow adipocytes to
the activation of the GSK3β/β-catenin pathway through PGE2-mediated EP receptor
activation in metastatic PCa tumors. We show that marrow fat cells are capable of
secreting prostaglandin E2 which activates the EP1, EP2, and EP4 receptors on the
tumor cell surface, leading to the downstream activation of GSK3β/β-catenin pathway and
a stabilization of HIF-1α. We also demonstrate that tumor cells are
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Table 1: Primer sequences for PCR analysis of EP receptors 1-4 in human prostate
cancer cells exposed to bone marrow adipocytes in transwell co-culture.
Gene
Forward Sequence
Reverse Sequence
EP1
CTTGTCGGTATCATGGTGGT GGTTGTGCTTAGAAGTGGCTGAG
(PTGER1)
GTC
G
EP2
CCACCTCATTCTCCTGGCTA CGACAACAGAGGACTGAACG
(PTGER2)
EP3
CTTCGCATAACTGGGGCAAC TCTCCGTGTGTGTCTTGCAG
(PTGER3)
EP4
TGGTATGTGGGCTGGCTG
GAGGACGGTGGCGAGAAT
(PTGER4)
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Figure 4: EP1 is upregulated in PC3 and ARCaP(M) cells exposed to bone marrow
adipocytes in vitro and in vivo. A. Oncomine gene analysis comparing the expression
of EP receptors 1-4 (PTGER1, PTGER2, PTGER3, PTGER4) in patient samples
collected from metastatic or primary sites. Data were ordered by “overexpression” and
the threshold was adjusted to P-value < 1E-4; fold change, 2 and gene rank, top 10%. B.
PCR analysis of EP1-4 expression status in PC3 cells alone or in transwell with
adipocytes. β-actin was used as a loading control. C. Gene expression analysis of EP1
in tumor cells from LFD- or HFD-fed mice. D. Taqman RT-PCR expression examination
of PC3 cells (Left) or ARCaP(M) cells (Right) alone or in transwell co-culture with
adipocytes or in LFD- or HFD-fed mice (E.).
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able to modulate the secretion of PGE2 from a fat cell. They do so by releasing interleukin1β (IL-1β), which then induces the expression and activity of cyclooxygenase-2 (COX-2).
This speaks to the importance of the supportive host microenvironment in tumor
progression and demonstrates the crosstalk between the tumor cells and host adipocytes.
This adipocyte-tumor cell interaction ultimately shapes the metabolism of the tumor cell
allowing for the adaptive survival in the metastatic niche [314].
We focused on the COX-2/PGE2 pathway because activation of the EP receptors by
PGE2 has been shown to facilitate tumor aggressiveness and survival within a harsh
metastatic niche by inducing the expression of many proteins involved in cell survival
[448, 449], proliferation [418], and hypoxia [439]. Activation of the β-catenin pathway has
been associated with tumor aggressiveness and chemoresistance [450, 451].
Additionally, activation of HIF-1α has been linked to a poor prognosis and higher rates of
chemoresistance [377, 452, 453]. The role of bone marrow adipocyte in mediating
chemoresistance in PCa cells is currently unknown and is subject of ongoing
investigations in our laboratory.
Our study was founded upon the Oncomine database analysis of human prostate
cancer samples of metastatic sites compared to primary sites. Using this database
allowed us to observe noticeable and significant increases in downstream targets of
GSK3β/β-catenin signaling in metastatic prostate tumor, illuminating a clear translational
relevance to the work presented within. Because the five-year survival of patients with
metastatic disease drops from close to 99% in patients with localized disease to around
29% in metastatic patients, it is of upmost importance to understand
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Figure 5: Bone marrow adipocytes activate the GSK3β/β-catenin pathway in PCa
cells through the tumor EP receptors. A. Western blot analysis of phosphorylated and
total GSK3β in PC3 cells alone or in transwell co-culture with bone marrow adipocytes.
B. Immunoblot expression examination of β-catenin in cytoplasmic or nuclear fractions
in PC3 cells grown alone or in transwell with adipocytes. Laminin A.C was used as a
control for nuclear fractions and tubulin for cytoplasmic fractions. C. Cyclin D expression
in PC3 cells cultured with or without adipocytes in transwell. Tubulin was used as a
loading control. D. Western blot analysis of phosphorylated and total GSK3β in tumor
cells grown alone or in transwell co-culture with adipocytes in the presence or absence
of EP1-3 receptor inhibitor AH6809 and EP4 receptor inhibitor GW627368X. Tubulin was
used as a loading control.
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Figure 6: Activation of the EP1 receptor in PCa cells leads to the activation of HIF1α signaling. A. Taqman RT-PCR analysis of CA9 and VEGF in tumor cells alone or
treated with PGE2 or 15-S-15 Methyl PGE2. B. Taqman RT-PCR analysis of CA9 in
tumor cells frown alone or in transwell with adipocytes in the presence or absence of EP
receptor inhibitors AH6809 or GW6627368X or TG4-0155.
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the signaling pathways responsible for the promotion of tumor growth and survival within
the bone[454]. We believe that this distinct signaling network mediated by adipocyteprovided PGE2 activation of the GSK3β/β-catenin pathway in metastatic tissues revealed
by our Oncomine analyses provides an important starting point for future studies
investigating the contribution of the COX-2/PGE2 axis to progression and survival of
metastatic prostate tumors in the bone microenvironment.
Data presented herein reveal marrow adipocytes as important players involved in
shaping tumor cell signaling known to be involved in cell survival, proliferation, and
chemoresistance in bone. To our knowledge, this is the first study demonstrating the
importance of bi-directional interactions between marrow fat cells and tumor cells in
activating tumor-secreted IL-1β activation of the COX-2/PGE2 axis in adipocytes, causing
an activation of the tumor EP receptors and downstream signaling networks.
Understanding the molecular mechanisms behind this regulation in bone is of critical
importance in terms of potential treatment options for metastatic disease.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

6.1 Conclusions
Metastatic prostate cancer (PCa) is currently a deadly disease that affects many
men throughout the world.

When prostate cancer cells metastasize to the bone

microenvironment, they come in contact with many different cell types present such as
the commonly studied osteoblasts, osteoclasts, fibroblasts, and immune cells; however,
one largely understudied component of the marrow space that tumor cells interact with
are the bone marrow adipocytes. Bone marrow fat cells were largely thought to be “filler”
in the bone space but increasing evidence has shown that these cells have endocrine,
and paracrine effects on neighboring cells [497, 498]. The original work presented within
this thesis was the first to investigate the interaction between metastatic prostate cancer
cells and bone marrow adipocytes in the context of adipocytes altering the metabolism of
PCa cells through lipid signaling. For our first project interrogating the effects of bone
marrow adipocytes on tumor metabolism we were able to make the following conclusions:
1) Patients with metastatic disease have increased expression of glycolytic and hypoxic
genes compared to primary PCa tumors; 2) tumors grown intratibially in vivo in dietinduced models of high marrow adiposity have increased expression of glycolytic and
hypoxic genes compared to mice with fewer marrow adipocytes; 3) paracrine interactions
between tumor cells and adipocytes in vitro induce expression of glycolytic and hypoxic
proteins in tumor cells; 4) PCa cells exposed to adipocytes with increased expression of
glycolytic markers exhibit enhanced Warburg metabolism with increases in lactate
production, decreases in oxidative phosphorylation, and decreases in ATP production
without perturbation of mitochondrial integrity or cellular viability; 5) tumor cells stimulate
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lipolysis within adipocytes but the inhibition of lipolysis does not affect adipocyte-driven
changes in PCa cell metabolism due to possible compensatory mechanisms; 6) metabolic
effects are driven through the activation of HIF-1α in PCa cells as shown by increased
expression of hypoxia-responsive genes and the reversal of adipocyte-induced metabolic
changes upon knockdown of tumor cell HIF-1α.
Stemming from these results we aimed to elucidate the specific lipid mediators
released by bone marrow adipocytes and involved in HIF-1α activation in our tumor cells.
Literature searches and lipidomics analyses revealed PGE2 as a candidate bioactive lipid
responsible for HIF-1α activation. After investigating the potential role of PGE2 in hypoxia
signaling, we were able to deduce the following conclusions: 1) metastatic prostate tumor
cells had increased expression of downstream targets of PGE2/EP1-4 axis in patients
compared to primary tumors; 2) mice with elevated marrow adiposity had higher levels of
COX2, enzyme responsible for PGE2 synthesis; 3) adipocytes exposed to tumor cells in
vitro had increased expression levels of COX-1 and COX-2 and elevated levels of
secreted PGE2 and paracrine signaling was involved in COX-2 regulation by tumor cells;
4) adipocyte expression of COX-1 and COX-2 was regulated by tumor-secreted IL-1B; 5)
PGE2 receptor 1 (EP1) was upregulated in metastatic tumors in patients, in PCa cells in
mice with elevated marrow adiposity, and in tumor cells co-cultured with adipocytes in
vitro; 6) PGE2 from adipocytes activated the EP1, EP2, and EP4 receptors in tumor cells
leading to downstream GSK3β/β-catenin signaling which are involved in cell growth ad
survival; 7) PGE2 activated HIF-1α in tumor cells as shown by the activation of carbonic
anhydrase 9.
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Lastly, while investigating PGE2 as a candidate lipid, we looked at sphingosine-1phosphate (S1P) an additional bioactive lipid responsible for the activation of HIF-1α in
tumor cells. Unfortunately, our studies with S1P did not yield positive results on HIF-1α
activation; however inhibition of SPHK1 does indeed inhibit HIF-1α-mediated metabolic
changes, showing that S1P may be a necessary, but not sufficient molecule in metabolic
regulation of tumor cells. The following conclusions can be drawn from our work with
adipocyte-supplied S1P and S1P receptor signaling in tumor cells: 1) the enzyme that
synthesizes S1P from sphingosine, sphingosine kinase 1 (SPHK1) was upregulated in
adipocytes exposed to intratibially injected prostate cancer cells and was increased in
mice with high marrow adiposity; 2) SPHK1 was upregulated in adipocytes exposed to
prostate cancer cells in vitro via paracrine interactions with the tumor cells; 3) inhibition
of SPHK1 abrogated the glycolytic and hypoxic phenotype of tumor cells exposed to bone
marrow adipocytes, suggesting a role of S1P in modulating tumor metabolism; 4) S1P
receptors 5 and 2 (S1PR5 and S1PR2) were upregulated in metastatic prostate tumors
in patients compared to primary sites, whereas S1PR status did not change and
decreases S1PR5 were observed in tumor cells exposed to adipocytes in vitro; 5)
inhibition of S1PR1-3 did not affect the metabolic response of tumor cells to adipocytes;
6) treatment with S1P did not affect metabolic or hypoxic responses; 7) intrinsic S1P as
shown by overexpression of SPHK1, did not make the cells more glycolytic or hypoxic;
and 8) SPHK1 induction in adipocytes was shown to be partially mediated through tumoractivated HSL-mediated lipolysis.
6.2 Future Directions
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Herein we show that major signaling pathways HIF-1α and GSK3β/β-catenin are
activated in tumor cells exposed to adipocytes and is at least partially through
prostaglandin E2 synthesis and release from adipocytes into the tumor microenvironment
and activation of the EP receptors in tumor cells. The HIF-1α and GSK3β/β-catenin
signaling pathways have been implicated in many functions critical to cancer growth,
survival, angiogenesis, and chemoresistance [377, 450, 499-503]. The work presented
within this thesis can be extrapolated to multiple projects looking at sruvaival of tumor
cells through the activation of pro-survival pathways and/or chemoresistance and drug
response.
6.2.1 Pro-survival Mechanisms/Chemoresistance
We have shown that interaction of PCa cells with marrow adipocytes increases
their clonogenic potential and activates pro-survival pathways (Chapter 4, Fig 21 and 22),
and this is coincident with upregulation of HK2, a glycolytic enzyme with pro-survival
functions. Future work to extrapolate these findings would be to determine if HK2 bound
to the mitochondria is critical for cellular survival through the inhibition of apoptosis. We
will be able to address this using apoptosis inducing agents on tumor cells that have been
exposed to adipocytes in vitro with or without HK2 knockdown via siRNA techniques or
using mutated HK2 that can no longer bind to the mitochondria. Expected results would
show that HK2 translocation to the mitochondria in tumor cells exposed to fat cells is
required for resistance to apoptosis-inducing agents, effect abrogated by the disruption
of mitochondrial binding of HK2. Additionally, examining their response specifically to
Docetaxel, and its next generation derivative Cabazitaxel, would shed light on possible
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adipocyte-mediated mechanisms of chemoresistance and survival of PCa cells within the
bone microenvironment.
7.3 Clinical Relevance/Novel Targets
The work presented herein aimed to elucidate novel interactions between
disseminated prostate cancer cells that have metastasized to the bone and residing bone
marrow adipocytes. There have been many efforts in the clinic to target HIF-1α signaling,
the COX-2/PGE2 axis, and the SPHK1/S1P axis that we have shown are dysregulated in
tumor cells via adipocyte-driven effects.
Targeting tumor metabolism has been a continuous effort over generations of
scientists and has been a hot topic over the recent years [504, 505]. Because we have
shown in our studies, that adipocytes activate HIF-1α in PCa cells, modulate their
metabolism and increase HK2 binding to the mitochondria, it is imperative to consider
HIF-1α and HK2 as potential therapeutic targets in metastatic prostate cancer patients.
There are many drugs that have been found to target various steps in HIF-1α signaling
such as its stabilization, translocation to the nucleus, binding to HIF-1β, and transcription
factor activity [502]. Current therapies for targeting tumor metabolism are highlighted in
Chapter 1 [506].
The COX-2/PGE2 axis has been less of a challenge to target.

Given the

inflammatory roles of COX-2 and PGE2 synthesis and action, there is extensive data
using non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase
activity, on cancer progression and prevention. In the context of metastatic prostate
cancer, there have been conflicting reports of the benefits of NSAIDS as a treatment
option. Recently, it was found that giving NSAIDs to patients with localized disease
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reduced the incidence of metastasis [507], while others have shown that NSAID treatment
actually was associated with an increase risk in PCa-related mortality [508]. Additionally,
a large ongoing STAMPEDE trial reported that adding celecoxib (COX-2 inhibitor) to
standard hormone therapy for men with metastatic prostate cancer showed no advantage
compared to the control group receiving the standard hormone therapy itself [509].
Collectively, there have been largely inconsistent results from COX-2 inhibition in
metastatic prostate cancer patients. In vitro assays have shown that NSAIDs induce
apoptosis in PC3 and LNCaP cells and G1 arrest [510-512], that COX-2 overexpression
in LNCaP cells makes them more resistant to radiation therapy [513], and that celecoxib
treatment in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice have
delayed tumor growth and progression [514, 515], suggesting the COX-2 axis as a viable
targetable network. Additionally, preclinical work has been done using inhibitors of the
prostaglandin receptors (EP1-4), showing benefits across many different cancer typed in
vitro [444].
Lastly, emerging data have pointed to benefits of inhibiting SPHK1 and S1P
signaling in cancer therapy. Many of the targets were created for treatment of multiple
sclerosis-related inflammation but recent work has shown that using anti-S1P antibodies,
small molecule inhibitors of S1P signaling [516], or SPHK1 inhibitors [517], effectively
halts tumor angiogenesis [518], growth and survival [519]. Two well-known antibodies
have been created to target S1P: Sphingomab and Sonepcizumab. Sonepcizumab
(ASONEP) failed in phase II clinical trials for both Renal Cell Carcinoma (NCT01762033)
and persistent pigment epithelial detachment in subjects with acute macular degeneration
(AMD) or polypoidal choroidal vaculopathy (PCV) (NCT01334255). Additional clinical
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studies have attempted inhibiting S1P receptors in multiple sclerosis and have had
promising clinical results [520]. FTY720 is now FDA approved as a S1PR antagonist that
competitively binds to S1PR1 as a structural analogue of S1P for multiple sclerosis [521]
and has been shown to have anticancer roles as a therapy in preclinical work [522].
Specifically FTY720 has been shown to sensitize prostate cancer cells to radiotherapy
[470], cause proteasomal degradation of SPHK1 in androgen-independent PCa cells
[523], inhibit cell-cycle entry and induce apoptosis in prostate cancer cells [524, 525],
inhibit in vivo tumor growth of androgen-independent PCa [526], inhibit invasion of
androgen-independent PCa cells [527], and suppress overall aggressiveness of PCa cells
[528].
Collectively, there have been many reports that suggest HIF-1α signaling, the
COX-2/PGE2 axis, and the SPHK1/S1P axis are targetable pathways that have now been
implicated in the crosstalk between metastatic prostate cancer cells and bone marrow
adipocytes to facilitate tumor growth and survival in the bone niche. Future directions
from the work presented within this thesis could use the aforementioned inhibitors to study
PCa growth in bone as potential therapeutic targets in vivo to characterize the importance
of these signaling networks for tumor growth in bone. [497]
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APPENDIX
Adipocyte-Derived Sphingosine-1-Phosphate does not affect the Metabolic
Phenotype of Metastatic Prostate Cancer Cells
A.1 Introduction
The uptake of lipids from the microenvironment, aberrant de novo lipid synthesis
and alterations in fatty acid catabolism and steroidogenesis pathways are now emerging
as key mechanisms linking dysregulated lipid metabolism in the primary prostate tumor
with subsequent progression and reduced survival [299, 303, 304]. These lipids have the
propensity to regulate signaling networks within cancer cells through receptor-mediated
signaling pathways [414]. Previous work stemming from our laboratory has shown that
metastatic prostate tumors in bone both induce lipolysis in bone marrow adipocytes and
also utilize lipids from adipocytes to fuel their own metabolic processes that are largely
lipid-driven [345, 360]; therefore, it is crucial to understand what lipids are responsible for
tumor growth and survival in bone.
There is increasing emerging evidence that the lysosphingolipid sphingosine-1phosphate (S1P), a bioactive lipid in the sphingolipid family, plays a role in cancer
progression [455-457]. S1P is synthesized by the conversion of sphingosine to
sphingosine-1-phosphate through its phosphorylation by the enzymes sphingosine
kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) [458, 459]. Once S1P is synthesized
it can be exported out of the cell by specific sphingolipid transporters such as spinster 2
(SPNS2) [460, 461] where it exerts its autocrine and paracrine effects. Secreted S1P has
the propensity to bind to five independent receptors known as S1PR1-5 [462]. S1P
receptor signaling has been implicated in regulating a multitude of functions important for
cancer progression such as autophagy [463], angiogenesis [464, 465], proliferation [466],
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and many other processes [467]. S1P has an additional intrinsic function where SPHK1
or SPHK2 can translocate to the nuclear envelope or endoplasmic reticulum and
synthesize S1P locally [468, 469].
Importantly, limited studies in prostate cancer have shown S1P receptor signaling
to play critical roles in tumor-promoting autophagy through S1PR5 [463], sensitization to
irradiation [470] and to Docetaxel, the standard chemotherapeutic agent for hormoneresistant PCa, docetaxel [471]. Re-sensitization of PCa cells was seen through the
inhibition of SPHK1 and intracellular S1P production. One study examining effects of
osteoblast-derived S1P on metastatic prostate cancer, ,showed its promoting effects on
tumor cell growth and survival [472]. S1P has been shown to promote adipogenesis [473]
and elevated serum levels of S1P were shown in obese patients compared to lean [474];
however, no studies have looked at the effects of bone marrow adipocyte-supplied S1P
on prostate cancer cell growth and survival within the bone. Extending from our previous
work we have shown that HIF-1α is activated in tumor cells exposed to bone marrow
adipocytes [360]. Intriguingly, S1P signaling has been shown to have the propensity to
activate HIF-1α signaling [475] and HIF-2α expression and activity [476].
The objective of this study was to elucidate the role of bone marrow adiposity in
the modulation of tumor signaling networks within the bone microenvironment. Using in
vivo models of diet induced marrow adiposity in combination with in vitro models of
paracrine signaling between bone marrow adipocytes and prostate cancer cells, we show
that tumor-stimulated activation of lipolysis in bone marrow adipocytes leads to induction
of SPHK1 and subsequent secretion of S1P into the tumor microenvironment. S1P then
activates the S1P receptors in tumor cells; however, this does not modulate the
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metabolism of the tumor cells or activate HIF-1α signaling as we had hypothesized.
These results introduce a potential mechanism underlying other functions regulated by
S1P in facilitating adaptation of metastatic tumors in bone and implicate bone marrow
adipocyte, a cell type so abundantly present in the skeleton especially in advanced age
and obesity, as a viable culprit in the progression of this currently incurable disease.
A.2 Results
A.2.1 Sphingosine Kinase 1 (SPHK1) is upregulated in adipocytes exposed to
intratibially injected prostate cancer cells in vivo
To determine whether the hypoxic phenotype observed in PCa cells exposed to
adipocytes was correlated with increased S1P production in adipocytes leading to
activation of the HIF-1α, we analyzed mRNA expression of mouse SPHK1 in adipocytes
exposed to intratibially injected PC3 and ARCaP(M) cells in LFD and HFD mice. Our
results revealed significantly increased host (mouse) transcript levels of SPHK1 in bone
tumors from HFD mice as compared to LFD mice (Figure 1), suggesting a potential
contribution of marrow adipocytes to this process. These findings implicate tumor cells
as potential regulators of adipocyte S1P production, which likely occurs through the
activation of the SPHK1 enzyme in bone marrow fat cells.

This led us to further

investigate the mechanism of this regulation in vitro.
A.2.2 SPHK1 and S1P are upregulated in adipocytes exposed to prostate cancer
cells in vitro
We utilized in vitro models of tumor cell-adipocyte interactions to determine if the
activation of SPHK1/S1P axis observed in intratibial tumors in vivo is a direct effect of
tumor cell action on adipocytes. We first examined SPHK1 expression in adipocytes
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exposed to PCa cells by employing a transwell system in which adipocytes were
differentiated in the bottom chamber and tumor cells were then plated in the traswell insert
and cultured together for 48 hours. This allowed the two cell types to share the media
without direct interaction. SPHK1 was significantly increased in adipocytes co-cultured
with PCa cells (Figure 2A). Interestingly, lipidomics analyses of S1P levels in PCa cell
lysates in transwell with adipocytes showed elevated levels of S1P (Figure 2B) This
corresponded with lower levels of intracellular ceramides and increased sphingosines
(Figure 2C and 2D). Additionally, adipocytes have elevated levels of sphingosine and
S1P as well (Figure 2B) when exposed to PC3 cells in transwell co-culture. Important to
note, S1P was only detected in a small amount of samples and further analysis is crucial
to conclude that S1P levels are significantly higher in cells PC3 cells or fat cells in coculture; however, these results suggest that adipocytes are synthesizing more
sphingosine which is in turn converted to S1P and that this effect is also happening in
tumor cells in which they are decreasing the balance of ceramide to sphingosine in favor
of sphingosine synthesis.
The fact that transwell co-culture with tumor cells caused the activation of SPHK1
and increase S1P production in adipocytes suggested that this process does not require
physical interaction between the tumor cells and adipocytes.

Therefore, we next

examined whether the media conditioned by the PCa cells alone (PC3/ARCaP(M) CM)
can facilitate similar changes in adipocytes as observed in transwell co-culture.
Interestingly, treatment with either PC3 or ARCaP(M) conditioned media induced
expression of SPHK1 in adipocytes (Figure 2D), suggesting that paracrine signaling is
required between the adipocytes and tumor cells for the subsequent phenotype.
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Figure 1: SPHK1 expression increases in bone marrow adipocytes exposed to
prostate cancer in vivo. Taqman RT-PCR analysis of mouse SPHK1 expression in
adipocytes exposed to both ARCaP(M) and PC3 cells that were intratibially injected and
allowed to grow in the marrow space in high fat diet- (HFD) or low fat diet (LFD) fed-mice.
Data were normalized to mouse Adiponectin and represent a mean of a minimum of 3
mice/group + SD.
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A.2.3 Inhibition of SPHK1 abrogates the metabolic effect of adipocytes on PCa cells
Because SPHK1 is upregulated in adipocytes exposed to tumor cells in vivo and
in vitro, we used a pharmacological inhibitor of SPHK1 activity, sphingosine kinase
inhibitor 2 (SKI-2) [207, 477, 478] and assessed the hypoxic and metabolic effects of
adipocytes on tumor cells in vitro.

We have previously shown that bone marrow

adipocytes enhance the Warburg phenotype in PCa cells through the activation of HIF1α [360]; Therefore, we looked at the genes involved in activation of HIF1a and glycolysis
in tumor cells interacting with adipocytes upon SPHK1 inhibition. Interestingly, we
observed that treatment with SKI-2 abrogated the effects of the adipocytes on tumor
metabolism, suggesting a role of S1P in regulating the hypoxic signature of tumor cells
exposed to adipocytes (Figure 3A and B). This effect was observed in both PC3 and C42B cells (Figure 3C).
A.2.4 Sphingosine-1-phosphate receptor expression status in patients with
metastatic prostate cancer compared to primary prostate cancer
S1P is a bioactive lipid that has the propensity to activate cellular signaling through
five different S1P receptors (S1PR1-5) [479]. We next performed an in silico Oncomine
database analysis of S1P receptors in metastatic prostate cancer tumors compared to
primary prostate tumors. Of the five receptors, S1PR5 and S1PR2 were significantly
upregulated in metastatic tumors (Figure 4A), showing a possible importance of individual
S1P receptors in S1P signaling in bone tumors.
A.2.5 S1P receptor 1-5 expression levels in tumor cells exposed to adipocytes in
vitro
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Stemming from the in silico analysis fo S1P receptor expression in metastatic
tumors compared to primary tumors, we then looked at the S1PR1-5 expression status in
vitro in tumor cells exposed to adipocytes in transwell co-culture (Figure 4B). Using
primers designed to recognize each of the five S1P receptors, we observed no significant
increases in S1PR1, S1PR2, or S1PR4, significant decreases in S1PR5, and
undetectable levels of S1PR3 in tumor cells exposed to adipocytes in transwell co-culture.
Although these results were disappointing, receptor expression levels do not always
correlate with receptor activity. Therefore we used antagonists to different S1P receptors
and assessed the hypoxic and metabolic activity of the tumor cells upon receptor
inhibition. Specifically, we utilized VCP23019 to inhibit the activity of S1PR1 and S1PR3
[480-482] and JTE-013, to selectively target S1PR2 [482, 483]; however, we did not
observe any changes in the induction of the hypoxia-associated gene CA9 or the
glycolysis associated genes ENO2 and HK2 (Figure 5), suggesting that S1P may not be
activating the HIF-1α pathway through S1PR1, S1PR3, or S1PR4.
A.2.6 S1P may act as a necessary, but not sufficient, cofactor for HIF-1α activation
in tumor cells
We then sought to determine which of the S1P receptors is involved in signaling
leading to HIF1a activation. We used pharmacological receptor agonists as well as
synthetic S1P itself, to activate each of the receptors and look at both a hypoxic and
metabolic response in the tumor cells (Table 1). Neither treatment with S1P itself nor any
of the agonists activated a hypoxic or glycolytic response in the tumor cells (Figure 6AC), suggesting that S1P signaling through the S1P receptors is not sufficient for HIF-1α
activation. S1P has been shown to activate Akt signaling and as a control, we assessed
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the phosphorylation of Akt. We observed that upon exposure to S1P, Akt is being
activated in the PC3 and ARCaP(M) cells suggesting that S1P is functionally active
(Figure 6D). We have previously shown that paracrine interactions between tumor cells
and adipocytes are critical for regulation of tumor metabolism. This was determined by
treating the tumor cells with media conditioned by a co-culture of tumor cells and
adipocytes. Treatment with adipocyte conditioned media alone is not sufficient to induce
metabolic changes in tumor cells therefore, we postulated that because tumor cells are
required to increase S1P levels from adipocytes through the induction of SPHK1, S1P is
the missing factor in adipocyte conditioned media compared to the co-culture conditioned
media. Conversely, adipocyte conditioned media induces the expression of lipid
transporters that are critical for the uptake of lipids such as S1P. To test this hypothesis,
experiments were performed in which tumor cells were treated with S1P that was added
to adipocyte conditioned media. We saw that even though lipid transporters were
increased under those conditions, they were not responding metabolically to the addition
of S1P as us we have observed upon treatments with direct co-culture conditioned media
(Figure 6E).
A.2.7 Intrinsic SPHK1 overexpression does not activate a hypoxic or glycolytic
phenotype in PCa cells
S1P can signal through its receptors but also has cellular-intrinsic signaling [468].
Because we see SPHK1 induction in adipocytes and the inhibition of SPHK1 using SKI2 abrogates the metabolic effects of adipocytes on tumor cells, a phenotype not inhibited
by receptor antagonists, we pursued cellular-intrinsic signaling within the tumor
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Figure 2: SPHK1 expression and activity increases in adipocytes exposed to
prostate cancer cells in vitro. A. Taqman RT-PCR analysis of SPHK1 expression in
adipocytes in transwell co-culture with PC3 and ARCaP(M) cells in vitro. Lipidomics
analysis of sphingosine-1-phosphate (S1P) levels (B.), sphingosines (C.), and ceramides
(D.) in tumor cells and adipocytes alone or in co-culture. E. Expression of SPHK1 in
adipocytes treated with PC3 or ARCaP(M) conditioned media.
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Figure 3: SPHK1 inhibition using SKI2 abrogates metabolic effects of adipocytes
on prostate cancer cells. A. Taqman RT-PCR analysis of Warburg Effect associated
genes ENO2, PDK1, HK2, GLUT1, and LDHa and hypoxic marker CA9 in tumor cells
alone or in transwell co-culture with adipocytes in the absence (top) or presence (bottom)
of SKI2, a SPHK1 inhibitor. Data are normalized to HPRT1 and shown relative to control.
B. Western blot analysis of Warburg Effect associated proteins HK2 and ENO2 and
phosphorylated PDH, indicative of enhanced PDK1 activity in PC3 cells alone or in
transwell with adipocytes with or without 5 uM SKI2. Tubulin was used as a loading
control. C. Taqman PCR of hypoxic and glycolytic genes in C4-2B PCa cells alone or in
transwell in the presence or absence of 5 uM SKI2. Results represent a mean of at least
3 independent experiments ± SD. Values * P < 0.05; ** P < 0.01, *** P < 0.001 are
considered statistically significant.
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Figure 4: S1P receptor expression status in patients with metastatic prostate
cancer compared to primary prostate cancer and PCa cells exposed to bone
marrow adipocytes in vitro. A. Oncomine gene analysis comparing the expression of
metabolic genes (S1PR1-5) in patient samples collected from metastatic or primary sites.
Data were ordered by “overexpression” and the threshold was adjusted to P-value < 1E4; fold change, 2 and gene rank, top 10%. B. Qualitative PCR of S1PR1-5 in PC3 cells
co-culture with adipocytes in transwell. Actin was used as a loading control.
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cells that is not receptor-mediated. We first looked at SPHK1 levels in tumor cells to see
if not only the adipocytes are increasing levels of SPHK1, but also tumor cells; however,
Taqman real-time PCR results showed no significant changes in SPHK1 levels in PCa
cells alone or exposed to adipocytes in transwell co-culture (Figure 7A). We then stably
overexpressed SPHK1 in the tumor cells to increase intrinsic S1P levels (Figure 7B) and
assessed the metabolic effects of increasing SPHK1 expression in tumor cells (Figure
7C).

Surprisingly, there was no effect of SPHK1 overexpression on the metabolic

phenotype seen in tumor cells exposed to adipocytes, showing that intrinsic S1P signaling
also does not have an effect on tumor metabolism.
A.2.8 Activation of hormone sensitive lipase-mediated lipolysis by PCa cells
enhances SPHK1 expression in adipocytes
Lastly, we pursued the regulation of SPHK1 in bone marrow adipocytes exposed
to PCa cells. Previous literature has shown that SPHK1 and the production of S1P is
regulated by hormone sensitive lipase (HSL-)-mediated lipolysis in white adipose tissue
[207]. We tested this in bone marrow adipocytes using a chemical inducer of lipolysis,
forskolin.

Upon treatment with forskolin, we observed a large increase in SPHK1

expression in bone marrow fat cells, suggesting that activation of lipolysis increases
SPHK1 levels (Figure 8A). We then used inhibitors of adipose triglyceride lipase (ATGL),
Atglistatin, and hormone sensitive lipase, BAY59-9435 (BAY), and saw a marked
decrease in SPHK1 expression with BAY treatment but not with Atglistatin, showing that
this regulation of SPHK1 is mediated by HSL activation during lipolysis (Figure 8B) similar
to studies in white adipose tissue [207]. Studies are currently ongoing to determine the
contribution of the phosphorylation (activation) of HSL in
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Figure 5: S1PR inhibition does not abrogate effects of adipocytes on tumor
metabolism. Taqman RT-PCR analysis of hypoxic response marker CA9 and glycolytic
genes ENO2, HK2, and PDK1. Data were normalized to HPRT1 and shown as fold
change relative to PC3 cells alone. Experiment was done one time and experimental
replicates are shown as SD.
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Figure 6: Treatment with S1P is not sufficient to induce Warburg phenotype in PCa
cells as seen by bone marrow adipocytes. A. Taqman RT-PCR analysis of glycolysis
markers ENO2, GLUT1, and PDK1 after treatment with 500 nM S1P for 0, 0.5, 1, 2, 4, or
6 hours. B. Gene expression analysis of CA9 and ENO2 in tumor cells treated with S1PR
agonists or S1P itself. C. Taqman RT-PCR of CA9 and ENO2 in PC3 cells (Left) or
ENO2 in ARCaP(M) cells (Right) at multiple concentrations of S1P. D. Immunoblot
measurement of phosphorylated Akt and ERK in tumor cells treated with 10 uM S1P over
a time course in PC3 cells (Left) and ARCaP(M) cells (Right). E. Taqman RT-PCR of
CD326, ENO2, HK2, and PDK1 in PC3 cells treated with 10 uM S1P, Adipocytes
Conditioned Media (Adipo CM), Adipo CM with 10 uM S1P, or Adipocyte tumor co-culture
conditioned media (CCM).
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adipocytes in co-culture with PCa cells and if this correlates with S1P synthesis. It has
been shown that HSL activation leads to upregulated c-Jun N-terminal kinase
(JNK)/activating protein-1 (AP-1) signaling and SPHK1 induction [207], so we will
examine the JNK/AP-1 pathway in adipocytes exposed to PCa cells to determine how
HSL activation regulates SPHK1. Also, we will determine if BAY treatment completely or
partially inhibits HSL activation because BAY only partially decreases the robust increase
in SPHK1 expression levels in adipocytes exposed to tumor cells. Additional experiments
will be designed to use other specific inhibitors of HSL [484-487] to show the importance
of this specific lipase to the regulation of SPHK1 expression.
A.3 Discussion
The results presented above reveal an important contribution of tumor cell-induced
lipolysis in bone marrow adipocytes leading to sphingosine-1-phosphate (S1P)
production and a possible regulation of tumor metabolism. We show that marrow fat cells
are capable of secreting S1P that either binds to S1PR1-5 or is internalized and used
within tumor cells but that S1P alone is not sufficient to cause a metabolic effect within
tumor cells, even though it may be necessary. We also demonstrate that tumor cells are
able to modulate the secretion of S1P from a fat cell. They do so by inducing lipolysis and
the activation of specifically hormone sensitive lipase (HSL). This speaks to the
importance of the supportive host microenvironment in tumor progression and
demonstrates the crosstalk between the tumor cells and host adipocytes. This adipocytetumor cell interaction ultimately shapes the cell signaling within the tumor cell allowing for
the adaptive survival in the metastatic niche.
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Figure 7: Overexpression of SPHK1 in PC3 cells does not affect the metabolic
phenotype. A. Taqman RT-PCR analysis of SPHK1 expression in tumor cells alone or
in transwell with adipocytes. B. Quantitative real time PCR of SPHK1 expression stably
expressed in PC3 cells in control Neomycin vector (Neo) or with SPHK1 overexpressing
vector (SPHK1) with two different concentrations of Lipofectamine3000 (3.75 and 7.5 ul).
C. Taqman RT-PCR of CA9, HK2, and PDK1 in PC3 cells overexpressing SPHK1
compared to control cells. Data were normalized to HPRT1 and shown as a fold change
relative to control.
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Figure 8: Adipocyte SPHK1 expression is regulated by the induction of HSLmediated lipolysis by tumor cells. A. Taqman RT-PCR analysis of SPHK1 in
adipocytes in the presence or absence of lipolysis inducing agent Forskolin. B. Gene
expression analysis of SPHK1 in adipocytes exposed to tumor cells in traswell co-culture
in the presence or absence of HSL inhibitor (BAY) or ATGL inhibitor (Atglistatin). Data
are normalized to Adiponectin and shown as fold change relative to control.
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We focused on the SPHK1/S1P pathway because activation of the S1P receptors by
S1P has been shown to facilitate tumor aggressiveness and survival by inducing the
expression of many proteins involved in angiogenesis [465, 488], proliferation [[472[Hu,
2010 #3960], migration [489] and many other hallmarks of cancer [490]. Additionally,
microarray studies have shown that high levels of SPHK1 and S1P signaling are
correlated with a poor prognosis in breast cancer [491] and other cancers such as lung
and ovarian cancer [456]. Importantly, for the context of our studies, it has been shown
that S1P can activate HIF-1α [475, 492]. Unfortunately, our data do not support these
findings in prostate cancer cells, showing that S1P is not sufficient to activate HIF-1α
signaling in PC3 or ARCaP(M) cells.
Although our data did not support our hypothesis, we have shown that sphingosine
and S1P levels are increased in both tumor cells and adipocytes in co-culture compared
to alone conditions. This S1P can be secreted into the tumor microenvironment and
regulate many different signaling networks in tumor cells that aid in growth and survival
within the bone. Additionally there are many intracellular targets of S1P [468, 493] and it
appears that tumor cells are also decreasing ceramide levels and increasing sphingosine
and sphingosine-1-phosphate levels, indicative of a shift in balance toward sphingosine
synthesis and away from ceramide. This is important because it has been shown that
increased ceramide levels correlate with induction of apoptosis and increasing the
sphingosine levels serves as a pro-survival mechanism for tumor cells [494]. Surprisingly,
we also observed that adipocytes exposed to tumor cells have increased production of
certain ceramide species (Figure 2D). This could possibly be due to the parasitic nature
of tumor cells feeding off of the adipocytes inducing lipolysis and lipid transfer [345],
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leading to apoptosis of the adipocytes. Experiments will be performed to determine if
adipocytes are undergoing early stages of apoptosis after tumor cells deplete them of
their lipid and nurients. Future studies will also be utilized to assess the expression and
function of ceramidase enzyme sphingolipid delta-4 desaturase (DES1) in tumor cells and
adipocytes that are responsible for ceramide catabolism to sphingosine and ceramide
synthase that converts sphingosine to ceramide. Collectively, this work will show us if
there are enzymes responsible for the accumulation of sphingosine and S1P, but also
increases in ceramides in the adipocytes. Also, lipidomics assays will be performed on
media conditioned by adipocytes and tumor cells and adipo/tumor co-cultures to
determine if this S1P is secreted and possible roles of S1P in the local or systemic tumor
microenvironment.
A future avenue that is worth consideration is the functional role of S1P in the
activation of autophagy in tumor cells leading to a cytoprotective effect via activation of
ER stress responses [463, 495, 496].

In the context of bone marrow adipocyte

interactions with prostate cancer cells, S1P levels driven by tumor-induced lipolysis within
the adipocytes could contribute to activation of ER stress and autophagy pathways within
adipocytes, a crosstalk that is yet to be explored.
The rationale for our study was based on the gene expression analyses of bone
marrow adipocyte samples suggesting clearly distinct increases in SPHK1 expression
and extensive literature showing SPHK1/S1P signaling has the propensity to activate HIF1α as a mechanism to explain the lipid-mediated crosstalk between bone marrow
adipocytes and prostate cancer cells within the bone microenvironment. Unfortunately,
however, we have shown that S1P itself is not sufficient to activate HIF-1α and induce
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metabolic changes in the tumor cells. We believe that showing that the SPHK1/S1P axis
is dysregulated, although not sufficient to alter the metabolism of the tumor cells, provides
an important starting point for future studies. These findings illuminate novel avenues of
investigation for elucidating the contribution of the SPHK1/S1P axis to progression and
survival of metastatic prostate tumors in the bone microenvironment.
Data presented herein reveal marrow adipocytes as important players involved in
shaping tumor cell signaling known to be involved in cell survival, proliferation, and
chemoresistance in bone. To our knowledge, this is the first study demonstrating the
importance of bi-directional interactions between marrow fat cells and tumor cells in
activating tumor-activated lipolysis, stimulating the expression and activity of the
SPHK1/S1P axis in bone marrow adipocytes, causing an activation of the tumor S1P
receptors or internalization, and activation of intracellular targets of S1P and downstream
signaling networks. Understanding the molecular mechanisms behind this regulation in
bone is of critical importance in terms of potential treatment options for metastatic
disease.
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Bone is a preferential site of metastasis from prostate cancer (PCa). Although
there have been many advances in therapeutic options for patients suffering from
metastatic PCa, this disease remains incurable with an estimated five-year survival of
33%. To design effective therapeutic interventions for metastatic PCa, it is essential that
we elucidate the molecular mechanisms responsible for tumor cell adaptation to and the
ability to thrive within the bone metastatic niche. Age and obesity, conditions that increase
adipocyte numbers in bone marrow, are risk factors for skeletal metastases from PCa;
therefore, our laboratory is focused on the interactions between marrow adipocytes and
PCa cells.
We initially detailed the metabolic alterations that occur in prostate cancer cells in
response to interactions with bone marrow adipocytes in multiple in vivo and in vitro
models. The following conclusions were drawn as a result of these experiments: 1)
Patients with metastatic disease have increased expression of glycolytic and hypoxic
genes compared to primary PCa tumors; 2) tumors grown intratibially in vivo in dietinduced models of high marrow adiposity have increased expression of glycolytic and
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hypoxic genes compared to mice with fewer marrow adipocytes; 3) paracrine interactions
between tumor cells and adipocytes in vitro induce expression of glycolytic and hypoxic
proteins in tumor cells; 4) PCa cells exposed to adipocytes with increased expression of
glycolytic markers exhibit enhanced Warburg metabolism with increases in lactate
production, decreases in oxidative phosphorylation, and decreases in ATP production
without perturbation of mitochondrial integrity or cellular viability; 5) tumor cells stimulate
lipolysis within adipocytes but the inhibition of lipolysis does not affect adipocyte-driven
changes in PCa cell metabolism due to possible compensatory mechanisms; 6) metabolic
effects are driven through the activation of HIF-1α in PCa cells as shown by increased
expression of hypoxia-responsive genes and the reversal of adipocyte-induced metabolic
changes upon knockdown of tumor cell HIF-1α.
Additionally, we found novel signaling pathways are activated in tumor cells due to
cross talk between tumor cells and adipocytes. We observed a regulation of COX-2 in
adipocytes by tumor-secreted IL-1β that leads to increased PGE2 synthesis and release
and this PGE2 signals through the EP receptors on the tumor cells to elicit downstream
GSK3β/β-catenin signaling and subsequent HIF-1α activation.
We also observed increased SPHK1 in adipocytes exposed to tumor cells as an
effect of tumor-stimulated lipolysis within adipocytes, but that S1P was not sufficient to
activate HIF-1α signaling in tumor cells or downstream metabolic alterations.
In summary, we have discovered novel crosstalk between metastatic prostate
tumor cells and bone marrow adipocytes that cause activation of many pathways involved
in tumor survival and growth within the bone. We have revealed a functional contribution
of bone marrow adipocytes to altered tumor metabolism and signaling in bone. The
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expected outcome of this research is the validation of the significance of adipocytederived lipids in growth and aggressiveness of metastatic PCa in bone. The ultimate goal
is utilize findings from this study to explore whether adipocyte-driven metabolic adaptation
contributes to chemoresistance of skeletal tumors and whether targeting tumor
metabolism offers new options for improved therapy and/or prevention of aggressive
disease.
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